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ABSTRACT 
Pseudomonic acid (42) is the major metabolite isolated from Pseudomonas 
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Previous biosynthetic studies have shown pseudomonic acid to be mainly 
polyketide in origin, possibly formed from a condensation of two distinct precursors: 9- 
hydroxynonanoic acid (69), the origins of which are unknown, and monic acid (50), 
which has been shown to be polyketide in origin. The aim of this research was to further 
investigate the biosynthetic pathway to pseudomonic acid. 
Synthetic routes to a range of possible starter units of 9-hydroxynonanoic acid 
were developed, including the synthesis of [1,2-13C2]malonate, and [1,2-13C2]-3- 
hydroxypropionate, together with the corresponding singly labelled versions. Of 
particular importance was the synthesis of 9-hydroxynonanoic acid in 13C2 labelled form. 
Our approach was based on the use of the Homer-Wadsworth-Emmons olefination of 7- 
hydroxyheptanal (147), and was flexible, thus allowing the synthesis of both [1,2-13C2]- 
9-hydroxynonanoic acid and [2,3-13C2]-9-hydroxynonanoic acid. 
To elucidate information on the monic acid moiety, synthetic mutes to the putative 
diketide (169) and triketide precursors (170) were developed. 
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Synthetic routes to the NAC thioesters of [1,2-13C2]monic acid A and monic acid 
C have also been investigated, in order to probe the later biosynthetic stages. 
Initial feeding studies of acetate, propionate, butyrate, and malonate into 
Pseudomonas fluorescens strains PF3/R and NCIB 10586 have been ineffective in 
producing any information on the biosynthetic pathway. On feeding these precursors, 
pseudomonic acid production was blocked, and no significant incorporation of isotopic 
label was detected in pseudomonic acid. 
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The following abbreviations are used within the text: 
acetyl CoA acetyl coenzyme A 
ACP acyl carrier protein 




CI chemical ionisation 
CoA coenzyme A 
D deuterium 
d doublet 
dd doublet of doublets 
dt doublet of triplets 




DIBAL-H diisobutyl aluminium hydride 
DMAP 4-dimethylaminopyridine 




El electron impact 
Enz enzyme bound intermediate 
Et ethyl 
FAB fast atom bombardment 




HPLC high pressure liquid chromatography 
Hz hertz 
J coupling constant 




M+ molecular ion 
mp. melting point 
m/z mass: charge ratio 
max maximum 
Me methyl 
nmr nuclear magnetic resonance 
v frequency 
PDC pyridinium dichromate 
PEP phosphoenol pyruvate 
Ph phenyl 
PKS polyketide synthase 
Pn pentyl 
pTSA para-toluenesulphonic acid 








TLC thin layer chromatography 
TMS trimethylsilyl 
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1.1 Natural Products 
In 1891, Emil Fischer first reported the structural elucidation of glucose (1). 















The two compounds are both natural products, yet glucose is ubiquitous and 
essential for the existence of life, whereas morphine is produced in just two species of 
poppy, Papaver somniferum and P. setigerum. Although morphine is widely used in 
medicine, it has no apparent function in these two plants. Similarly, penicillins (3) are 
produced by only a few fungal species, and despite them having no apparent use to the 
fungi, they have become invaluable to man as antibiotics in the last fifty years. 
All organisms possess similar metabolic pathways by which they synthesise and 
utilise certain essential chemical species, sugars, common fatty acids, amino acids, 
nucleotides, and the polymers derived from them (polysaccharides, lipids, proteins, 
RNA, and DNA). This is primary metabolism, and these compounds are primary 
metabolites, which are essential for survival and well-being of the organism. 1 
Natural products such as morphine and the penicillins, which serve no apparent 
function for the organism, and which are found in relatively few species, are termed 
secondary metabolites. 2,3 For many years, these metabolites have been used as 
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Fig. M: Examples of secondary metabolites. 
1 
Primary and secondary metabolites are connected via complex metabolic 
pathways, as shown below in Scheme 1.1. The two areas of metabolism can be regarded 
as connected, since primary metabolism produces a number of small starter units: acetate, 
mevalonate, and shikimate. These are responsible for the biosynthesis of the secondary 
metabolites. Acetate, in the form of acetyl CoA (4) is the precursor for phenols and 
aromatics, and of polyketides and fatty acids, and their metabolites, the prostaglandin 
and leukatrienes. However, mevalonate (5), also derived from two molecules of acetyl 
CoA (4), is the precursor for the terpenes, steroids and carotenoids. Shikimate produces 
aromatics, whilst the amino acids are the precursors for the alkaloids, penicillins, and 
cephalosporins. 
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Scheme 1.1: Links between primary and secondary metabolism. 
2 
1.2 The elucidation of biosynthetic pathways 
The isolation of natural products, in recent years has become a much simpler 
procedure with the advent of modern chromatographic techniques, such as HPLC. The 
advances in separation techniques, coupled with advances in nmr spectroscopy, infrared 
spectroscopy, mass spectrometry, and X-ray crystallography have facilitated the 
structural elucidation of a wide range of complex natural products. As a result, more time 
and effort can now be devoted to testing biogenetic hypotheses. 
These biosynthetic investigations benefited initially from the availability of 
precursor molecules isotopically labelled with 14C and 3H, and more recently isotopically 
labelled with the stable isotopes 13C, 2H, and 180; all of which have low natural 
abundance, and with the exception of 180, are nmr active. 13C and 2H are now the most 
widely used isotopes in such studies. For example, if a single 13C labelled precursor is 
incorporated into a metabolite, then the 13C nmr spectrum will show enhanced signals 
corresponding to the carbon atoms where the 13C label has been incorporated (Fig. 1.2 
(b) and (c)). 
Other more sensitive techniques involve the use of double labelled precursors, 
normally using 13C together with another 13C, 2H, or 180. The positions at which the 
label is incorporated can then be determined by using 13C nmr spectroscopy. If [1,2- 
13C2]acetate is incorporated intact into the metabolite, then the signals in the 13C nmr 
spectrum corresponding to the carbons at the sites of incorporation will appear as 
'triplets', in which the natural abundance signal is flanked by 13C-13C coupled satellites 
(Fig. 1.2(d)). However, if during the biosynthesis the labelled bond does not remain 
intact, and is broken, then only enhancement of the natural abundance singlet signals will 
be observed in the metabolite (Fig. 1.2(e)). These incorporation experiments therefore 
allow the determination of the origins of the carbon framework of natural products. 
To deduce biosynthetic information on the origins of the hydrogen and oxygen 
atoms in a metabolite, 2H and 180 labelling techniques have been used to great effect. The 
use of deuterium labelled precursors, which can be monitored by 2H nmr or by 
monitoring isotope induced shifts in the 13C nmr spectrum, can help determine these 
origins. As mentioned, if a single 13C labelled precursor is incorporated into a metabolite, 
then the 13C nmr spectrum will show enhanced signals corresponding to the carbon 
atoms, where the 13C label has been incorporated. Analogous results are obtained with 
the use of 2H labelled precursors, and the resulting SH nmr spectra. 
3 
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Fig. 1.2: The use of singly and doubly 13C labelled precursors in biosynthetic studies, 
using 13C nmr spectroscopy. 
However, 2H nmr spectroscopy has its limitations. It often produces poorly 
resolved spectra, due to its quadrupole nucleus (spin=1), a low gyromagnetic constant, 
and a small chemical shift range, compared with 13C. The advantage of 2H nmr 
spectroscopy is that deuterium has a very low natural abundance (0.012% for 2H, 
compared with 1.1 % for 13C), hence, it is particularly suitable for studying incorporation 
of assembly intermediates into secondary metabolites, where low incorporation of a 
labelled precursor into the metabolite is often found. Low incorporation of a labelled 
precursor into a metabolite is also a reason why nmr spectroscopy is used in preference to 
mass spectrometry. 
The deuterium can be located either one (a) or two (ß) bonds away from the 13C 
nucleus. Hence, incorporation of [2-13C, 2H3]acetate leads to a multiplet in the 13C nmr 
spectrum, due to 13C/2H coupling. This coupling has the effect of CD appearing as a 
triplet, CD2 as a quintet, and CD3 as a septet. Also, the presence of each deuterium also 
produces an upfield a-isotope shift of the signal by approximately 0.03ppm. (Fig. 
1.3(a)). This can lead to complex spectra, but can be overcome using deuterium 
decoupling, or by using deuterium placed 0 to the 13C nucleus. Here, the 13C/2H 
coupling is too small to be resolved, and the signals appear as upfield singlets with a (3 
isotope shift of the 13C nmr spectrum, typically 0.01 to 0. lppm. Incorporation of [1-13C, 
2H3]acetate illustrates this point (Fig. 1.3(b)). 
Incorporation of [1-13C, 1802]acetate into a metabolite enables the biosynthetic 
origins of acetate derived oxygen to be determined. This leads to an upfield a-isotope 
shift of 0.01 to 0.05ppm (Fig. 1.3 (c)). A similar effect can be observed when organisms 
4 
are grown in an 1802 enriched atmosphere. Atmospheric derived oxygen atoms may be 
labelled within the metabolite, and as a result, show a small 180-isotope shift in the 13C 
nmr spectrum (Fig. 1.3(d)). 
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Fig. 1.3: Predicted patterns in 13C nmr spectra of 2H and 180 labelled metabolites. 
Specific examples of the use of 13C, 2H, and 180, in the elucidation of the 
biosynthetic pathways to polyketides, will be discussed in section 1.3. 
1.3 Polyketide Biosynthesis 
The work described in this thesis was aimed at elucidating the biosynthesis of 
pseudomonic acid, a polyketide derived antibiotic, produced by Pseudomonas 
fluorescens. Polyketides comprise of a wide range of naturally occurring products, and 
have been isolated by fungi, bacteria, insects, marine organisms, and higher plants 4,5 
The polyketide biosynthetic pathway is one of the most widespread in nature. A 
wide range of biologically active natural products are polyketide derived, including the 
antibiotics 6-methylsalicylic acid (6-MSA) (6), tetracycline, and erythromycin B (7), the 
antifungal agents griseofulvin and the strobilurins (8), the cholesterol lowering agents 
lovastatin and squalestatin (9), and the immunosuppressive agents rapamycin (10) and 
FK506; some of which are shown in Fig. 1.4. 
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Fig. 1A Examples of the structural diversity exhibited by polyketide derived 
metabolites. 
Despite their structural diversity, all of the polyketides are related by their 
common biosynthetic origins. The biosynthetic pathway has been studied for many years. 
In 1907, Collie put forward a series of biosynthetic hypotheses, 6 based on the 
observation that many natural products contained within them the repetitious [CH2-CO]n 
unit. To verify these hypotheses he described experiments which showed that orsellinic 
acid (11) could be formed from two molecules of acetoacetic acid (12), via dehydroacetic 
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Scheme 1.2: The biosynthesis of orsellinic acid as proposed by Collie. 
These ideas were largely ignored, until 1953, when Birch proposed that the 
structures of many secondary metabolites could be correlated with the repeating [CH2- 
CO] units, that would result from a biogenesis via acetate.? Thus orsellinic acid (12) 
could be thought of as arising through the poly-ß-ketoacyl CoA derivative, derived by a 
linear combination of acetate units. This invoked a hypothesis involving retention of the 
ß-keto functions in the linear chain, resulting from sequential acetate-malonate 
condensations, as shown in Scheme 1.3. 
0 
00 Mc SR 
H. 
0H SR 00 Fatty acids 
M)SR M4d'J `SR 
Me SR - Polyketides 
n 
Scheme 1.3: Acetate-malonate condensations leading to fatty acids and polyketides. 
Birch provided the first experimental evidence to support his hypothesis, showing 
that 14C-acetate was incorporated into 6-MSA (6) in Penicillium griseofulvin, with the 
correct alternate labelling pattern, as outlined in Scheme 1.4.8 
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Scheme 1.4: The biosynthesis of 6-MSA. 
Further work showed that other metabolites were of polyketide origin, including 
griseofulvin (14) an antifungal isolated from Penicillium griseofulvin. 9 This was shown 
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Scheme 1.5: The biosynthesis of griseofulvin. 
Birch showed that many polyketide metabolites share a common biosynthetic 
origin through the folding of poly-(3-keto chains, derived from sequential acetate- 
malonate condensations. Hence, polyketide biosynthesis was found to be analogous to 
fatty acid biosynthesis, in terms of the starter unit acetate condensing with a malonate 
unit. 
To explain the structural diversity and various oxidation states exhibited by the 
polyketides, it is important to realise that the poly-ß-keto chains can undergo cyclisations, 
aromatisations, and reductive modifications in any order, starting from a different 
conformation. Consider a poly-ß-keto heptaketide, it may fold in many ways, thus giving 
rise to a whole range of metabolites. These products can exhibit different oxidation levels, 
e. g. griseofulvin and rubrofusarin (15). 
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Scheme 1.6: Modifications of poly-ß-keto heptaketide chains, 
giving griseofulvin and rubrofusarin. 
8 
Birch introduced the idea of the sequential condensation of acetate and malonate, 
prior to chain modifications, in order to explain the formation of many aromatic 
polyketides. The hypothesis was modified to accommodate the introduction of structural 
diversity, by the use of different chain starting or extending units. 10 For example, 
chalcone (16) and stilbene (17) biosyntheses were shown to originate from a trans 
-cinnamic acid starter unit (18), as shown in Scheme 1.7.11 
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Scheme 1.7: Cinnamic acid as a chain starter unit in chalcone 
and stilbene biosynthesis. 
Further work has shown that many non-aromatic natural products belong to the 
polyketide class. For example, the macrodiolide colletodiol (19), is a simple non-aromatic 
polyketide. Isotopic labelling studies by MacMillan and Lunnon, 12 and by Simpson and 
Stevenson, 13 accounted for the origins of all the carbons, oxygens, and hydrogens in 
colletodiol. These observations led to a proposed biosynthetic pathway to colletodiol, 
starting with an acetate and malonate condensation to give enzyme bound acetoacetate 
(20) (Scheme 1.8). Subsequent reduction, condensation, and reduction would produce 
the intermediate diol (21). Dehydration of the diol may occur to either give the C6 
hydroxy acid triketide (22) with a trans double bond, or following addition of another C2 
unit may afford the C8 hydroxy acid tetraketide (23). Coupling of a C6 hydroxy acid (22) 
and a C8 hydroxy acid (23) would lead to colletotriene (24), which on oxidation with 
atmospheric oxygen would lead to colletoepoxide (25). Hydrolytic ring opening of the 
epoxide with water from the medium leads to colletodiol. 
Intact incorporation of both deuterated colletotriene and deuterated colletoepoxide 
into colletodiol have confirmed the later stages of the proposed biosynthetic 
pathway. 14,15 
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Scheme 1.8: The proposed biosynthesis of colletodiol. 
Although, it was originally proposed that extended poly-ß-keto chains were 
formed, and then modified in later steps, 7 studies on compounds such as colletodiol led 
to the idea of a 'processive' mode of polyketide biosynthesis, in which the intermediates 
are reduced and modified during chain elongation, rather than afterwards. As a result, it is 
now accepted that there is substantial similarity between the assembly of polyketides by 
the polyketide synthases (PKSs), and the assembly of fatty acids by fatty acid synthases 
(FASs). 
The construction of fatty acids is accomplished within a multienzyme complex, 
known as fatty acid synthase (FAS). Fatty acid biosynthesis begins with the starter unit 
acetyl CoA (Scheme 1.9). Acetyl CoA is carboxylated to malonyl CoA, using acetyl CoA 
carboxylase, with retention of configuration (Scheme 1.9). 16,17 Acetyl CoA is then 
transfered to the active site of the thiol of the condensing enzyme, ketoacyl synthase 
(KS), whilst malonyl CoA is transferred to the acyl carrier protein (ACP) by malonyl 
transferase (MT). Condensation of enzyme bound acetate with enzyme bound malonate 
produces enzyme bound acetoacetate, with simultaneous loss of carbon dioxide, with 
inversion of configuration (Scheme 1.9). 16,17 
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Scheme 1.9: Carboxylation of acetyl CoA, showing retention of configuration, 
and condensation of acetate and malonate to produce enzyme bound acetoacetate, 
with inversion of configuration. 
Stereospecific reduction by ketoreductase (KR) produces the (3R)-(3-hydroxy 
intermediate, and syn elimination by dehydratase (DH) follows to give the a, ß- 
unsaturated intermediate. 18 Further reduction by enoyl reductase (ER) produces the fully 
saturated moiety, before further chain extension takes place. 
Polyketides are derived from highly functionalised carbon chains whose 
assemblies are controlled by multifunctional enzyme complexes, called polyketide 
synthases (PKSs). Like the FASs, PKSs catalyse a repetitious sequence of 
decarboxylative condensation reactions between acyl thioesters and malonate chain 
extender units. Each condensation is followed by a varying cycle of reductive 
modifications: ketoreduction, dehydration, and enoyl reduction. In contrast to fatty acid 
biosynthesis, where the full cycle of reductive modifications normally follows each 
condensation, the PKSs can use this sequence in a controlled fashion to assemble 
polyketides of great structural diversity, and of varying oxidation states. 
As shown in Scheme 1.9, the reduction sequence can be completely omitted, thus 
producing the classical polyketide, with a carbonyl group on every alternate carbon. 
However, reductive modifications can be used fully or partially after each condensation to 
yield highly functionalised intermediates. This is known as the processive mode of 
assembly of polyketides. 19 
It is important to note several differences between fatty acid and polyketide 
biosynthesis: 
(i) In fatty acid biosynthesis, the acyl thioesters normally involved in the 
condensations are acetyl CoA and malonyl CoA. However, PKSs can use 
a variety of chain starter units, including acetate, propionate, benzoate, 
cinnamate and some amino acids. 
(ii) Different extender units maybe employed in polyketide biosynthesis; 
including malonate, methylmalonate, and ethylmalonate. Branching 
methyl groups may also be introduced by S-adenosylmethionine. 
11 
(iü) PKSs can use all, some, or none of the post-condensation reductive 
modifications, thus producing a wide range of metabolites containing 
keto, ß-hydroxy, a, ß-unsaturated, or fully saturated units. Formation of 
a polyketide therefore involves condensation of acetate (or another starter 
unit) with the appropriate number of malonate units, modification of the 
poly-(3-ketoacyl CoA where required, and then the release of a stable form 
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Acyl transferase BCCP: Biotin carboxylate carrier 
Ketosynthase protein 
Ketoreductase ACP: Acyl carrier protein 
Dehydratase MT: Malonyl transferase 
Enoyl reductase CoA: Coenzyme A 




Scheme 1.11 shows the two possible routes for the biosynthesis of tylactone (26): 
the processive mode of assembly (Path (a)), and the classical polyketide route (Path (b)). 
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Scheme 1.11: Two possible routes for the biosynthesis of tylactone. 
To discriminate between the two pathways, Hutchinson fed isotopically labelled 
putative intermediates along the processive pathway to cultures of Streptomyces 
fradiae. 20 [2-13C]-(2R, 3R)-3-Hydroxy-2-methylpentanoic acid was fed as the free acid 
and the sodium salt, but led to random incorporation of carbon-13 into tylactone. 
However, when the N-acetylcysteamine thioester of [2-13C]-(2R, 3R)-3-hydroxy-2- 
methylpentanoic acid (27) was administered to cultures, and the isolated tylactone 
13 
analysed by 13C nmr spectroscopy, specific incorporation of the label into C-18 was 
observed, as predicted by the processive mode of assembly (Scheme 1.12) 20 The use of 
N-acetylcysteamine thioesters in feeding studies will be discussed in section 2.4. 
As predicted from the processive mode of assembly feeding the N- 
acetylcysteamine thioester of [4-13C]-(2E, 4R, 5R)-2,4-dimethyl-5-hydroxyhept-2-enoic 
acid (28) to cultures of Streptomyces fradiae gave specific incorporation of carbon-13 











Scheme 1.12: Incorporation of chain assembly intermediates into tylactone, 
produced by S. fradiae. 
Cane provided evidence that a processive mode of assembly was operating in the 
biosynthesis of erythromycin B. 21 The N-acetylcysteamine thioester of [2,3-13C2]-(2S 
, 3R)-3-hydroxy-2-methylpentanoic acid (29) was 
fed to Streptomyces erythreus, 
isolation of erythromycin B and analysis of its 13C nmr spectrum revealed specific 
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Scheme 1.13: Incorporation of chain assembly intermediates into 
erythromycin B, produced by S. erythreus. 
Subsequently, Cane reported further success with the intact incorporation of 
isotopically labelled putative intermediates to confirm a processive mode of assembly of 
14 
polyketides. In 1988, he reported the intact incorporation of the N-acetylcysteamine 
thioester of [2,3-13C2]-(2S, 3R)-3-hydroxy-2-methylpentanoic acid into nargenicin (30), 
in Nocardia agentinesis (Scheme 1.14), 22 and in 1995, the intact incorporation of the 











Scheme 1.14: Incorporation of the diketide and pentaketide 
into nargenicin, produced by N. agentinesis. 
Tetronasin (32), 24 an antibiotic produced by Streptomyces longisporoflavus, is of 
commercial interest as a growth accelerator in cattle, and as an antiparasitic agent 25,26 
Preliminary biosynthetic studies, using acetate and propionate precursors labelled with 
13C, 2H, and 180, have shown the carbon skeleton of tetronasin to be made up of seven 
acetate and six propionate units linked in a head to tail fashion, typical of a polyketide 
pathway. The O-methyl has been shown to be derived from S-adenosylmethionine, but 
the origin of the C2 unit of C-33, C-34 remains unclear. 27'28 
A biosynthetic pathway was proposed, in which the linear polyketide intermediate 
(33) is assembled by a PKS, via a sequence of enzyme bound intermediates (Scheme 
1.15). From acetyl CoA, twelve extension cycles with varying degrees of reduction are 
required to produce (33). It was suggested that if chain assembly was to follow a 
processive mode, in which, after each condensation, the required reductive modifications 
take place before the next condensation, the first three intermediates on the biosynthetic 
pathway would be (34), (35), and (36). 
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Scheme 1.15: A proposed biosynthetic pathway for tetronasin. 
In order to investigate this hypothesis, Staunton and coworkers prepared a range 
of deuterated isotopomers of the putative diketide (34), 29,30 triketide (35), 29-31 and 
tetraketide (36). 31-33 They reported the intact incorporation of the deuterated triketide (37) 
into C-27 of tetronasin on administration to Streptomyces Iongisporoflavus, thus 
supporting the hypothesis that the proposed triketide (35) was a biosynthetic intermediate, 
and therefore by implication, so was the diketide (34) (Scheme 1.16). 29 They later noted 
that the isotopically label from the deuterated tetraketide (38) was incorporated intact into 
C-27 of tetronasin. It was also shown that only the correct diastereoisomer (36) was 


























Scheme 1.16: Incorporation of chain elongation intermediates into tetronasin. 
A range of structural analogues of the diketide, triketide, and tetraketide were also 
synthesised, including fluorinated analogues, or methyl groups replaced by ethyl, iso- 
propyl, or benzyl moieties 30,32 Staunton and coworkers reported that the precursor 
analogues containing smaller groups, e. g. fluorine or ethyl, were incorporated intact 
giving the corresponding analogues of tetronasin. However, the analogues containing 
larger, unnatural groups, e. g. iso-propyl or benzyl, did not produce any structural 
analogues of tetronasin 34' 
In summary, the findings that diketide, triketide, tetraketide and pentaketide chain 
elongation intermediates, administered as their N-acetylcysteamine thioesters, can be 
incorporated intact has provided a powerful tool for probing the detailed sequence of the 
biosynthesis of many polyketide natural products. Other examples where this approach 
has been successfully used include the elucidation of the biosynthesis of the bacterial 
metabolite methymycin (39), 35 and the fungal metabolites aspyrone (40)36-40 and 
dehydrocurvularin (41) 41,42 
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1.4 Pseudomonic acid: Discovery 
The antagonistic effects of Pseudomonas fluorescens, a Gram negative 
bacterium43 upon various fungi, bacteria and yeasts were first noted in 1887 by Garre 44 
Later, Chain and coworkers published the antibiotic activity of cultures and extracts of 
Pseudomonas fluorescens. 45 In 1971, a metabolite was isolated from submerged 
fermentations of Pseudomonasfluorescens NCIB 10586, which was responsible for 
nearly all of the biological activity. 46 This metabolite was named pseudomonic acid A 
(42). 
Structural elucidation studies by Chain and Mellows47'48 revealed that 
pseudomonic acid (42) has an unusual carbon framework, based upon a vicinally 
dihydroxylated pyran ring The side chain attached to C-8 contains an epoxide at C-10,11, 
and an alcohol at C-13. The side chain attached to C-5 contains an 0c, ß unsaturated acid, 
which is condensed with 9-hydroxynonanoic acid, to give the ester. Further X-ray 
crystallography and nmr studies by Clayton and coworkers showed the absolute 
stereochemistry of pseudomonic acid A (42) to be as shown below. 49 
H 
17 H42' 
14 Me 765, 
'. "3\ IO 
86421. OH 
M 11 10 O me 
ýO 9ý 5' 30 
12 
O9 16 15 
OH 
(42) 
1.5 Pseudomonic acid: Other metabolites 
Following extensive purification of the crude antibiotic mixture, isolated from 
Pseudomonas fluorescens by Chain and coworkers in 1971,46 essentially all of the 
18 
antibacterial activity was found to be associated with a family of structurally related 
substances, the 'pseudomonic acids'. 
Pseudomonic acid A, which exhibits the strongest antibiotic activity, represents 
95% of the crude mixture, and was the first member of the family to be isolated, 46 and 
structurally characterised. 49 Further work with Pseudomonas f luorescens NCIB 10586 
has led to the discovery and isolation of four other members of the pseudomonic acid 
family: Pseudomonic acids B (43), 50 C (44), 51 D (45), 52 and E (46). 53 Structural 
elucidation studies have shown that pseudomonic acid B differs from pseudomonic acid 
A in that it contains a hydroxyl at C-8, whereas pseudomonic acid C differs in that it has a 
double bond in place of the epoxide functionality at C-10,11. Pseudomonic acids D and E 
differ from pseudomonic acid A in the nature of the side chain ester. In pseudomonic acid 
A there is a 9-hydroxynonanoic acid side chain, in pseudomonic acid D there is a 9- 
hydroxynon-4-enoic acid side chain, and in pseudomonic acid E there is a 10- 
hydroxydecanoic acid side chain. 
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Fig. 1.5: Other members of the pseudomonic acid family. 
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These minor metabolites have biological activities similar to or less than 
pseudomonic acid A. Throughout the remainder of this thesis pseudomonic acid will refer 
to the major metabolite pseudomonic acid A. 
Many other structurally related derivatives of pseudomonic acid have been isolated 
in recent years. Two novel pseudomonic acid derivatives (47) and (48) were isolated 
from an Alteromonas species bacterium, which is isolated from the marine sponge 
Darwinella rosacea. 54 In both metabolites, the 9-hydroxynonanoic acid side chain has 
been replaced by an 8-hydroxyoctanamide side chain. The derivative (48) also possesses 
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Thiomarinol (49) has been isolated from a marine bacterium Alteromonas reva sp. 
nov. SANK 73390, and found to have stronger inhibitory antimicrobial activity against 
Gram positive and Gram negative bacteria, as compared with pseudomonic acid. 55 
Structural elucidation of thiomarinol (49) revealed that it was a hybrid of two types of 
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This raises some interesting evolutionary questions concerning the biosynthesis of 
such hybrid metabolites, as well as answering the questions posed concerning its 
antimicrobial activity. 
1.6 Pseudomonic acid: Biological activity and mode of action 
Currently, pseudomonic acid is marketed under the generic name, mupirocin, as 
the active component (2% pseudomonic acid in a polyethylene glycol base) in the topical 
skin cream Bactroban. In vitro tests have shown that its activity is enhanced in an acid 
medium, being 2 to 4 times more active at pH 6 than at pH 7.4, and being even less active 
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at pH 8. The greater activity at acid pH reinforces the suitability of Bactroban for the use 
in the acid environment of the skin 56 
The biological activity of Bactroban was found to be restricted to the pH range 4 
to 9,46 but within these limits it has a wide spectrum of activity. It shows high levels of 
activity against not only the Gram-positive cocci most commonly associated with skin 
infections, i. e. staphylococci and streptococci species, 56 but also a variety of other 
potential pathogens, both Gram-positive and Gram-negative, aerobic and anaerobic. 56 
Another advantage of Bactroban is that, whilst being highly active against 
staphylococci and streptococci responsible for the majority of skin pathogens, it shows a 
relatively low level of activity against those members of the normal skin flora, the skin 
commensals, whose presence is considered to make a positive contribution to the 
prevention of infection to the individual, such as corynebacteria, micrococci and 
anaerobic propionibacteria. 56 
Following oral or intravenous administration, pseudomonic acid is rapidly 
converted to the inactive monic acid (50), which is eliminated primarily in the urine 57 It 
has been shown that subcutaneous administration to mammals resulted in rapid excretion, 
via hydrolysis, of mainly monic acid (3-glucoronide (51) (Scheme 1.17) 58 
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Scheme 1.17: Metabolism and excretion of pseudomonic acid. 
These observations indicate that any pseudomonic acid or monic acid, which 
reaches the systemic circulation should be quickly metabolised and excreted from the 
body. Whilst it is desirable that a topical antibiotic should not be absorbed systemically, it 
is also important that it should penetrate the superficial layers of the skin itself. 
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In summary, the pharmacological characteristics of pseudomonic acid A that make 
it particularly suitable for topical use include 
(i) it is stable and persistent on the skin, and does not disturb the skin 
commensals, 
(ii) it achieves good penetration of the superficial layers of the skin, but 
(iii) shows negligible systemic absorption, 
(iv) rapid systemic metabolism makes it unsuitable for systemic use. 
The mode of action of pseudomonic acid has been studied in Staphylococcus 
aureus and Escherichia coli, in which the primary effect was found to be inhibition of 
protein synthesis. Bactroban, therefore, has an unusual mode of action. It exerts its 
antibacterial activity by blocking protein synthesis within the bacterial cell 59 
Subsequent studies identified the enzyme isoleucyl t-RNA synthetase as a target 
of the antibiotic in the bacterial cell. 60 This enzyme catalyses the formation of isoleucyl t- 
RNA, from t-RNA and isoleucine (52), which serves to transport isoleucine to the 
ribosome for the insertion into the growing protein chain. The action of Bactroban was 
shown later by Hughes and Mellows60 to be the result of pseudomonic acid acting as a 
competitive inhibitor of the enzyme isoleucyl t-RNA synthetase, by competing with 
isoleucine for the enzyme binding sites. This will therefore halt protein synthesis within 
the bacterial cell. 
It has been suggested that the active part of pseudomonic acid is the terminus of 
the C-8 side chain, which has a similar carbon skeleton as isoleucine, and so may 
compete with isoleucine for the single isoleucine binding site on the enzyme, 60 but has a 













Fig. 1.6: Structural similarity of pseudomonic acid and isoleucine. 
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As a result, at low concentration, pseudomonic acid slows down bacterial protein 
synthesis, and produces bacteriostasis. 58 However, at high concentrations, as are 
achieved with Bactroban therapy, it blocks protein synthesis with bacteriocidal results 61 
As already mentioned, the biological activity is only observed between the pH 
limits of 4 and 9. This results from the instability of pseudomonic acid to strong base and 
acid. 62 At low pH, rapid rearrangement occurs, leading to a 1.6: 1 ratio of the isomeric 
compounds (53) and (54) (Scheme 1.18). Under strongly alkaline conditions, a slower 
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Scheme 1.18: Acid and base rearrangement of pseudomonic acid. 
The fact that it is the C-8 side chain that is disrupted on addition of acid or base, 
supports the hypothesis that it is this part of pseudomonic acid that is responsible for the 
observed biological activity. However, Klein and coworkers, 63 and Yanagisawa and 
coworkers64 noted that the remaining structure of pseudomonic acid differs greatly from 
isoleucine, but it is indispensable for the inhibition of isoleucyl t-RNA synthetase by 
pseudomonic acid. This suggested that, in addition to the putative isoleucine binding site 
on isoleucyl t-RNA synthetase, an additional site must participate in binding the 
remainder of the pseudomonic acid. It was concluded that pseudomonic acid is an 
inhibitor of isoleucyl t-RNA synthetase, possessing characteristic features of both an 
isoleucine analogue, and an ATP analogue, e. g. isoleucyl adenylate. 64 
23 
1.7 Pseudomonic acid: Biosynthetic studies 
The nmr techniques described in section 1.2 were used in the initial investigations 
into the biosynthetic origins of the pseudomonic acids. 65 These studies involved feeding 
variously isotopically labelled acetates, propionates, and [methyl-13C]-L-methionine to 
Pseudomonas fluorescens, and determination of the resultant labelling pattern in 
pseudomonic acid (Fig. 1.7). 
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Fig. 1.7: Isotope labelling pattern in pseudomonic acid from 
feeding labelled precursors to Pseudomonasfluorescens. 
The incorporation of acetate units in a 'head to tail' manner along much of the 
carbon framework appeared to be consistent with a polyketide/ fatty acid biogenesis. 
However, there were notable inconsistencies. 
Firstly, whilst C-16 and C-17 were found to be labelled from methionine, thus 
indicating methylation, via S-adenosylmethionine, the branched C-15 methyl group was 
found to originate from the C-2 of a cleaved acetate unit. When this incorporation of a 
cleaved acetate unit was first discovered, it was unique to pseudomonic acid biosynthesis. 
However, similar results have been reported more recently for the biosynthesis of 
virginamycin Mi (55), 66 myxopyronin A (56) and B (57), 67 aurantin A (58) and B 
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This unusual labelling pattern may rationalised by invoking an aldol condensation 
of acetyl CoA onto a preformed polyketide chain, followed by thioester hydrolysis, 
decarboxylative dehydration and alkene isomerisation, as shown in Scheme 1.19 66,70 
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Scheme 1.19: Mechanism for the introduction of a cleaved acetate unit onto a 
polyketide chain. 
The origin of the 9-hydroxynonanoic acid side chain was unusual. Intact acetate 
units were incorporated in the expected 'head to tail' manner at C-1'/C-2', C-3'/C-4', and 
C-57C-6'. However, C-87C-9', although also shown to be derived from acetate, it was 
apparent that the direction of acetate incorporation was opposite to the rest of the 9- 
hydroxynonanoic acid moiety, with C-T acting as the pivotal point for this reversal. The 
carboxyl of an acetate unit was found to specifically label C-T, but the enrichment was 
only 50% that of the other carbons. 
[1-13C]Propionate was fed to Pseudomonas fluorescens, giving pseudomonic 
acid, which was found specifically labelled the C-7' position. However, on feeding [3- 
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13C]propionate, a labelling pattern identical to that of [2-13C]acetate was obtained, 
indicating incorporation of propionate through to acetyl CoA, via cc-oxidation to pyruvate 
(61) (Scheme 1.20). 65 
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Scheme 1.20: a-oxidation of propionate to acetyl CoA, via pyruvate. 
The fact that both C-1 and C-9' were derived from C-1 of acetate, implied that the 
ester functionality did not arise from a Baeyer-Villager type oxidation. To confirm that the 
bonding oxygen of the ester moiety was acetate in origin, [1-13C, 1802]acetate was fed to 
Pseudomonas fluorescens. 71 Examination of the 13C nmr spectrum of isolated 
pseudomonic acid confirmed that the (C-9')-O bond and the (C-1)-O bond are both 
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Scheme 1.21: Results of feeding [ 1- 13C, I 802]acetate to Pseudomonas fluorescens . 
From this feeding study, it was shown that the oxygen at C-5 was derived from 
acetate. Simpson and Martin71,72 proposed a mechanism for the formation of the 




Scheme 1.22: Proposed mechanism for the tetrahydropyran ring formation. 
This proposal is in accord with the results from feeding studies with [1-13C, 2H3] 
acetate to Pseudomonas fluorescens (Scheme 1.23). 71,72 The lack of a ß-shift on the 
signal assigned to C-7 in the 13C nmr spectrum of pseudomonic acid indicated the 
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Scheme 1.23: Results of feeding [1-13C, 2H3]acetate to Pseudomonas fluorescens . 
Mellows and coworkers65 accounted for these anomalies by proposing a cascade 
pathway, involving ß-hydroxy-ß-methylglutarate (62), as shown in Scheme 1.24. 
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Scheme 1.24: Cascade hypothesis. 
This theory also gave an explanation for C-15 being derived from a C-2 cleaved 
acetate unit. Hence, a polyketide derived C12 unit (63) then undergoes nucleophilic attack 
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from a C5 unit (64), originating from (3-hydroxy-(3-methylglutarate. The resultant C17 
thioester (65) was postulated to undergo nucleophilic attack from a C9 moiety (66), also 
derived from ß-hydroxy-ß-methylglutarate followed by a fatty acid type chain elongation. 
Enzyme-bound pseudomonic acid (67) would be released to produce pseudomonic acid. 
To explain the labelling pattern observed at C-7', competition between ß- 
hydroxy-ß-methylglutarate and (3-hydroxy-ß-ethylglutarate (68) was proposed, based on 
evidence of incorporation of homomevalonate into juvenile hormone JH II 73 No 
experimental results were given to support this theory. 
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Scheme 1.25: ß-Hydroxy-ß-ethylglutarate as a precursor to the C9 moiety. 
This hypothesis was readdressed in 1988, when Mantle and Somner reported 
high incorporation of radiolabelled ß-hydroxy-ß-methylglutarate into pseudomonic 
acid. 74 This was interpreted as strong evidence for the cascade hypothesis, despite the 
lack of degradative studies to establish the position of the incorporated radio-label. 
Further work, by Simpson and Martin, using 13C and 13C2 labelled ß-hydroxy-p- 
methylglutarate, indeed confirmed that carbon-13 was incorporated into pseudomonic 
acid. However, in both cases, it was shown that the labels incorporated throughout the 
molecule, with no evidence of specific incorporation. 71'72 This implied that ß-hydroxy- 
ß-methylglutarate had been degraded to acetate by ß-oxidation, prior to incorporation into 
pseudomonic acid. Further work by Mantle and MacGeorge confirmed these fmdings75 
After these findings, a simpler hypothesis involving two distinct precursors, 
monic acid and 9-hydroxynonanoic acid (69), was postulated (Scheme 1.26). 
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Scheme 1.26: Postulated biosynthesis of pseudomonic acid 
via monic acid and 9-hydroxynonanoic acid. 
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Preliminary investigations into this hypothesis were carried out by Mantle and 
MacGeorge. 76 They obtained [16,17-14C2]monic acid, via feeding radiolabelled 
methionine to bacterial cultures, and subsequent saponification of the resultant 
radiolabelled methyl pseudomonate. However, on feeding [16,17-14C2]monic acid to 
cultures of Pseudomonasfluorescens, it was found that all of the radioactivity remained 
in the medium and did not cross cell walls. Therefore this hypothesis still needs to be 
proven. 
From the results of feeding studies isotopically labelled precursors to 
Pseudomonas fluorescens, it has been established that the monic acid moiety of 
pseudomonic acid is derived from a series of acetate units in a 'head to tail' fashion. It has 
been suggested that monic acid is therefore polyketide in origin, and a proposed 
biosynthetic pathway is outlined in Scheme 1.27. 
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Scheme 1.27: Postulated processive mode of assembly of monic acid. 
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The initial acetate and malonate condensation produces enzyme bound acetoacetate 
(20), which undergoes methylation. Reduction of the 0-keto function gives the (2S, 3S)- 
3-hydroxy-2-methylbutanoate enzyme bound moiety (70), which on furtther condensation 
with malonate produces a hexanoyl moiety. A further reduction, and subsequent 
dehydration leads to the (2E, 4S, 5S)-5-hydroxy-4-methylhex-2-enoate enzyme bound 
intermediate (71). Further malonate condensations, together with the required reductive 
modifications, all being controlled by PKS enzymes, lead eventually to the putative 
heptaketide (72), prior to post-PKS translation to enzyme bound monic acid (65). 
1.8 Aims 
The overall aim of this project was to further investigate the biosynthetic pathway 
to pseudomonic acid, with particular emphasis on the assembly of the unusual 9- 
hydroxynonanoic acid fragment and its coupling with monic acid. 
The approach required: 
1) that an efficient, consistent production of pseudomonic acid by Pseudomonas 
fluorescens NCIB 10586 was established. Martin7l and Sugden77 had both previously 
reported problems with inconsistent production of pseudomonic acid. The optimum time 
for feeding isotopically labelled substrates to Pseudomonas fluorescens for maximum 
incorporation into pseudomonic acid needed to be determined. 
2) the synthesis of a series of isotopically labelled free acids and NAC thioesters 
of 9-hydroxynonanoic acid, and to carry out feeding studies with cultures of 
Pseudomonasfluorescens. 
3) the preparation of isotopically labelled NAC thioesters of monic acid and its 




Synthetic routes to the proposed intermediates 
2.1 Introduction 
As discussed in chapter 1, previous biosynthetic studies have led to a hypothesis 
invoking the condensation of 9-hydroxynonanoic acid (69) and monic acid (50) to give 
pseudomonic acid (42). The work described in this chapter is focused on developing 
synthetic routes to a number of putative biosynthetic precursors to pseudomonic acid, 
required for feeding studies to test this hypothesis. 
In terms of the biosynthesis of pseudomonic acid, these precursors fall into two 
distinct categories: 
(i) those intermediates that may help to explain the origins of 
9-hydroxynonanoic acid and, 
(ii) those intermediates required to elucidate the biosynthetic pathway to 
monic acid. 
2.2 The value of N-acetylcysteamine thioesters in 
biosynthetic studies on fatty acids and polyketides 
The use of N-acetylcysteamine thioesters (NAC thioesters) in biosynthetic studies 
was first demonstrated with studies on fatty acid biosynthesis 78,79 It was suggested that 
the NAC thioester, obtained from N-acetylcysteamine (73), aids the transfer of the 
precursor onto the polyketide synthase (PKS) by mimicking the phosphopantotheine side 
chain of coenzyme A (75), and of the acyl carrier protein (ACP) component (74) of the 
PKS, which mediate the process in vivo (Fig. 2.1). 
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Fig. 2.1: Structural similarities between N-acetylcytsteamine (NAC) (73), the ACP 
component of the PKS (74), and coenzyme A (75). 
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It has been demonstrated in many biosynthetic studies, such as those involving 
erythromycin B (7), 80 tylactone (26), 20 and aspyrone (40)37 that feeding precursors in 
the form of the free acids leads to complete degradation before incorporation. Whereas 
when the precursors were administered as their N-acetylcysteamine thioesters (NAC 
thioesters), intact incorporation was observed. 
Simpson and coworkers81 recently reported that the intact incorporation of double 
deuterium labelled hexanoic acid into norsolorinic acid (76) is almost negligible. Whereas 
when administered as its NAC thioester (77), it was almost all incorporated intact, at a 
level of enrichment of 40%. Deuterium labelled ethyl hexanoate gave a lower level of 
enrichment, with a significant degree of incorporation via degradation. 
In the same paper the substrate specificity of the PKS, norsolorinic acid synthase 
(NSAS), was investigated by feeding deuterium labelled NAC thioesters of butyric acid, 
pentanoic acid, heptanoic acid, and octanoic acid to cultures of Aspergillus parasiticus. 
No incorporation of the deuterium label from butyrate, heptanoate, and octanoate was 
observed, whereas incorporation of the NAC thioester of the deuterium labelled pentanoic 
acid (78), was essentially identical to that observed with the hexanoate thioester, giving 
the corresponding analogue (79) of norsolorinic acid. Also, 6-fluorohexanoate (80) was 
synthesised and fed to cultures of Aspergillus parasiticus. Intact incorporation at a level of 
36% was observed and a new metabolite (81) isolated. However, on feeding the 
corresponding 2-fluorohexanoate, there was no evidence of incorporation, and the 
analogue (82) of norsolorinic acid was not detected. This was possibly due to 
degradation, via ß-oxidation, of 2-fluorohexanoate to the highly toxic 2-fluoroacetate, or 
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Scheme 2.1: Incorporation of labelled starter units into 
norsolorinic acid (76), and their structural analogues. 
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In addition, Westaway has shown that administering [1-13C]benzoic acid and 
fluorinated benzoates as their NAC thioesters to the squalestatin producer Phoma sp. 
gives a greater level of incorporation compared to the free acid. 82 
In order to synthesise the NAC thioester from the free carboxylic acid, a 
condensation reaction between the free acid and N-acetylcysteamine (HSNAC) (73) must 
take place. The reaction is mediated by dicyclohexylcarbodiimide (DCC) (83), and is 












Scheme 2.2: Synthesis of NAC thioesters. 
The postulated mechanism for a DCC/DMAP mediated thioesterification is shown 
below in Scheme 2.3.84,85 The thioesterification is driven by the production of reactive 
N-acylpyridinium salts (85) and the formation of dicyclohexylurea (DCU) (86), which 
precipitates out of solution. After initial activation of the free acids by DCC, an 
equilibrium is set up between the activated carboxylic acid and the N-acylpyridinium salt. 































Removal of the precipitated DCU (86) is achieved by filtration through Celite, 
followed by flash column chromatography. It is often difficult to remove the last traces of 
DCU from the thioester, and this problem may be avoided by using 1-(3- 
dimethylaminopropyl)-3-ethylcarbodiimide (EDC) (88) rather than DCC. The 




N-acetylcysteamine may be prepared in high yield from readily available starting 
materials. 86 Acetylation of 2-mercaptoethylamine hydrochloride (89) gives N, S- 
diacetylcysteamine (90) in quantitative yield. Base hydrolysis of N, S-diacetylcysteamine 








Scheme 2.4: Synthesis of N-acetylcysteamine. 
For the majority of this work described in this chapter, the synthetic targets were 
the NAC thioesters of the corresponding free acids. 
2.3 Investigation of the 9-hydroxynonanoic acid moiety 
2.3.1 The biosynthesis of long chain hydroxy acids 
9-Hydroxynonanoic acid is a biosynthetically unique precursor. Reviewing the 
literature reveals a shortage of long chain dialkanoic acids involved in the biosynthesis of 
natural products. However, pimelic acid (91), or heptanedioic acid, has been found to be 
involved in biotin biosynthesis. Intact incorporation of [1-14C]pimelic acid into 
dethiobiotin (92) and biotin (93) has led to pimeloyl CoA (94) being the earliest known 




The biosynthesis of biotin from pimeloyl CoA has been shown by Eisenberg, 87 
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and Izumi and Ogata, 88 to proceed via the following intermediates, 7-oxo-8-amino- 
pelargonate (95), 7,8-diamino-pelargonate (96), and dethiobiotin (Scheme 2.5). 
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Scheme 2.5: Biosynthesis of biotin from pimeloyl CoA. 
Lezius and coworkers89 proposed that pimeloyl CoA is formed from the 
condensation of three molecules of malonyl CoA, on the basis of isotopic studies using 
Achromobacter grown in the presence of 14CO2 with isovaleric acid as the main carbon 
source. These condensations of malonyl CoA can be explained as equivalent to normal 
fatty acid biosynthesis, but with a malonate starter unit. However, Ifuka and 
coworkers, 90 have shown that L-[3-13C]alanine labelled the carbons of dethiobiotin in the 
same positions as that of D-[3-13C]glucose. They inferred that alanine can be used as an 
alternative carbon source, and suggested that acetyl CoA (4) is a possible precursor for 
pimeloyl CoA. They also suggested that pimeloyl CoA may be biosynthesised from acetyl 
CoA, via methylation of caproyl CoA, which is derived from the normal fatty acid 
pathway. 
This work did not further clarify the biosynthetic pathway of fatty acids with an 
odd number of carbon atoms in the chain. They concluded that pimeloyl CoA may be 
biosynthesised via the odd-numbered chain fatty acid metabolic pathway from propionyl 
CoA, or by co-oxidation of odd-numbered chain fatty acid derived from the normal even- 
numbered chain fatty acid metabolic pathway. 
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2.3.2 Investigation of the starter units to 9-hydroxynonanoic acid 
9-Hydroxynonanoic acid may be formed by 'normal' fatty acid type chain 
elongation of a C-3 starter unit, the origins of which are obscure. It was therefore 
necessary to develop synthetic routes to a number of possible C-3 starter units to 9- 
hydroxynonanoic acid. These include disodium malonate (97), 3-hydroxypropionic acid 
(98), and the NAC thioester (99) of 3-hydroxypropionic acid, in isotopically labelled 
form. 
ýO2Na 00H 
CO2Na Ha- v 'OH HO"v `SyMe 
(97) (98) (99) 
0 
To investigate the role of malonate in pseudomonic acid biosynthesis, the 
synthesis of disodium malonate, via the route outlined in Scheme 2.6 was developed. 
Before proceeding with labelled material, the synthesis of disodium malonate was carried 
out on unlabelled material. 
(EtO)3P0 LIHMDS <O2Et O2Et NaOH ý02Na 
McCOZNa ' McCO2Et "CICO2Et 
CO2Na 
(100) (101) (102) (97) 
Scheme 2.6: Synthesis of disodium malonate. 
Based on a procedure reported by Ropp91 in 1950, sodium acetate (100) was 
converted to ethyl acetate (101) in 70% yield, by heating under reflux with triethyl 
phosphate, and distillation into a liquid nitrogen trap. The lithium enolate was formed and 
reacted with ethyl chloroformate to produce diethyl malonate (102) in 57% yield. 
Saponification with sodium hydroxide of (102) gave disodium malonate (97) in 92% 
yield. The synthesis was then repeated, using sodium [ 1,2-13C2] acetate (103) as the 
source of isotopic labels giving disodium [1,2-13C2]malonate (104), via ethyl [1,2- 
13C2]acetate (105) and diethyl [1,2-13C2]malonate (106) with similar yields to those for 
unlabelled material. 
It is possible that 3-hydroxypropionic acid may be a starter unit, to 9- 
hydroxynonanoic acid, and that three fatty acid type chain elongations would produce the 
required C-9 moiety. Due to increased sensitivity in using a double 13C2 label, as 
explained in section 1.2, a synthetic'route to sodium [1,2-13C2]-3-hydroxypropionate 
was designed. Preliminary investigations have been carried out into the possible synthesis 
of sodium [1,2-13C2]-3-hydroxypropionate, using the procedure of Fujisawa and 
92 coworkers, who reported the chemoselective reduction of a range of carboxylic acids 
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into alcohols, using N, N-dimethylchloromethyleniminium chloride and sodium 
borohydride. This is readily available from N, N-dimethylformamide and oxalyl chloride. 
Of particular interest was that they reported the chemoselective reduction of 6- 
bromohexanoic acid to 6-bromo-1-hexanol in 93%, and cyanohexanoic acid to 
cyanohexan-l-ol in 89%, as shown in Scheme 2.7. 
C1->=Q, Me 













Scheme 2.7: Chemoselective reduction of aliphatic carboxylic acids. 
[2-13C]Bromoacetic acid and [1-13C]sodium cyanide are both commercially 
available, and were proposed as starting materials to [1,2-13C2]-3-hydroxypropionate 
(Scheme 2.8). Bromoacetic acid (107) was converted into cyanoacetic acid (108) by 
reaction with sodium cyanide in 82% yield, using the procedure of Lapworth and 
Baker. 93 The IH nmr spectrum was identical to that of an authentic sample. 












HO' v 'ONa HO" ""v 
(109) 
Scheme 2.8: Proposed synthesis of sodium 3-hydroxypropionate. 
The chemoselective reduction of cyanoacetic acid was then attempted. The paper 
recommended the use of more than 2 equivalents of sodium borohydride to reduce 
aliphatic carboxylic acids. However, none of the conditions listed in Table 2.1 gave any 
of the required 3-hydroxypropionitrile (109). 
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Reaction Amount of Amount of Amount of Temp. on Production 
Number oxalyl cyano- NaBH4 addition of of the 
chloride acetic acid NaBH4 hydroxynit 
rile (109) 
1 3e. le. 5e. -300C No 
2 3e. 1e. 2e. -780C No 
3 3e. 1e. 2e. -30°C No 
Table 2.1: Conditions used for the attempted chemoselective 
reduction of cyanoacetic acid 
As an alternative, the route shown in Scheme 2.9 was proposed to synthesise 
isotopically labelled 3-hydroxypropionic acid, using readily available 2-bromoethanol 
(110) and potassium [1-13C]cyanide, as the source of label introduction. 
^ý HOýýBr 
KCN 




^ý H0 v 'OH 
(98) 
Scheme 2.9: Proposed synthesis of 3-hydroxypropionic acid (98). 
A literature search showed that although the first step proceeded well under 
temperature controlled conditions, 94 the hydrolysis of the nitrile to 3-hydroxypropionic 
acid was low yielding. 95 This was indeed found to be the case. Reaction of 2- 
bromoethanol with potassium cyanide gave 3-hydroxypropionitrile (109) in 81 % yield. 
The 1H nmr spectrum was identical to that of an authentic sample. Base hydrolysis of the 
nitrile led to isolation of 3-hydroxypropionic acid in only 13% yield, probably due to 3- 
hydroxypropionic acid being very water soluble. 
To overcome this problem of water solubility, 3-hydroxypropionitrile was 
protected as its THP ether (111), using dihydropyran and a catalytic amount of pTSA, in 
72% yield. Attempted base hydrolysis of the protected nitrile gave a 1H nmr spectrum, 
indicating a complex mixture of products, no signals of which corresponded to the 
required THP protected 3-hydroxypropionic acid (112) (Scheme 2.10). 
DBP NaOH O 






Scheme 2.10: Attempted synthesis of the THP protected 3-hydroxypropionic acid. 
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The problem was finally overcome by synthesising the sodium salt (113) of 3- 
hydroxypropionic acid (Scheme 2.11) 96,97 
0 
Br RCN y^ 
ýN NaOH 
HO^ý Hý vH ONa 
(110) (109) (113) 
Scheme 2.11: Synthesis of sodium 3-hydroxypropionate. 
3-Hydroxypropionitdle was prepared as before, and was hydrolysed with sodium 
hydroxide. Upon completion, the mixture was not acidified, and the aqueous extracts 
were freeze-dried to yield sodium 3-hydroxypropionate, as a crystalline solid in 95% 
yield. 
As already discussed in section 2.2, the use of feeding putative labelled 
precursors as their NAC thioesters has been used to great effect to provide information on 
the biosynthetic pathways of a large number of polyketides. A synthesis of the NAC 
thioester of 3-hydroxypropionic acid (99) was therefore required. 
The first attempt involved designing a route, suitable for a singly labelled version. 














(109) (98) (99) 
Scheme 2.12: Synthesis of the NAC thioester of 3-hydroxypropionic acid. 
As discussed above, formation of 3-hydroxypropionic acid, via base hydrolysis 
of 3-hydroxypropionitrile, was achieved in only 13% yield 95,98 The NAC thioester of 3- 
hydroxypropionic acid was prepared in 32% yield, using DCC/DMAP mediated 
coupling. Although the target product had been prepared, the overall yield of 
approximately 4% yield over the final 2 steps was unacceptable for the synthesis of the 
NAC thioester of [1-13C]-3-hydroxypropionic acid to be carried out. Other possible 
routes were therefore investigated. 
(4S)-[1,2-13C2]-3-Acetyl-4-(1-methylethyl)-2-oxazolidinone (114) had been 
prepared previously from sodium [1,2-13C2]acetate, via the mixed anhydride of 


















Scheme 2.13: Synthesis of (4S)-[1,2-13C2]-3-acetyl- 
4-(1-methylethyl)-2-oxazolidinone. 
The N-acetyloxazolidinone (116) has proved to be a valuable intermediate in the 
synthesis of a range of isotopically labelled precursors to polyketides, e. g. the NAC 
thioester of [1,2-13C2]-(2R)-benzyl propionic acid (117) (Scheme 2.14). 82 
O 
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Scheme 2.14: Synthesis of the NAC thioester of (2R)-benzyl propionic acid. 
Westaway82 has also shown that by forming the dianion of N-acetylcysteamine 
with 2 equivalents of sodium hydride, it is possible to directly displace the chiral auxiliary 







NaH (4eq. ) 
PhSNAC 
PhCOCI Me NAC (2eq. ), 
THF, OTC 
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Me me 
Scheme 2.15: Synthesis of the ß-keto NAC thioester via direct displacement of the 
chiral auxiliary. 
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Although, we are not introducing any stereocentres in the NAC thioester of 3- 
hydroxypropionic acid (99), an oxazolidinone would be a useful handle, not only to 
reduce the volatility of these small molecules, but also to reduce their water solubility. 
The 2-oxazolidinone can readily be removed, and recovered for reuse. By directly 
displacing the 2-oxazolidinone with N-acetylcysteamine, formation of the free acid is 
avoided. In order to utilise the direct displacement reaction, in the synthesis of the NAC 
thioester of [1,2-13C2]-3-hydroxypropionic acid, our intermediate target was the 3- 
hydroxypropionyl-4-(1-methylethyl)-2-oxazolidinone (119) 
In 1985, Gutman and Ribon99 reported the formation of sodium [1,2-13C2]-3- 
hydroxypropionate (120), starting from sodium [1,2-13C2]acetate (103) (Scheme 2.16). 
The key step was the reaction of ethyl acetate with gaseous formaldehyde, formed by 
heating the paraformaldehyde trimer, and passing the gas in a steady stream of nitrogen. 
"" (EtO)3PO "" LIHMDS "" NaOH "" MeCO2Na -- McCO2Et -" HOCH2CH2CO2Et - HOCH2CH2CO2Nt 
(103) (105) 
HCHOW 
"= 13C (120) 
Scheme 2.16: Synthesis of sodium [1,2-13C2]-3-hydroxypropionate 
An analogous procedure was used in the hydroxymethylation of the 
acetyloxazolidinone (116) (Scheme 2.17). 
BuLI, THF 0 
K2C03 
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(123) NaHMDS, HMPA, 
HCHO, -78°C 
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(99) Me (119) itJ 
Scheme 2.17: Proposed synthesis of the NAC thioester of 3-hydroxypropionic acid. 
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This approach also allows the introduction of a double 13C2 label at the N- 
acylation stage. The oxazolidinone (122) was prepared by heating to reflux (RS)-valinol 
(121) and diethyl carbonate in 66% yield. 100 N-acylation of the auxiliary gave 3-acetyl-4- 
(1-methylethyl)-2-oxazolidonone (116) in 84% yield, via the sodium enolate. 
Hydroxymethylation of the sodium enolate of the N-acetyl oxazolidonone was 
examined using two different methods to generate formaldehyde. 
Method 1 
By heating flask 1 (Fig. 2.2) to 150 'C the paraformaldehyde trimer was monomerised 
and an excess of formaldehyde gas transferred into flask 2 (by pressure, via a length of 
PTFE tubing) to saturate the preformed sodium enolate of the N-acetyl oxazolidinone. 
The reaction mixture was allowed to stir at -78 'C for three hours after which work up 





Fig. 2.2: Apparatus used for attempted formylation of the N-acetyloxazolidnone. 
The 1H nmr spectrum revealed that the desired product, 3-hydroxypropionyl-4- 
(1-methylethyl)-2-oxazolidinone (119) had not been formed, but that 3-hydroxymethyl-4- 
(1-methylethyl)-2-oxazolidinone (124) had been obtained in 83% yield. There was some 
evidence by TLC for the return of some oxazolidinone (122). 
O 








Flask 1 FLsk 2 
signals from 6 2.40,4,24, and 4.43 to 6 2.15,4.01, and 2.28 respectively, due to the 
loss of the electron withdrawing (deshielding) effect of the N-acetyl group. In addition 
the singlet at 6 2.54, assigned to CH3CO, had disappeared, but two doublets at 6 4.68 
and 4.95 (each showing coupling of J 11.6Hz) were apparent, and assigned to the 
hydroxymethyl group. The mass spectrum showed the expected molecular ion of 159. 
The formation of (124) may be rationalised by the decomposition of the sodium enolate 
(125) to give the anion of the oxazolidinone (126), which was subsequently reacted with 






















Scheme 2.18: Proposed mechanism for the formation of (124). 
It is known that as the 2-oxazolidinone is a good leaving group, and that the 
enolate can decompose via a ketene pathway (Scheme 2.18). 101 Similar observations 
have been reported by Westaway, 82 who obtained the benzyl oxazolidinone (127) on 
reaction of N-propionyloxazolidinone (128) with benzyl bromide, as shown in Scheme 
2.19. 
O0OO00 
ý/`Ný WA JýO-- QN PhCH2Br Ph' N10 
ýP v ýP v Me-( Me-( Me_I Me--c 
IMe 
Mle Me +O Me 
(128) (127) 
Scheme 2.19: Reaction of N-propionyl oxazolidinone with benzyl bromide. 
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Evans101 reported that lithium enolates decompose at temperatures above 0 'C, 
but Westaway observed decomposition above -60 C. Although the reaction mixture in 
method 1 was maintained at -78 'C, it was thought that the formaldehyde gas introduced 
into the reaction flask 2 via the PTFE tubing could possibly have created pockets of 
higher temperature. Thus method 2 was attempted to maintain consistently low 
temperatures of -78 'C while adding the formaldehyde to the reaction mixture. 
Method 2 
The apparatus shown in Figure 2.3 was designed for effective transfer of formaldehyde 
to the pre-formed anion at -78 C. A saturated solution of formaldehyde in THE was 
prepared by heating anhydrous paraformaldehyde to 150 'C, and the formaldehyde gas 
produced was transferred via a length of PTFE tubing into a flask containing anhydrous 
THF. The saturated solution was then transferred to flask 1, as shown in Fig. 2.4, which 
was then added to the preformed anion of the N-acetyl oxazolidinone in flask 2 by 
carefully tipping the apparatus, while at -78 C. This method ensured the temperature of 




Fig. 2.3: Apparatus for transfer of a saturated THE with formaldehyde 
to the anion at -78 T. 
However, again 3-hydroxymethyl-(1-methylethyl)-2-oxazolidinone (124) was the 
sole product isolated from the reaction mixture. Miller, in our laboratories, experienced 
similar difficulties in synthesising (4S)-3-hydroxypropionyl-4-(1-methylethyl)-2- 
oxazolidinone (119), using these routes. 102 However, she obtained (4S)-3-acetoxy-4-(1- 
methylethyl)-2-oxazolidinone (129) as the sole product from the reaction. Esters may 
therefore be formed (Scheme 2.20). 
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Scheme 2.20: Proposed mechanism for the formation of (129). 
Recently, Watts103 has reported the successful hydroxymethylation, by reacting the 
titanium enolate of the N-acetylyloxazolidinone (116) with trioxane, in the presence of 
titanium tetrachloride (TiC14) (Scheme 2.21). 104 
O0 (a) TiC14, iPr2EtN, 





(116) Me \117) 
Scheme 2.21: Synthesis of 3-hydroxypropionyl-4-(1-methylethyl)-2-oxazolidinone. 
On purification by column chromatography, the alcohol (119) decomposed. 
However, acetylation of (119) under standard conditions gave the acetate (130), which 
was stable to chromatography. 
Work towards the direct displacement of the chiral auxiliary, using a derivative of 
(119) with a protected alcohol, by N-acetylcysteamine to give the NAC thioester of 3- 
hydroxypropionic acid is currently being examined by Watts. 
2.3.3 Synthesis of isotopically labelled 9-hydroxynonanoic acid 
Sugden77 has prepared [1-13C]-9-hydroxynonanoic acid (131), as shown in 
Scheme 2.22. 
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Scheme 2.22 Synthesis of [1-13C]-9-hydroxynonanoic acid. 
On addition of [1-13C]-9-hydroxynonanoic acid to Pseudomonas fluorescens 
NCIB 10586, following isolation of the pseudomonic acid, he found that the label had 
been efficiently incorporated into pseudomonic acid, but that it was incorporated non- 
specifically. Degradation to acetate, through (3-oxidation, had occurred prior to 
incorporation into pseudomonic acid. 77 The process of (3-oxidation is outlined in Scheme 
2.23. 
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Scheme 2.23: ß-Oxidation of 9-hydroxynonanoic acid. 
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A number of inhibitors to fatty acid catabolic enzymes have been developed, of 
which one of the most effective is tetradecyithiopropionic acid (134). 105 
CH3(CH2)13SCH2CH2CO21 
(134) 
On feeding [1-13C]-9-hydroxynonanoic acid along with tetradecylthiopropionic 
acid to Pseudomonas fluorescens, Sugden again found efficient non-specific 
incorporation of isotopic label. 77 Due to the result of competitive catabolism ß-oxidation, 
no firm conclusions could be made from these series of experiments. 
It has previously been shown that feeding NAC thioesters, rather than the free 
acid, overcomes the problem associated with intact incorporation (see section 2.2). 
Therefore, our target molecules were the NAC thioesters of [1,2-13C2] and [2,3-13C2]-9- 
hydroxynonanoic acid. The need for both patterns of labelling are as follows. 
Firstly, as catabolism had already been shown to be a dominant pathway, the 
labels needed to be present such that any intact incorporation could be observed. It may 
therefore be expected that ß-oxidation of 9-hydroxynonanoic acid may cause cleavage of 
acetate units from the C-1 end of the molecule, as shown in Fig. 2.4. It is therefore 
necessary to synthesise the NAC thioester of [2,3-13C2]-9-hydroxynonanoic acid, so that 
we can discriminate, in terms of coupling, the difference between intact incorporation and 
degradation to acetate. 
0 
9 
H0' ' ' '' `ý 1 SNAG 
Fig. 2.4: Possible cleavage of acetate during n-oxidation of 9-hydroxynonanoic acid. 
On the other hand, it is not known whether there may be a competing biological 
oxidation at C-9 followed by cleavage of acetate units from this end of the molecule, as 
outlined in Fig. 2.5. For the same reasons given above, it is therefore necessary to 
synthesise the NAC thioester of [1,2-13C2]-9-hydroxynonanoic acid in order to probe 
this possible oxidation process. 
H1 SNAG HO" 9 SNAG 




Commercially available 7-bromo-l-heptanol (135) was used as the starting 
material in the first proposed route for the synthesis of the NAC thioester of [1,2-13C2]- 



















Scheme 2.24: Proposed synthetic route to the NAC thioester (137) 
of 9-hydroxynonanoic acid. 
The first step in the synthesis involved protection of the primary alcohol, and a 
range of protecting groups was examined (Scheme 2.25). 
DHP THPO(CH2)7Br (136)18% yield 
HCI 
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(139) 87% yield 
Ethoxyethene, EO-'--O(CH2)7Br 
TFA 
Scheme 2.25: Protection of 7-bromo-l-heptanol. 
Protection of the alcohol as the tetrahydropyranyl ether, using the method of 
Okuno and coworkers, 106 gave (136) in 92% yield, whereas, using the method of Burton 
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and coworkers, 107 (136) was obtained in only 18% yield. 
The next step was the alkylation of the protected bromide. McNicholas108 had 
already shown that 1-bromobutane (140) could be alkylated in 65% yield, using LDA and 








Scheme 2.26: Alkylation of a primary bromide. 
Reaction of the bromide with ethyl acetate in the presence of a range of bases, 
including LDA, LIHMDS, sodium hydride, and sodium ethoxide, gave no reaction. 
Model reactions, involving short chain bromides were carried out to ensure that the anion 
of ethyl acetate was being formed. For example, reaction of 2-bromopropane (142) with 
its anion, generated from ethyl acetate and lithium hexamethyldisilylazide, gave the 
alkylated product (143) in 72% yield (Scheme 2.27). 
Me LWNIDS eO 




Scheme 2.27: Alkylation of 2-bromopropane. 
Alkylation of the protected bromide was then attempted using diethyl malonate in 
place of ethyl acetate. The best results were obtained, using the procedure reported by 
Thompson and Reeve, 109 involving a phase-transfer-catalysed alkylation of diethyl 
malonate. Addition of potassium carbonate and 18-crown-6 to diethyl malonate and the 
protected bromide gave diethyl-(1'-tetrahydropyran-2-yl)oxynonylmalonate (144) in 98% 
yield. The IH nmr spectrum of (144) showed the expected signals at 8 3.3 1, assigned to 
2-H, and 8 1.27 and 8 4.17, due to the diethyl ester. 
Table 2.2 provides a summary of the various conditions employed for alkylation 
of the protected 7-bromo-1-heptanol. 
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Protecting Group Base Other reagents % Yield of 
Product 
THP IDA Ethyl acetate No reaction 
THP L1HMDS Ethyl acetate No reaction 
THP Sodium ethoxide Ethyl acetate No reaction 
THP Sodium hydride Ethyl acetate No reaction 






THP Sodium hydride Diethyl malonate, 
DMF 
91.0 
TBDMS LDA Ethyl acetate No reaction 






EE IDA Ethyl acetate No reaction 






Table 2.2: Attempted alkylation conditions. 
As shown, these alkylations were attempted with three different protecting 
groups: THP, TBDMS and EE. However, further reactions were carried out only using 
the diethyl-(1'-tetrahydropyran-2-yl)oxynonylmalonate (144), as this was prepared in the 
highest yield over the two steps. 
The THP protected malonate (144) was then converted to the corresponding 
diacid (145) in 89% yield using sodium hydroxide and a phase-transfer catalyst (Scheme 
2.28). The IH nmr spectrum indicated a triplet at 8 3.41, assigned to 2-H, and loss of a 
triplet at S 1.27 and a quartet at 8 4.17, corresponding to loss of the ethyl groups. the 
mass spectrum gave a molecular ion in accordance with the diacid structure (145). 
O0 
NaOH 
Tflp OEt THP OH 
(1ýý 0 OR 
H' 
(14 0 OH 
Scheme 2.28: Synthesis of the protected diacid. 
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Treatment of the diacid either with acid or in refluxing xylene gave none of the 
expected decarboxylated product (146). At this stage, this route was abandoned for two 
reasons. Firstly, in a labelled synthesis of diethyl malonate, a double 13C2 labelled 
malonate is effectively triply labelled, so that on decarboxylation half of the label would 
be lost. Secondly, this synthesis was only suitable for synthesising the NAC thioester of 
[1,2-13C2]-9-hydroxynonanoic acid. Meanwhile, another route was being developed, 
which would lead to both the NAC thioester of [1,2-13C2]-9-hydroxynonanoic acid and 
the NAC thioester of [2,3-13C2]-9-hydroxynonanoic acid. 
Retrosynthetic analysis of the NAC thioester of 9-hydroxynonanoic acid (137) 
indicated a possible route may be though a Wittig reaction between a C7 aldehyde (147) 







Scheme 2.29: Retrosynthetic analysis of the NAC thioester (137) of 
9-hydroxynonanoic acid. 
The reaction of aldehydes with Wittig reagents of the structure Ph3PCHCO2R 
constitute an extremely powerful method for two carbon chain extension. This synthesis 
would hopefully allow the synthesis of the NAC thioester of [1,2-13C2]-9- 
hydroxynonanoic acid by coupling unlabelled aldehyde with the NAC thioester of [1,2- 
13C2]triphenylphosphorane acetate. The synthesis of the NAC thioester of [2,3-13C2]-9- 
hydroxynonanoic acid would be achieved by coupling the corresponding [1-13C] C7 
aldehyde with the NAC thioester of [2-13C]triphenylphosphorane acetate (Scheme 2.30). 
00 





Scheme 2.30: Proposed syntheses of the NAC thioesters of [1,2-13C2] 
and [2,3-13C2]-9-hydroxynonanoic acid. 
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Keck and coworkers110 reported the preparation and use of the ethane thiol 
phosphorane (148), with aldehydes (149) to give the unsaturated thioesters (150) 
(Scheme 2.31). 
O CHC13 0 
Ph3. + RCHO -ý 
I 
SEt R""\ SEt 
(148) (149) (150) 
Scheme 2.31: Generalised Wittig reaction of the ethane thiol phosphorane. 
The ethane thiol phosphorane was prepared from bromoacetic acid, as shown in 
Scheme 2.32. Reaction of bromoacetic acid (107) and ethanethiol, under DCC/DMAP 
mediated coupling conditions gave the ethane thiol of bromoacetic acid. 83 Subsequent 
reaction with triphenylphosphine, followed by the addition of 10% sodium carbonate 















Scheme 2.32: Synthesis of the ethane thiol of triphenylphosphorane acetate. 
An analogous procedure was used to prepare the NAC thioester (151) of 



















Scheme 2.33: Synthesis of the NAC thioester of triphenylphosphorane acetate. 
52 
Bromoacetic acid (107) was coupled with N-acetylcysteamine in the presence of 
DCC/DMAP in 85% yield. 83 Reaction of the resultant thioester (152) with 
triphenylphosphine in toluene produced the NAC thioester of (triphenylphosphonium 
acetate) bromide (153) in 72% yield. Formation of the required ylid (151) was achieved 
by titration of (153) with sodium hydroxide. 
For the second half of the coupling, 7-hydroxyheptanal (147) was required. It 
was initially thought to protect the hydroxy group as its THP ether. Hence, the target 
became 7-(1'-tetrahydropyran-2-yl)oxyheptanal (154). Several routes were developed to 
allow the synthesis of both unlabelled and [1-13C] versions of the protected aldehyde. 
7-(1'-Tetrahydropyran-2-yl)oxyheptanal was prepared from readily available 1,7- 
heptanediol (155). Mono-protection of (155), using dihydropyran and pTSA, as its THP 
ether was achieved in 39% yield. Oxidation of (156) with PDC or under Swern 
conditions gave 7-(1'-tetrahydropyran-2-yl)oxyheptanal in 84% and 73% yield 
respectively (Scheme 2.34). 106,111 Despite the low yield of mono-protected alcohol, the 
scheme was deemed useful as a cheap, reliable, and quick route to large quantities of the 
protected aldehyde. 
DHP PDC or 
O 
HO(CH2)7OH -" THPO(CH2), OH 
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(155) (156) (154) 
Scheme 2.34: Synthesis of 7-(1'-tetrahydropyran-2-yl)oxyheptanal. 
Another route for the preparation of (154) was developed, using the commercially 
available aleuritic acid as the starting material. '07 Cleavage of aleuritic acid (157) with 
periodate gave 7-hydroxyheptanal (147) in 83% yield. Protection as its THP ether was 
achieved in 78% yield, using dihydropyran and pTSA. Comparison of the 1H nmr 
spectrum with the aldehyde formed via PDC oxidation confirmed successful oxidative 
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Scheme 2.35: Periodate cleavage of aleuritic acid. 






unlabelled 7-(1'-tetrahydropyran-2-yl)oxyheptanal, and so can only be used in 
conjunction with the NAC thioester of [1,2-13C2]triphenylphosphorane acetate in the 
synthesis of the NAC thioester of [1,2-13C2]-9-hydroxynonanoic acid. 
Another route was therefore developed for the preparation of [1-13C]-7-(1'- 
tetrahydropyran-2-yl)oxyheptanal, to be used in the preparation of the NAC thioester of 
[2,3-13C2]-9-hydroxynonanoic acid (Scheme 2.36). The source of the isotopic label was 
to be potassium [1-13C]cyanide, but first the route was optimised using unlabelled 
material. 
KCN DHP. 
HO(CH2)6Br - HO(CH2)6CN - THPO(CH2)6CN 





Scheme 2.36: Synthesis of 7-(1'-tetrahydropyran-2-yl)oxyheptanal, via DIBAL 
reduction of 7-(1'-tetrahydropyran-2-yl)oxyheptanitrile (160). 
Treatment of 6-bromo-l-hexanol (158) with sodium cyanide gave 7- 
hydroxyheptanitrile (159) in 69% yield. An upfield shift of the triplet (J 7Hz) from 6 3.4 
to 6 2.4 assigned to 6-methylene in (159), indicating that the nitrile had been formed. 
This was confirmed by 13C nmr, in which the signal at 8 119 was assigned to the nitrile 
carbon. Protection of the primary alcohol as the THP ether gave 7-(1'-tetrahydropyran-2- 
yl)oxyheptanitrile (160) in 60% yield. Addition of 1.5 equivalents of DIBAL-H solution 
to (160) led to the successful formation of 7-(1'-tetrahydropyran-2-yl)oxyheptanal (154) 
in 73% yield. 
The Wittig coupling between the protected aldehyde (154) and the phosphorane 
(151) was carried out in refluxing chloroform, giving the required a, ß unsaturated 
thioester (161) in 45% yield. The 1H nmr spectrum of (161) confirmed that the trans 
double bond had been formed, showing the signals at 6 5.80 and 6.95 were coupled to 
each other with a coupling constant of 15.4 Hz. A small allylic coupling of 1.5 Hz was 
also observed at S 5.80, resulting in a doublet of triplets. 
Subsequent hydrogenation, using a palladium/carbon catalyst was unsuccessful, 
with the return of starting material. This is possibly due to poisoning of the catalyst by the 
presence of the sulphur atom. 
Hence an alternative approach for the synthesis of the NAC thioester of 9- 
hydroxynonanoic acid was required, and use of a more divergent route was investigated 
(Scheme 2.37). 
54 
0 NaH, ,0 
TIC H TBP 0Et 
O0 
(154) ( h' 
JLOEt (163) 














Scheme 2.37: Proposed coupling, and subsequent modifications to synthesise the 
NAC thioester of 9-hydroxynonanoic acid. 
A Homer-Wadsworth-Emmons reaction with ethyl diethylphosphonacetate (162) 
was to be used for the 2 carbon chain homologation of the aldehyde (154). Reaction of 
ethyl bromoacetate with triethyl phosphate, in toluene, gave ethyl phosphonoacetate in 
79% yield (Scheme 2.38). By use of either ethyl [1,2-13C2] or [2-13C]bromoacetate, the 
required isotopically labelled phosphonate may be prepared. 
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Scheme 2.38: Synthesis of ethyl phosphonoacetate, enabling 
incorporation of a single or double 13C label. 
Chain extension of the protected aldehyde (154) with ethyl phosphonoacetate was 
achieved using 1.5 equivalents of sodium hydride giving ethyl 9-(1'-tetrahydropyran-2- 
yl)oxynon-(2E)-enoate (163) in 62% yield. Hydrogenation of (163), using a 
palladium/carbon catalyst in methanol, produced the saturated ethyl ester (164) in 71 % 
yield. As expected, the IH nmr spectrum of (164) showed no signals at 8 5.80 and 7.0, 
confirming that the saturated ester (164) had been formed. Base hydrolysis of (164), 
using a phase-transfer catalyst, gave the THP protected 9-hydroxynonanoic acid (165) in 
78% yield. 
At this point, DCC/DMAP mediated coupling of the THP protected 9- 
hydroxynonanoic acid with N-acetylcysteamine produced the THP protected NAC 
thioester (166) of 9-hydroxynonanoic acid in a crude yield of 93%. Subsequent 
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deprotection of the THP protecting group was attempted using the amberlyst-15 and 
methanol, as already described. However, instead of deprotection of the THP group, 9- 
(1'-tetrahydropyran-2-yl)oxynonanoate (167) was isolated in 77% yield, presumably due 
to preferential attack of the methanol on the carboxyl carbon, thus displacing the thioester 
group. Deprotection of the THP group gave methyl 9-hydroxynonanoate (168) in 65% 




At this point, it was decided to return to the THP protected 9-hydroxynonanoic 
acid (165), and attempt a similar deprotection. Removal of the THP ether was achieved 
by treatment of (165) with amberlyst-15 in methanol to give 9-hydroxynonanoic acid (69) 
in 49% yield. The final step was the DCC/DMAP mediated coupling of N- 
acetylcysteamine and 9-hydroxynonanoic acid, which gave the NAC thioester (137) of 9- 
hydroxynoanoic acid in 79% yield. 
This route (Scheme 2.39) enables the synthesis of both the NAC thioesters of 
[1,2-13C2] and [2,3-13C2]-9-hydroxynonanoic acid. 
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2.4 Synthesis of isotopically labelled intermediates required 
to investigate the biosynthesis of monic acid 
As discussed in chapter 1, previous feeding studies have suggested that monic 
acid is polyketide in origin, and a processive mode of assembly has been postulated 
(Scheme 1.27). To summarise this assembly pathway, an acetate and malonate 
condensation produces enzyme bound acetoacetate (20). Subsequent methylation and 
reduction gives the enzyme bound diketide, (2S, 3S)-3-hydroxy-2-methylbutanoate (70), 
which on further condensation, reduction, and dehydration leads to the (2E, 4S, 5S)-5- 
hydroxy-4-methylhex-2-enoate enzyme bound moiety (71). Further condensations with 
the appropriate number of reductive modifications lead to the putative heptaketide (73), 
prior to PKS translation to the enzyme bound monic acid (65). 
In order to determine the validity of this scheme, isotopically labelled diketide, 
and triketide were chosen as targets for synthesis, as their NAC thioesters (169) and 
(170), and subsequent incorporation studies. 
OH OH OH H 
Me S^ýNyMe Me S,. ýýNyMe 
Me 0 Me 0 
(169) (170) 
Once again, the position of the label was important, to ensure the experiments 
could distinguish between catabolism, and intact incorporation. 
The branching methyl group of the NAC thioester (169) of (2S, 3S)-3-hydroxy-2- 
methylbutanoic acid is postulated to correspond to C-17 of monic acid (50), by the 
processive mode of assembly. This carbon is known to be biosynthetically derived from 
methionine. Therefore, should an isotopically labelled compound undergo ß-oxidation 
after administration to Pseudomonas fluorescens, the label would not be expected to 
appear at C-17 in the isolated pseudomonic acid, as ß-oxidation leads only to acetate. 
Therefore, if a label is introduced into the branching methyl group, detection of a label at 
C-17 would imply intact incorporation of this compound. The initial target molecule was 
therefore the NAC thioester (171) of [2-2H3]-(2S, 33)-3-hydroxy-2-methylbutanoic acid. 
OH 0H 




The compound has been previously prepared by Martin using [2H3] methyl iodide 
as the source of isotopic label (Scheme 2.40). 71 
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Scheme 2.40: Martin's synthesis of the NAC thioester of 
(2S, 3S)-3-hydroxy-2-methylbutanoic acid 
Work in our laboratories, on related systems, has made direct use of DCC/DMAP 
mediated coupling of a free acid with N-acetylcysteamine. 83 Using this methodology, a 
more direct route to the required thioester was examined, via the free acid (180) rather 
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Scheme 2.41: Synthesis of the NAC thioester of (2S, 3S)-3- 
hydroxy-2-methylbutanoic acid. 
The required stereochemistry was introduced in the first step, by means of a 
Baker's yeast reduction of the readily available ethyl acetoacetate (172) giving ethyl (3S)- 
3-hydroxybutanoate (173) in 53% yield. 112 This method allowed large quantities of this 
compound to be prepared. However, the enantiomeric excess was estimated to be 70%, 
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based on the aD reading obtained, and comparing it with a known literature value. 
Methylation, using LDA and methyl iodide was carried out producing ethyl 
(2S, 3S)-3-hydroxy-2-methylbutanoate (179) in 54% yield. As outlined in Fig. 2.6, the 
presence of the methyl group causes facial bias in the electrophilic attack of the methyl 
group. 113 
Fig 2.6: Methylation of ethyl (3S)-3-hydroxybutanoate, using LDA. 
Saponification of ethyl (2S, 3S)-3-hydroxy-2-methylbutanoate (179) gave the 
corresponding free acid (180) in 92% yield, which was successfully converted to the 
NAC thioester (169) of (2S, 3S)-3-hydroxy-2-methylbutanoic acid in 25% yield, using 
DCC/DMAP mediated coupling. 83 
The NAC thioester (181) of [4-2H3]-(2E, 4S, 5S)-5-hydroxy-4-methylhex-2-enoic 
77 acid has been prepared by Sugden, who reported a linear synthesis of this compound 
(Scheme 2.42). 
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Scheme 2.42: Linear synthesis of the NAC thioester (181) of (2E, 4S, 5S)-5-hydroxy- 
4-methylhex-2-enoic acid. 
In order to reduce the number of steps, subsequent to the addition of isotopically 
labelled material, Sugden77 prepared the NAC thioester (170) of (2E, 4S, 5S)-5-hydroxy- 
4-methylhex-2-enoic acid, as shown in Scheme 2.43. 
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Scheme 2.43: Sugden's convergent synthesis of the NAC thioester (170) of 
(2E, 4S, 5S)-5-hydroxy-4-methylhex-2-enoic acid. 
A synthetic route of increased convergence, based on further modifying Sugden's 
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Scheme 2.44: Synthesis of the NAC thioester of (2E, 4S, 5S)-5-hydroxy-4-methylhex- 
2-enoic acid. 
Ethyl (2S, 3S)-3-hydroxy-2-methylbutanoate (179) was protected as its THP 
ether (187), by using dihydropyran and a catalytic amount of pTSA, in 95% yield. 
Reaction of (187) with 1 equivalent of DIBAL-H gave the aldehyde (188) in 86% yield. 
The 1H nmr spectrum of (188) showed doublets (J 2.4Hz) at S 9.74 and 9.77, assigned 
to the aldehydic protons of the two THP diastereomers of (188). 
A Wittig reaction114 was then carried out between the NAC thioester (151) of 
triphenylphosphorane acetate and the aldehyde in refluxing chloroform. The a, ß 
unsaturated thioester (189) was formed in a crude yield of 92%. The 1H nmr spectrum 
showed four sets of signals at 8 6.13 and 6.15 (each dt, J 15.4 Hz, 0.5 Hz), and 8 6.92 
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and 6.97 (each dt, J 15.4 Hz, 5.5 Hz), indicating the presence of the trans unsaturated 
bond. 
Successful deprotection of the THP protecting group was achieved using 
amberlyst-15 and methanol in 27% yield, giving the required thioester (170). The 1H nmr 
spectrum of the deprotected thioester was simplified, compared with the THP protected 
thioester (188). Since it no longer is a mixture of diastereomers. For example, the olefin 
protons now were apparent simply as two sets of doublets of triplets at 6 6.15 (J 15.4 
Hz, 1 Hz) and 8 6.92 (J 15.4 Hz, 7.8 Hz) 
More recently, it has also been found in our laboratories that TBDMS and EE 
protecting groups may be used in conjunction with these and related systems. The 
analysis of the 1H nmr of these compounds is much easier than the corresponding 1H 
nmr spectra obtained when using the THP protecting group. 
A problem inherent in the synthesis of (170), shown in Scheme 2.44, is that the 
triphenylphosphine oxide formed as a by product in the Wittig reaction has proved 
difficult to remove. Staunton and coworkers30 have reported similar problems. They 
overcame the problem using an approach based on the Horner-Wadsworth-Emmons 
reaction. 115 Initially, bromoacetic acid (107) was coupled with N-acetylcysteamine (73) 
in 64% yield, and the product was converted, via the Arbusov reaction, 116 to the NAC 
thioester (190) of diethylphosphonoacetic acid in 69% yield (Scheme 2.45). This route 
was repeated, and was found to be successful. The NAC thioester of bromoacetic acid 
(152) was prepared in 85% yield, and conversion to the NAC thioester of 
diethylphosphonoacetic acid occurred in 79 % yield. 







(107) (152) (190) 
Scheme 2.45: Synthesis of the NAC thioester diethylphosphonoacetic acid. 
Staunton and coworkers30 reported the successful reaction of this thioester with a 
number of aldehydes, including iso-butraldehyde (191) (Scheme 2.46), and so this 
would be an alternative approach to the Wittig reaction for the 2 carbon chain 
homologation of our aldehyde (154). 
OO 
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Scheme 2.46: Synthesis of an a, ß unsaturated thioester. 
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2.5 Synthesis of the monic acid moiety of pseudomonic acid 
Pseudomonic acid C (44) is a co-metabolite of pseudomonic acid A (42), and has 
an identical carbon backbone. The difference in the two structures is that the epoxide 
moiety at C-10,11 has been replaced by a trans double bond. It is more likely that 
epoxidation of the double bond leads to pseudomonic acid A in vivo, as opposed to the 
deoxygenation of pseudomonic acid A leading to pseudomonic acid C. However, such an 
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Scheme 2.47: Relative timing of epoxidation and esterification steps on the biosynthetic 
pathway to pseudomonic acid. 
Using the methodology developed in this work, the NAC thioester of 9- 
hydroxynonanoic acid can now be synthesised in doubly 13C-labelled form. Synthetic 
routes to the NAC thioester (194) of monic acid A and the NAC thioester (195) of monic 
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Methyl ketone (196) has proved to be a valuable intermediate for the preparation 












Alexander and coworkers49 prepared the methyl ketone in quantitative yield, by 
ozonolysis of methyl pseudomonate (197), followed by reductive work up with 
triethylphosphite. Coulton and coworkers 118 later reported, however, that treating the 





Reaction of the methyl ketone with the Horner-Wadsworth-Emmons reagent, 
ethyl diethylphosphonoacetate (162), in a stirred suspension of sodium hydride in THF, 
resulted in a complex mixture, in which ethyl monate (199) and ethyl isomonate (200) 















Scheme 2.48: Synthesis of ethyl monate from the methyl ketone. 
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Ethyl monate (199): Ethyl isomonate (200) 3: 1 
They showed that the total yield was improved to 80%, when the experiment was 
repeated with prior protection of the hydroxy groups in the methyl ketone as trimethylsilyl 
(TMS) ethers. Condensation of the TMS protected ketone (201) with ethyl 
diethylphosphonoacetate (162) produced the required (E) isomer (202) and the (Z) isomer 
(203) in a ratio of 3: 1.117 
This methodology was employed, in order to reach the target molecule, the NAC 
thioester (194) of monic acid A. Initially, the route below was attempted (Scheme 2.49) 
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Scheme 2.49: Proposed approach for the synthesis of the 
NAC thioester of monic acid A. 
Ozonolysis of methyl pseudomonate, in methanol, followed by reductive work up 
led to the formation of the methyl ketone (196). The 1H nmr spectrum of (196) showed a 
characteristic singlet at 2.19 confirmed successful ozonolysis in 63% yield. Subsequent 
TMS protection was achieved, using the procedure of Crimmin and coworkers. 119 The 
methyl ketone, in THF, was treated with triethylamine, followed by trimethylsilylchloride 
(TMSCI) and a catalytic amount of DMAP led to the required product (201) in 70% yield. 
The sample was spectroscopically identical to an authentic sample supplied by P. J. 
O'Hanlon. 120 
Chain extension of (201) with ethyl diethyl phosphonoacetate (162), in a stirred 
suspension of sodium hydride in THF, gave (202). The optimum yields were obtained 
when 8 equivalents of sodium hydride and 10 equivalents of the phosphonoacetate were 
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used. The product was obtained in 30% yield. However, the 1H nmr spectrum of the 
product indicated the presence of the required (E)-isomer (202) and the TMS protected 
ethyl isomonate (203) in a ratio of 4: 1 respectively, which could not be separated. It has 
been shown that the natural (E) isomer of methyl pseudomonate can be distinguished 
from the (Z) isomer, methyl isopseudomonate by comparison of the vinylic methyl 
groups in both the 1H and 13C nmr spectra. A similar application was employed here to 
distinguish between the two monate esters. The 1H nmr chemical shift of the vinylic 
methyl group in the TMS protected ethyl monate was S 2.16, consistent with a 
deshielding effect of the cis-orientated ester group, and S 1.98 in the TMS protected ethyl 
isomonate, in which the deshielding effect was absent. By measuring the integration of 

















Ethyl monate (202): Ethyl isomonate (203) 4: 1 
Scheme 2.50: Synthesis of the TMS protected ethyl monate. 
Treatment of the TMS protected ethyl monate (202) with sodium hydroxide 
solution gave, after acid work up, ethyl monate (204) in 85% yield. Similar results were 
obtained when using HCI/sodium hydrogen carbonate conditions. It is important that the 
experimental procedure is followed exactly, otherwise rearrangement products are likely 
to occur. 
In an attempt to hydrolyse the ester, (204) was further treated with sodium 
hydroxide, but the rearrangement products (53) and (54) were isolated. 62 Neither monic 
acid A (50) nor the TMS protected monic acid A (205) were successfully prepared via this 
approach. 
Monic acid A (50), supplied by SmithKline Beecham, has been shown to undergo 
DCCIDMAP mediated coupling with N-acetylcysteamine, leading to the formation of the 
NAC thioester (194) of monic acid A. Therefore, once the conversion problems of the 
conversion of TMS protected ethyl monate through to monic acid have been solved, the 
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route will be complete, and may be applied to the synthesis of the NAC thioester of [1,2- 
13C2]monic acid A. 
An alternative approach for the synthesis of the required thioester is shown in 
Scheme 2.51. 
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Scheme 2.51: Proposed synthesis of the NAC thioester of monic acid A. 
Masamune and Roush121 reported the use of lithium chloride, an amine, and ethyl 
diethylphosphonoacetate (162) to prepare a, ß unsaturated esters in high yield, with an 
E: Z ratio of >50: 1 with saturated aliphatic aldehydes, >20: 1 with unsaturated aldehydes, 
and > 100: 1 with aromatic aldehydes. Their rationale behind this method was that lithium 
cations affect the course of Wittig and Horner-Wadsworth-Emmons reactions, by 
forming a tight complex with the carbanion derived from the phosphonate, thereby 




Treatment of the TMS protected ketone (199) with ethyl diethylphosphonoacetate 
and the TMS protected methyl ketone (201), under Masamune conditions, has proved 
unsuccessful. On work-up, the 1H nmr spectrum showed only the presence of starting 
material. Similarly, treatment of the TMS protected ketone (201) with sodium hydride in 
THE and the NAC thioester of diethylphosphonoacetic acid (190) simply returned starting 
material. Once this step has been achieved, removal of the TMS groups, using 
HCl/sodium hydrogen carbonate is needed to reach the required thioester. 
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2.6 Conclusions and further work 
The syntheses of a range of possible of isotopically labelled starter units of 9- 
hydroxynonanoic acid have been synthesised, including disodium malonate (97). 
Synthetic routes to sodium 3-hydroxypropionate (113) and the NAC thioester of 3- 
hydroxypropionic acid (99) have been developed. Work towards the synthesis of the 
NAC thioester of [1,2-13C2]-3-hydroxypropionic acid, utilising 2-oxazolidinones, is at 
present being completed. 
A route has now been developed for the synthesis of the NAC thioester (137) of 
9-hydroxynonanoic acid. The versatility of this route allows the synthesis of both the 
NAC thioesters of [1,2-13C2] and [2,3-13C2]-9-hydroxynonanoic acid. In addition, 
routes have been developed to the NAC thioester (169) of (2S, 3S)-3-hydroxy-2- 
methylbutanoate, and to the NAC thioester (170) of (2E, 4S, 5S)-5-hydroxy-4-methylhex- 
(2E)-enoic acid, required to investigate the biosynthesis of the monic acid moiety of 
pseudomonic acid. It is to be noted that the Baker's yeast reduction step was only 
effective in 70% enantiomeric excess. Thus, subsequent successful steps could only be 
assessed, based on a 70% e. e. starting material. 
With reference to the synthesis of the NAC thioester of [1,2-13C2]monic acid A, 
the route is complete with the exception of the hydrolysis of the TMS protected ethyl 
monate A (202) to the TMS protected monic acid A (205). Once this route is complete, 
work can be directed towards the synthesis of the NAC thioester of [1,2-13C2]monic acid 
C. This requires conversion of the monic acid A to monic acid C, somewhere along the 
route, prior to the remaining steps to reach the thioester. There exist many methods for 
deoxygenating epoxides to produce olefins. For example, it is known that trifluoroacetyl 
iodide has been found to react with epoxides, in the presence of excess sodium iodide to 
produce related olefins in high yield. 122 The trifluoroacetyl iodide is generated in situ 





As described in chapter two, synthetic routes have now been developed to a 
number of putative biosynthetic precursors to pseudomonic acid (42). The next stage 
involves feeding these putative precursors, in isotopically labelled form, to Pseudomonas 
fluorescens to determine whether they are intermediates in the assembly of pseudomonic 
acid. Before incorporation experiments could be attempted, it was necessary to establish 
consistent growth conditions for Pseudomonas fluorescens NCIB 10586. For 
biosynthetic studies, a growth production curve needed to be determined in order to 
ascertain the optimum time to supplement the fermentation medium with isotopically 
labelled precursors. The following section will deal with each of the stages involved in 
establishing the production pattern of Pseudomonasfluorescens, and feeding studies with 
isotopically labelled putative biosynthetic intermediates. 
3.2 Production of pseudomonic acid in Pseudomonas 
fluorescens NCIB 10586 
The strain of Pseudomonasfluorescens originally selected for isolation studies 
was a soil isolate, and from this was developed a higher producing strain, Pseudomonas 
fluorescens NCIB 10586. This strain has been used for the majority of the work 
undertaken, except for a series of feeding studies carried out use the production strain 
Pseudomonas fluorescens PF3/R. The media used for growing Pseudomonas 
fluorescens were based on those developed by workers at SmithKline Beecham, and 
employed by Sugden. 77 
A lyophilised pseudomonic acid producing strain of Pseudomonas fluorescens 
NCIB 10586 was donated by SmithKline Beecham. This was used to produce agar 
slants, which would be viable for 3 months. Primary medium was inoculated with a lOµ1 
loopful of Pseudomonas fluorescens grown on agar slants. After 24 hours at 25 'C, an 
aliquot was transferred to secondary medium, and grown for 120 hours. This secondary 
medium was glucose rich, thus enabling metabolite production to occur. The details of 
production of pseudomonic acid in Pseudomonas fluorescens are provided in the 
experimental section. 
Pseudomonic acid production was monitored by HPLC. An aliquot (lml) was 
taken from a flask, so as to determine the titre of pseudomonic acid present in the medium 
at that time. Examples of typical traces of the pseudomonic acid standards, and 
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Fig. 3.2: HPLC trace of the pseudomonic acid production during fermentation. 
For a growth production study, Pseudomonas fluorescens NCIB 10586 was 
grown in primary medium for 24 hours at 25 'C, and then an aliquot was transferred to 
secondary medium, where it was grown at 22 T. An aliquot (Iml) was taken from at 
least two flasks every two hours, after a period of 10 hours after inoculation of the 
secondary medium, so as to determine the titre of pseudomonic acid present in the 
medium at that time. Each aliquot (lml) was micro-centrifuged, and then diluted ten fold 
with distilled water. The samples were then either analysed immediately, or were stored at 
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-20'C prior to analysis. 
HPLC analysis enabled the growth production curve of pseudomonic acid to be 
constructed, as shown below in Fig. 3.3. 
0.5 
0.4 







0 20 40 60 80 100 120 140 
Time after inoculation (hours) 
Fig. 3.3: Time course of pseudomonic acid production. 
As shown in Fig. 3.3, pseudomonic acid production commenced about 12 hours 
after inoculation of the secondary medium. There then followed a rapid increase in 
pseudomonic acid production between 12 and 45 hours, which then reached a maximum 
concentration of 400mg/litre after about 50 hours. 
In order to obtain the maximum incorporation of the isotopically labelled 
intermediate, this study indicated that these intermediates should be added to the 
fermentation medium at 12 hours, and isolation of pseudomonic acid should occur at 50 
hours. However, it should be noted that in a typical 0.5 litre fermentation, the amount of 
isolated pseudomonic acid was considerably lower than that predicted by HPLC analysis. 
Typically, HPLC predicted a yield of 200mg of pseudomonic acid from a 0.5 litre 
fermentation. However, only 60mg, at most, of pseudomonic acid was ever isolated. 
This is probably due to the isolation procedure. In the isolation of pseudomonic acid, the 
combined secondary media was centrifuged, and the supernatant was then acidified to 
pH4.5, saturated with sodium chloride, and extracted with 500m1 of ethyl acetate. 
However, during extraction, the formation of emulsions were a constant problem, and it 
usually took several hours for the extraction to be carried out. It was at this stage, that 
pseudomonic acid may have been lost. 
The pH is also another important marker during pseudomonic acid production. An 
observed pH gradient decrease from pH 7.0 to 5.5 occurs whilst the pseudomonic acid 
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production increases. On reaching the maximum concentration, the pH then rises to 8.5, 
indicating the possible release of the enzyme bound pseudomonic acid. As previously 
shown in Scheme 1.18, pseudomonic acid rearranges at acid or alkaline pH, so that 








Fig. 3.4: Growth production curve, in terms of the pH of the fermentation broth. 
On completion of the fermentation, pseudomonic acid was isolated, then 
methylated using diazomethane, and purified to give methyl pseudomonate (197). 
The product was characterised by 1H and 13C nmr spectroscopy. The 1H and 13C 
nmr spectra were first assigned in 1977 by Mellows and coworkers, 65 and confirmed by 
Tyler and Everett in 1985.123 Tables 3.1 and 3.2 show the 1H and 13C nmr spectral 
assignments, respectively, for an unlabelled, purified sample of methyl pseudomonate. 
The spectra are shown in Figures 3.5 and Fig. 3.6. 
H 
1ý OMe 17 H432 8' 4' 2' 
14 c 10 
7 9' T S' 3' Me 
M 13 12 1 , ý. ""8 





0 20 40 60 80 100 120 140 
Time after inoculation (hours) 
SH (ppm) Multiplicity J (Hz) 1H Assignment 
0.94 d 7.0 17-H 
1.22 d 6.2 14-H 
1.24-1.38 br s 4'-11,5'-Ii, 6'-li, 
7'-H, 12-H 
1.46-1.98 br s 8'-11,9-H 
2.07 m 8-H 
2.22 s 4ax-Jj, 15-H 
2.31 t 7.2 2'-ff 
2.58-2.64 m 4e -H 
2.78-2.84 m 10-H 
3.44-3.59 m 6-H, 16 -H 
3.67 s OCH3 
3.72-3.96 m 5-$, 7-fl, 13-$, 
16ax-$ 
4.08 t 6.8 9'-H 
5.76 s 2-H 
Table 3.1: 1H nmr spectral assignment of methyl pseudomonate. 
öc (ppm) 13C Assignment 6c (ppm) 13C Assignment 
12.7 C-17 51.4 OCH3 
19.0 C-15 55.5 C-10 
20.7 C-14 61.3 C-11 
24.9 C-3' 63.8 C-9' 
25.9 C-7' 65.3 C-16 
28.6 C-8' 68.9 C-6 
29.0 C-4' 70.3 C-7 
29.1 C-5', C-6' 71.4 C-13 
31.5 C-9 74.8 C-5 
34.1 C-2' 117.6 C-2 
39.4 C-8 156.6 C-3 
42.8 C-4 166.8 C-1 
42.8 C-12 174.4 C-1' 
Table 3.2: 13C nmr spectral assignment of methyl pseudomonate. 
72 










Fig. 3.5: 270 MHz 1H nmr spectrum of methyl pseudomonate in CDC13. 
73 
a a 0 
0 In 





3.3 Incorporation studies with Pseudomonas fluorescens 
PF3/R and NCIB 10586 
A growth production study was carried out similarly using Pseudomonas 
fluorescens PF3/R. Pseudomonic acid production was slower than with NCIB 10586, 
and was found to reach a maximum after 7 days. The study indicated the best time to 
supplement the fermentation was at 43 hours, and that for maximum incorporation of 
labelled substrates, isolation should take place at 144 hours. 
Eight feeding studies were carried out using PF3/R. The eight substrates were 
sodium [1-13C]acetate, sodium [2-13C]acetate, sodium [ 1,2-13C2] acetate, sodium [1- 
13C]propionate, sodium [2-13C]propionate, sodium [3-13C]propionate, sodium [1- 
13C]butyrate, and disodium [1,2-13C2]malonate. In each case, the substrate was fed after 
43 hours of inoculation of the final stage medium, a stage which HPLC analysis had 
shown a value of 11 % of the value of the control medium at 144 hours. 
However, after leaving the flasks shaking at 22 'C for 6 days, the pH was 5.5, 
instead of the expected pH 8.0. In order to release the pseudomonic acid that had been 
produced, 150µ1 of 8M KOH was added to adjust the pH to 8.0. A HPLC assay was 
then carried out on each feed. However, for the acetate feeds HPLC gave a value of 12%, 
for the propionate feeds HPLC gave a value of 14%, and for the butyrate feed HPLC 
gave a value of 15% of the value of the control medium at 144 hours. 
Hence these results show that on feeding the labelled substrates, no more 
pseudomonic acid was produced, and hence no significant incorporation was achieved. 
This was verified by isolating pseudomonic acid, converting to the methyl ester by 
reacting it with an excess of diazomethane, and purified by preparative TLC. Low yields 
of methyl pseudomonate, which equated to the pseudomonic acid present before the 
labelled substrates were fed. This process was repeated for each feed, after which 1H and 
13C nmr spectra were obtained for each feed. In each case, the 13C nmr spectrum of 
methyl pseudomonate showed no significant incorporation of the labelled substrate. 
Pseudomonasfluorescens PF3/R is a much higher producing engineered strain, 
in which feeding labelled substrates appears to have halted the further production of 
pseudomonic acid. Subsequent studies were carried out with the lower producing strain 
of Pseudomonasfluorescens NCIB 10586. 
The growth production study was repeated with Pseudomonasfluorescens NCIB 
10586, with the addition of unlabelled sodium acetate. The pH was monitored every three 
hours to see if the pH remained at 4.5, and then increased to pH 8.0 at 120 hours, as 
expected, or whether the pH of the broth remained low. In fact, the pH was found to stay 
at 4.5, once pseudomonic acid had commenced at 12 hours. 
Two sets of experiments were then carried out. One experiment involved ten 
flasks being inoculated with sodium [1-13C]acetate as a single feed at 15 hours (at a level 
of 1mg/ml); the other in which ten flasks were inoculated with a pulse feed at 14,16,18 
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hours (at a level of 0.4 mg/ml, 0.4 mg/ml, and 0.3 mg/ml). After 50 hours all the flasks 
were harvested. The pH of the combined broths of the single feed was 4.5, as was the 
pH of the pulse feed broths, indicating inhibition of pseudomonic acid production. HPLC 
assay confirmed very little pseudomonic acid production had been produced. The pulse 
feed produced 4mg of pseudomonic acid, compared with 2 mg of pseudomonic acid with 
the single feed. However, the control flasks produced 30mg of pseudomonic acid, so the 
acetate is inhibiting production of pseudomonic acid. 
Feeding studies with sodium [1-13Cjacetate, sodium [2-13C]acetate, sodium [1,2- 
13C2]acetate, sodium [1- 13C]propionate, sodium [2-13C]propionate, sodium [3- 
13C]propionate, and sodium [1-13C]butyrate were also carried out with the NCIB 10586 
strain. Analogous results were obtained with NCIB 10586, as with PF3/R, with there 
being inhibition of pseudomonic acid production to those flasks, which were fed with 
labelled substrates. In each case, very low yields of methyl pseudomonate were isolated, 
from which unsatisfactory 13C nmr spectra were obtained. 
Feeding labelled substrates to Pseudomonasfluorescens PF3/R and NCIB 10586 
has been shown to inhibit the production of pseudomonic acid, under the present 
conditions. A possible explanation for these results is that essentially the labelled 
substrates are acid buffers, and as a result inhibit or stop producing pseudomonic acid 
when in acidic conditions. One way to avoid this problem may be to buffer the system, 
so that on addition of the labelled substrate there is not such a sharp drop in the pH of the 
broth. 
With all these feeding experiments, either 100 mg or 200 mg of the labelled 
substrate have been added. Perhaps this is far in excess of what Pseudomonas 
fluorescens can cope with. It may be worth attempting to feed smaller quantities of the 
labelled substrate. Pulse feeding the labelled substrate has also shown that there is less 
inhibition of pseudomonic acid production, compared with a single feed of the labelled 
substrate. For future incorporation studies, pulse feeding, as opposed to a single feed, 
would be recommended. 
Finally, it may be worth reverting to the initial conditions employed by Mellows 
and coworkers for future studies. 65 This will entail changing the constituents of the 
primary and secondary media, establishing a new growth production curve, and then 
carrying out preliminary [1-13C]acetate feeds, before utilising the putative precursors to 
pseudomonic acid in future incorporation studies. 
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3.4 Enzyme inhibitor studies 
Cytochrome P450 is an oxidase present in numerous organisms from bacteria to 
mammals, and plays an important role in the biosynthesis of sterols and the gibberellin 
plant hormones. Oxidase inhibition been successfully used in the elucidation of 
biosynthetic pathways of many secondary metabolites, such as rifamycin124 and 





This inhibitor has been shown to block the conversion of kaurene (208) to 













Scheme 3.1: The oxidation of kaurene to kaurenol; a biosynthetic step 
inhibited by ancymidol. 
Ancymidol has also been applied to the study of betaenone B (211) biosynthesis, 
a polyketide metabolite produced by the fungus Phoma betae. Betaenone B is formed via 
the condensation of acetate with eight malonate units, with the branching methylation 
resulting from methionine. 129 The use of [1-13C, 1802]acetate indicated that the ketone 
oxygen at C-1 was not acetate derived. From this, a biogenetic hypothesis involving an 
intramolecular Diels-Alder reaction was postulated (Scheme 3.2). 130 
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Scheme 3.2: The biosynthesis of betaenone B. 
Oikawa and coworkers then showed that, by using ancymidol as a 
monooxygenase inhibitor, betaenone B production was suppressed. The reduction in titre 
was directly proportional to the amount of ancymidol administered, and a new metabolite 
was found to accumulate, which was shown to be the intermediate (212) proposed as the 
initial Diels-Alder product. 130 This information provided further evidence that such a 
biosynthetic pathway towards betaenone B was in operation. 
Martin and Simpson71,72 showed that pseüdomonic acid has two oxygen atoms 
which are not derived from acetate. These are the epoxide oxygen, and the hydroxyl on 
C-6. These are assumed to originate from atmospheric oxygen, although experiments 
designed to confirm this, by using an 1802 enriched atmosphere, did not produce enough 
metabolite for any deductions to be made. If this assumption is correct, the oxidase 
involved is likely to be a cytochrome P450 type enzyme. 131 
Hence, our aim was to carry out a similar experiment to that with betaenone B, so 
as to measure the effect of ancymidol on pseudomonic acid biosynthesis. Due to the 
expense of commercially available ancymidol, it was prepared by Dickinson, 132 












Scheme 3.3: Synthesis of ancymidol. 
To each flask of secondary medium, inoculated with Pseudomonas fluorescens 
NCIB 10586 was added 0 mg, 5 mg, 10 mg, 25 mg, 50 mg, and 100 mg of ancymidol at 
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the start of pseudomonic acid production at 15 hours. The cultures were then left to grow 
for 5 days, before HPLC analysis. No significant difference in the titre of pseudomonic 
acid was found, compared with the control flasks. No new metabolites were observed by 
HPLC. 
3.4 Conclusions and future work 
In conclusion, synthetic routes have been developed to a series of putative 
precursors of pseudomonic acid. In order to investigate the role of 9-hydroxynonanoic 
acid biosynthesis, synthetic routes have been developed to various forms of the two 
possible starter units of 9-hydroxynonanoic acid: malonate (97) and 3-hydroxypropionate 
(113). Also, a synthetic route to the NAC thioester (137) of 9-hydroxynonanoic acid was 
required, and has been completed. The versatility of this synthesis allows both the [1,2- 
13C2] and [2,3-13C2] isotopically labelled forms to be prepared, making use of the 
Horner-Wadsworth-Emmons methodology in coupling a C7 aldehyde and a C2 
phosphonate. 
Synthetic routes have also been developed to the diketide (169) and triketide (170) 
putative intermediates of monic acid. The development of a route enabling the synthesis 
of the NAC thioester of [1,2-13C2]monic acid A has been undertaken, but still requires 
completion. 
To date, several initial feeding studies have been carried out. Further work needs 
to be carried out in this area, to investigate why the growth of Pseudomonasfluorescens 
is inhibited on feeding precursors to the fermentation broth. Only when these problems 
are solved, can other putative intermediates, including the proposed later stage 
precursors, be fed with the hope of elucidating more information on the biosynthetic 




4.1 General experimental details 
(i) Techniques 
Unless otherwise stated, all non-aqueous reactions were carried out under a nitrogen 
atmosphere, and all solvents were purified according to literature procedures. 134 Nitrogen 
was dried by passage through a silica gel / calcium chloride column. 
Preparative Thin Layer Chromatography 
Preparative thin layer chromatography was carried out on 200 x 200 mm glass 
plates coated with silica gel (0.25,0.5 or Icm, Fluka 60765, Kieselgel Gf245). 
Flash Column Chromatography 
Flash column chromatography was carried out according to the procedure of Still 
et al 135 using Fluka silica gel 60 (70638) as the solid support. Compounds were loaded 
in the minimum amount of ethyl acetate, and eluted with mixtures of ethyl acetate and 40- 
60 'C petroleum ether of varying polarity. 
Thin Layer Chromatography (TLC) 
Thin layer chromatography was carried out using Merck Kieselgel 60 glass 
backed TLC plates, with various ethyl acetate and 40-60'C petroleum ether mixtures 
used as an eluent. Bands were visualised by using one of the following methods: 
i) fluorescence on exposure to short wave ultra-violet light (245 nm) 
ii) by developing in an ammonium molybdate (10% w/v in 2M sulphuric acid), 
followed by heating with a hot air gun 
iii) by developing in an aqueous potassium permanganate (0.5%) and sodium 
hydrogen carbonate (2.5 %) solution, followed by heating with a hot air gun. 
Microbiological work 
At Bristol, microbiological work was performed under sterile conditions, in a 
Biomat Class II microbiological cabinet. At Worthing, the work was carried out in an 
open plan sterile air flow room. Sterilisation of all materials prior and subsequent to use 
was carried out in an autoclave under the described conditions. 
For growth of Pseudomonas fluorescens, the constituents of the primary and 
secondary media are commercially available. Agar No3 was obtained from Oxoid. Spray 
dried corn steep liquor, antifoam, and spray dried yeatex were obtained from Sigma. 
80 
(ii) Instrumentation 
Nuclear Magnetic Resonance (NMR) 
1H and 13C nmr spectra were recorded as solutions in deuterochloroform, unless 
otherwise stated, using CDC13 as a reference to SH 7.25 and SC 77.0 respectively. The 
spectra were recorded on a Jeol GX270 or a GX400 spectrometer. Those spectra run in 
2H20 were referenced to sodium 2,2-dimethyl-2-silapentane-5-sulphonate. The chemical 
shift values for all spectra are given in parts per million with the coupling constants in 
Hertz (Hz). 
Mass Spectrometry 
Low and high resolution mass spectra were recorded on a Fisons Autospec 
spectrometer. Spectra were obtained using electronic ionisation (EI) (at a potential of 
70eV) or chemical ionisation (CI) techniques. Data given is for EI, except were indicated. 
Infra Red Spectroscopy 
Spectra were recorded on a Perkin Elmer 881 infra red spectrometer as thin films, 
except were indicated. 
Optical rotations 
Optical rotations were measured using the sodium-D line on a Perkin-Elmer 
241MC polarimeter as solutions in chloroform, except were indicated. 
Melting points 
Melting points were determined on a Gallenkamp Melting Point apparatus, and are 
uncorrected. 
High Pressure Liquid, Chromatography (HPLC) 
At Bristol, HPLC was carried out using a Gilson 303 system. At Worthing, 
HPLC was carried out using a Gilson apparatus. In both cases, a 12.5cm Whatman 
Perisphere C-18 (10U packing) was used. The mobile phase was 20% methanol, 80% 
water, acidified with ammonium acetate at 0.58 g/l. A flow rate of 1.5 cm3 min-1 was 
used, with the peaks being detected at 233nm. 
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4.2 Experimental for the syntheses discussed in Chapter 2 
S-2-(Acetylamino)ethyl ethanethioate (90) (N, S-Diacetylcysteamine)86 
OH 
MA S,, -,,.,, 
N y Me 
(90) 0 
To a 3-necked flask at 0 'C containing 2-mercaptoethylamine hydrogen chloride (89) 
(5.76 g, 50.7 mmol) in water (50 cm3) was attached two dropping funnels and a pH 
probe. In one funnel was placed potassium hydroxide (8M, 50 cm3), and in the other 
was placed acetic anhydride (14.5 cm3). These were both then added dropwise at such a 
rate that the pH was maintained at 8.0. After all the acetic anhydride was added, the pH 
was adjusted to 7.0 with 2M HCI, and the mixture was stirred at room temperature for 1 
h.. The reaction was saturated with sodium chloride, and was extracted with 
dichloromethane (4 x 50 cm3). The combined organic extracts were dried over 
magnesium sulphate, filtered and concentrated in vacuo to yield S-2-(acetylamino)ethyl 
ethanethioate (90) as a colourless oil (8.1 g, 99%), which solidified upon refrigeration. 
vmax 1655 cm-1; SH 1.99 (3H, s, Cf3COS), 2.36 (3H, s, CCON), 3.03 (2H, t, J 
6.5, CIhS), 3.41 (2H, t, J 6.5, CH2N), 6.66 (1H, br s, NH); SC 22.81 (rH2S), 28.46 
((H2NH), 30.39 (. QH3COS), 39.16 (CH3CON), 170.50 (EON), 195.99 (rOS); m1z 
161 (M+, 0.2%), 119 (60), 118 (21), 86 (9), 72 (19), 60 (30), and 43 (100). 





N, S-Diacetylcysteamine (90) (5.3 g, 32.9 mmol) in water (80 cm3) was cooled to 10 'C. 
Solid potassium hydroxide (5.57 g, 99.5 mmol) was added, and the reaction was stirred, 
under a nitrogen atmosphere, at 10 'C for 50 minutes. The pH was adjusted to pH 7 with 
hydrochloric acid (2M), and the reaction was saturated with sodium chloride and 
extracted with dichloromethane (10 x 50 cm3). The organic extracts were dried over 
magnesium sulphate, and concentrated in vacuo to yield S-2-(acetylamino)ethanethiol 
(73) (3.63 g, 93 %) as a colourless oil. vmax (thin film) 2547,1650,1562 cm-1; SH 1.41 
(1H, t, J 8.5, SID, 2.00 (3H, s, Ct3CON), 2.67 (2H, dt, J 8.5,6.5, CAS), 3.42 
(2H, q, J 6.5, CH, 2N), 6.40 (1H, br s, Nif); SC 23.03 (-QH2N), 24.24 (-QH2S), 42.30 
82 
(CH3CO), 170.37 (CH3-CO); m/z 119 (M+, 29%), 118 (5), 86 (22), 72 (31), and 60 
(100). 




To anhydrous sodium acetate (100) (1.00 g, 12.20 mmol) was added triethylphosphate (5 
cm3), and the reaction mixture was heated to reflux for three hours. After cooling in an 
ice-bath for 0.5 h., the condenser was linked to a vacuum pump via two traps. The first 
of these was cooled with ice/salt, whilst the second was cooled with liquid nitrogen. The 
system was evacuated, and the reaction mixture warmed, so ethyl acetate collected in the 
second trap, whilst any triethylphosphate collected in the first trap. This yielded ethyl 
acetate (101) (0.74 g, 70%) as a colourless oil. vmax 1742 cm-1; 5H 1.26 (3H, t, J 7.0, 
C, "'CH2), 2.05 (3H, s, CH3CO), 4.12 (2H, q, J 7.0, CH3CtO). 
Diethyl malonate (102)77 
OO 
"kA EtO OR 
(102) 
To THE (20 cm 3) at -78 'C under a dry nitrogen atmosphere was added 
hexamethyldisilazide (2.04 g, 12.64 mmol). To this was added n-butyl lithium (2.5M in 
hexanes, 5 cm3,12.50 mmol). The stirred solution was then warmed to 0 'C, and then 
cooled again to -78 C. After 0.5 h., ethyl acetate (101) (0.74 g, 8.41 mmol) was added 
dropwise as a solution in THE (3 cm3). After 40 minutes, ethyl chloroformate (1.37 g, 
12.63 mmol) was added. The resulting solution was then left for 3 hours, after which it 
was quenched with HCl (2M, 15 cm3). The THE was removed in vacuo to leave a pale 
orange oil. The residue was then extracted with diethyl ether (3 x 50 cm3) and HCl (2M, 
40 cm3). The combined organic extracts were dried over magnesium sulphate, filtered, 
and the solvent was removed in vacuo. Purification by Kugelrohr distillation (66 'C, 6 
mmHg) yielded diethyl malonate (102) (0.76 g, 57%) as a colourless oil. lit., 77 bp. 66'C 
at 6 mmHg; umax 1759 cm-1; SH 1.25 (6H, t, J 6.2,2 x CH3CH2O), 3.37 (2H, s, C&), 
4.21 (4H, q, J 6.2,2 x CH3C#ýI O); SC 13.98 QH3CH2O), 41.63 (rH2(CO2Et)2), 
61.44 (CH3_QH2O), 166.59 (-QO2Et); mlz 160 (M*, 22%), 115 (39), 87 (26), 43 (43), 
83 
and 29 (100). 
Disodium malonate (97)77 
OO 
NaO ' ONa 
(97) 
To diethyl malonate (102) (0.68 g, 4.25 mmol) was added 2M sodium hydroxide 
solution (4.25 cm3,8.5 mmol). The mixture was stirred at room temperature for 18 
hours. The water was removed in vacuo. The remaining water was then removed by 
freeze-drying giving disodium malonate (97) (0.72 g, 92%) as a white crystalline solid. 
mp. >2700C; i ),,,. x 1580 cm-1; SH (2H20) 3.12 (2H, s, Cth); Sc (2H20) 47.30 
(CH2OH), 177.41 (QO2Na). 
Ethyl [1,2-13C2]acetate (105)77 
O 
M 13 OEt 
13 
(105) 
The same procedure used to synthesise ethyl acetate (101) was employed to prepare ethyl 
[1,2-13C2]acetate (105), starting with sodium [1,2-13C2]acetate (103) (1.00 g, 11.90 
mmol), giving ethyl [1,2-13C2]acetate (105) (0.61 g, 57%) as a colourless liquid. v 
1742 cm-1; SH 1.26 (3H, t, J 7.0, Cf3CH2), 2.05 (3H, dd, J 130,7.2,13Ct3), 4.18 
(2H, dq, J 7.0,3.0, CH3 Cf O); SC 21.05 (d, 13 
.H 313 
C O2Et), 171.18 (d, 
13CH313-QO2Et); z 90 (M+, 28%), 89 (7), 88 (1), 75 (29), 74 (12), 73 (7), 72 (55), 63 
(100), 62 (25), and 61 (3); 13C Incorporation, 85.1 % with 2x 13C, 13.1 % with 1x 13C, 
1.8% with 0x 13C. 
Diethyl [1,2-13C2]malonate (106)77 
00 
M-kA 13 OR 
(106) 
The same procedure used to synthesise diethyl malonate (102) was employed to prepare 
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diethyl [1,2-13C2]malonate (106), starting with hexamethyldisilazide (1.42 g, 8.80 
mmol), n-butyl lithium (2.5M in hexanes, 3.5 cm3,8.75 mmol), ethyl [1,2-13C2]acetate 
(105) (030 g, 5.56 mmol), and ethyl chloroformate (0.96 g, 8.85 mmol). This method 
yielded diethyl [1,2-13C2]malonate (106) (0.41 g, 46%) as a colourless liquid. lit. 77 bp. 
66 'C at 6 mmHg; v, x 1759 cm-1; SH 1.29 (6H, t, J 7, CH3CH2O), 
3.35 (2H, dd, J 
132,7.4,13Cjj2), 4.18 (4H, m, 13Cjj2); SC 41.69 (d, 13 . 
H2), 166.62 (d, 
13CH213-CO2Et); fi 162 (M+, 4%), 161 (3), 160 (3), 117 (100), 116 (21), 115 (2.1), 
91 (17), 90 (19), and 89 (37); 13C Incorporation, 86.0% with 2x 13C, 12.3% with 1x 
13C, 1.7% with 0x 13C. 




The same procedure used to synthesise disodium malonate (97) was employed to 
synthesise disodium [1,2-13C21malonate (104), starting with diethyl [1,2-13C2]malonate 
(106) (0.37 g, 2.28 mmol) was added sodium hydroxide solution (2M, 2.28 cm3,4.56 
mmol). This method yielded disodium [1,2-13C2lmalonate (104) (0.30 g, 88%) as a 
white crystalline solid. mp. >270'C; umax (nujol) 1580 cm71; SH (2H20) 3.15 (2H, dd, J 
130,6.4,13CI12); 8c (2H20) 47.43 (d, 13-CH2), 177.31 (d, 13CH2'3. CO2Na). 





Bromoacetic acid (107) (2.42 g, 17.4 mmol) in distilled water (20 cm3) was heated to 50 
T. The solution was then neutralised to the sodium salt, using sodium hydrogen 
carbonate (1 g, 11.9 mmol), and cooled to 0' C. Sodium cyanide (0.93 g, 19.0 mmol) in 
distilled water (10 cm3) was added, and the solution was left to warm to room 
temperature overnight. The solution was acidified to pH 1.0 using hydrochloric acid 
(2M), saturated with sodium chloride, and then extracted with ethyl acetate (4 x 75 cm3). 
The combined organic extracts were then dried over magnesium sulphate, filtered and 
concentrated in vacuo to yield cyanoacetic acid (108) (1.21 g, 82%) as a white crystalline 
solid. mp. 65-66 'C, (lit., 136 66-68 "C); u (nujol) 2267,1708 cm-1; SH (d6-acetone) 
85 
3.56 (2H, s, CJj2CN), 6.15 (1H, br s, COZH); Sc (d6-acetone) 24.25 (CH2CO2H), 
114.76 (CN), 165.21 QO2H); m/z 85 (M+, 5%), 68 (15), 59 (73), 44 (100), and 41 
(75). 
Attempted reduction of cyanoacetic acid (108) to 3-hydroxypropionitrile, 
via a mixed anhydride 
Oxalyl chloride (0S cm3,5.73 mmol) was added to a solution of DMF (0.2 cm3,2.57 
mmol) in dichloromethane (3 cm3) at 0 -C under a nitrogen atmosphere. The resulting 
solution was stirred for 1 hour, until a white precipitate formed. The solvent was then 
removed in vacuo. To the white residue was added dry acetonitrile (3 cm3), THE (10 
cm3), and then cyanoacetic acid (108) (0.17 g, 2.00 mmol) at -30 'C, and the resulting 
solution was stirred for 1 h. Sodium borohydride (0.15 g, 3.95 mmol) was added at -30 
T. The solution was warmed to room temperature over 2 h., quenched with HCI (2M, 
50 cm3), washed with saturated sodium hydrogen carbonate (50 cm3), and then extracted 
with diethyl ether (3 x 100 cm3). The combined organic extracts were dried over 
magnesium sulphate, filtered and concentrated in vacuo to yield a pale yellow oil. The 1H 





To 2-bromoethanol (110) (0.95 g, 7.60 mmol) in methanol (5 cm3) was added potassium 
cyanide (035 g, 5.38 mmol) in water (10 cm3). The mixture was heated at 48 'C for 9 
hours. After this time, it was cooled in an ice-bath and extracted with diethyl ether (5 x 20 
cm3). The combined organic extracts were dried over magnesium sulphate, filtered and 
concentrated in vacuo. Purification by Kugelrohr distillation (125 'C, 1 mmHg) yielded 
3-hydroxypropionitrile (109) (0.31 g, 81%) as a colourless oil. lit., 95 bp. 107-109 'C at 
12 mmHg; vmax 3408,2252 cm-1; SH 2.62 (2H, t, J 6.4, CH2CN), 3.32 (1H, br s, 
Off), 3.86 (2H, t, J 6.4, CH2OH); SC 21.52 (CH2CN), 57.65 (rH2OH), 118.48 
CC. N); m/z (CI) 71 (M+, 3.9%), 70 (M+-1,6.5), and 54 (100). 
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3-Hydroxypropionic acid (98)95.98 
O 
HOB v 'OH 
(98) 
To 3-hydroxypropionitrile (109) (0.06 g, 0.85 mmol) was added sodium hydroxide 
solution (8mM, 100 cm3), and the reaction mixture was stirred at room temperature for 
12 hours. This was then acidified with sulphuric acid (4mM, 100 cm3), stirred for 30 
minutes, and then extracted with diethyl ether (5 x 50 cm3). The combined organic 
extracts were dried over magnesium sulphate, filtered and concentrated in vacuo to yield 
3-hydroxypropionic acid (98) (0.01 g, 13%) as a colourless oil. SH 2.62 (2H, in, 
C&CO2H), 4.84 (2H, br s, Off and COQ); m/z (CI) 91 (MH+, 6%), 90 (1), 89 (7), 
73 (37), 72 (26), 71 (11), 56 (13), and 55 (100). 
3-(1'-Tetrahydropyranyl-2. yl)oxypropionitrile (111) 
ý0tiN 
(111) 
Dihydropyran (2.41 g, 28.6 mmol) in dry dichloromethane (5 cm3) was added dropwise 
to a solution of 3-hydroxypropionitrile (109) (2.01 g, 28.3 mmol) in dry dichloromethane 
(5 cm3). A catalytic amount of pTSA was added, and the solution was stirred at room 
temperature overnight. The mixture was washed with saturated sodium hydrogen 
carbonate solution (50 cm3), and then extracted with dichloromethane (4 x 50 cm3). The 
combined organic extracts were dried with sodium sulphate, filtered and concentrated in 
vacuo. Purification by flash column chromatography (SiO2,10% ethyl acetate/ petroleum 
ether 40-60'C) yielded 3-(1'-tetrahydropyranyl-2-yl)oxypropionitrile (111) 
(3.14 g, 72%) as a colourless oil. vmax 2252 cm-1; 6H 1.54-1.85 (6H, in, 3x CH), 
2.65 (21L t, ! 6.0, Cf CN), 3.52-3.69 (2H, m, OCHOCtCH2CH2), 3.82-3.97 (2H, 
m, OCJCH2CN), 4.67 (11L in, OCfO); m/z (CI) 156 (MH+, 18%), 155 (M+" 6), 85 
(91), 72 (24), 71 (7), and 57 (11). Found MH+, 156.1037 C8H13NO2 requires MH+, 
156.1025. 
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3-(1'-Tetrahydropyranyl-2-yl)oxypropionic acid (112) 
O QOOH 
(112) 
To 3-(1'-tetrahydropyranyl-2-yl)oxypropionitrile (111) (0.13 g, 0.84 mmol) was added 
sodium hydroxide solution (8mM, 100 cm3), and the reaction mixture was stirred at 
room temperature for 12 hours. The mixture was then acidified with sulphuric acid 
(4mM, 100 cm3), stirred for 0.5 h., and then extracted with diethyl ether (3 x 50 cm3). 
The combined organic extracts were dried over magnesium sulphate, filtered and 
concentrated in vacuo to yield a yellow oil. The 1H nmr spectrum indicated a complex 
mixture, no signals of which corresponded to the required product. 
Sodium 3-hydroxypropionate (113)99 
O 
HO v _ONa 
(113) 
To 3-hydroxypropionitrile (109) (2.00 g, 28.2 mmol) was added 2M sodium hydroxide 
solution (14.1 cm3,28.2 mmol). This was heated to reflux overnight at 75 Sc. The 
solution was cooled in ice, water (20 cm3) was added, and then the solution was 
extracted with ethyl acetate (20 cm3). The organic layer was then backwashed with water 
(2 x 20 cm3). The combined aqueous layers were extracted, and the water was removed 
in vacuo. The residue was recrystallised from ethanol, and then freeze-dried to leave 
sodium 3-hydroxypropionate (113) (3.00 g, 95%) as a white crystalline solid. mp. 140- 
142 'C (lit., 137 143 'C); Umax (nujol) 3367,1571 cm-1; 6H (2H20) 2.40 (2H, t, J 6, 
CICO2Na), 3.78 (2H, t, J 6, C112OH); 5C (2H20) 39.97 (., H2CO2Na), 58.83 
(CH2OH), 180.42 (CO2Na). 
S-2-(Acetylamino)ethyl 3-hydroxypropanethioate (99) (N-acetylcysteamine 
thioester of 3-hydroxypropionic acid) 
OH 




To freshly prepared N-acetylcysteamine (73) (0.27 g, 2.27 mmol) was added 
dichloromethane (3 cm3) with stirring at 0'C under a nitrogen atmosphere. 
Dicyclohexylcarbodiimide (83) (0.38 g, 1.84 mmol) in dichloromethane (4 cm3) was 
added, followed by 4-dimethylaminopyridine (84) (0.01 g, 0.08 mmol), in 
dichloromethane (1 cm3). 3-Hydroxypropionic acid (98) (0.16 g, 1.78 mmol) in 
dichloromethane (5 cm3) was then added dropwise. An immediate white precipitate of 
dicyclohexylurea formed. The solution was left at 0 'C for 3 hours and was then allowed 
to warm to room temperature overnight. The resulting solution was filtered through Celite 
to remove the precipitate. To the filtrate was added saturated ammonium chloride (25 
cm3), and was extracted with dichloromethane (2 x 20 cm3). The combined organic 
extracts were dried over magnesium sulphate, filtered and concentrated in vacuo. 
Purification by flash column chromatography (Si02,95% ethyl acetate, 5% methanol) 
yielded the S-2-(acetylamino)ethyl 3-hydroxypropanethioate (99) (0.11 g, 
32%) as a colourless oil. Umax 3386,1701,1685 cm-1; 8H 2.82 (2H, m, C$2COS), 
3.08 (2H, t, J 6.5, CfI2S), 3.45 (2H, q, J 6.5, C$. 2NH), 3.92 (2H, t, Cff2OH), 6.20 
(1H, br s, NH); SC 23.12 (C. H2NH), 28.81 (. H2S), 39.14 QH3CON), 46.62 
(C'H2COS), 61.42 (rH2OH), 171.06 (EON), 191.43 (SOS); mz (CI) 192 (MH*, 
12%), 174 (100), 132 (60), 120 (55), 118 (59), 86 (76), 73 (22), 55 (30). Found (M- 







A round bottomed flask (250 cm3), fitted with a vigreux column (20cm), and equipped 
with a distillation set-up, was charged with (RS)-amino-3-methylbutan-l-ol (121) (10.00 
g, 98.0 mmol), potassium carbonate (0.14 g, 1.0 mmol), and diethyl carbonate (23.8 
cm3,196.0 mmol). The solution was heated and stirred to 125 'C, until approximately 12 
cm3 of ethanol had been collected. To the remaining solution was added diethyl ether 
(300 cm3). The reaction was then filtered through Celite under vacuum, in order to 
remove potassium carbonate. Diethyl ether was removed in vacuo, to yield a white solid, 
which was recrystallised from ethyl acetate/petroleum 40-60 'C to yield a white crystalline 
solid. Concentration of the mother liquors gave a second crop of white crystals, so 
yielding 4-(1-methylethyl)-2-oxazolidonone (122) (8.39 g, 66%) as a white crystalline 
solid. mp. 69-70'C (lit., 100 71-72'C); vmax (nujol) 1743 cm-1; SH 0.90 (3H, d, J 6.5, 
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CH3CH), 0.96 (3H, d, J 6.5, CH3CH), 1.73 (1H, m, Cff(CH3)2), 3.61 (1H, q, J 6.5, 
OCH2CHNH), 4.10 (1H, dd, J 8.5,6.5, OCHHCHNH), 4.44 (1H, t, J 8.5, 
OCILHCHNH), 6.63 (1H, br s, NIL); Sc 17.60 ((H3CH), 17.91 (CH3CH), 32.64 
(cH(CH3)2), 58.38 (CH2-CHNH), 68.29 ((H2CHNH), 160.42 (C=O); m/z 129 (M+, 






Sodium acetate (100) (1.00 g, 12.2 mmol) was suspended in THE (50 cm3) under a 
nitrogen atmosphere. Pivaloyl chloride (1.7 cm3,13.4 mmol) was then added as a 
concentrated solution, and the reaction was stirred at room temperature for 48 hours. 
After this time a white precipitate, of sodium chloride, in solution was observed. The 
mixed anhydride (123) was used immediately in the acylation reaction, without further 
analysis. To THE (40 cm3) under a nitrogen atmosphere at -78 'C was added (4S)-4-(1- 
methylethyl)-2-oxazolidonone (122) (1.72 g, 13.3 mmol). Butyl lithium (1.6M, 9.5 cm3, 
15.2 mmol) was added, and stirred for 20 minutes at -78 'C. A white precipitate 
immediately formed. The anion was added to the mixed anhydride under a nitrogen 
atmosphere at -78 T. No change was observed on addition. This solution was stirred at 
-78 'C for 6 hours, then washed with saturated ammonium chloride (50 cm3), and then 
extracted with ethyl acetate (4 x 75 cm3). The combined organic extracts were dried over 
magnesium sulphate, filtered, and concentrated in vacuo. Purification by flash column 
chromatography, eluting with 5% ethyl acetatetpetroleum ether 40-60 'C yielded 3-tert- 
butyl-4-(1-methylethyl)-2-oxazolidonone oxazolidonone as a pale yellow oil. 82 Umax 
1788,1688 cm-1; 6H 0.86 (3H, d, J 6.5, CH3CH), 0.90 (3H, d, J 6.5, C CH), 1.39 
(9H, s, C(CH- )3), 2.23 (1H, m, CJj(CH3)2), 4.18 (1H, m, OC$HCHN), 4.27 (1H, m, 
OCfHCHN), 4.52 (1H, m, OCH2CEN); m/z 213 (M+, 1%), 158 (50), 142 (10), 129 
(12), 86 (62), 85 (83), 83 (100), and 57 (88). 
Eluting with 10% ethyl acetate/petroleum ether 40-60 'C yielded 3-acetyl-4-(1- 
methylethyl)-2-oxazolidonone (116) (0.88 g, 84%) as a pale yellow oil. The yield is 
based on recovered starting material. vmax 1784,1702 cm. 1; 6H 0.88 (3H, d, J 6.5, 
C3CH), 0.92 (3H, d, J 6.5, CCH), 2.40 (1H, m, Cll(CH3)2), 2.54 (3H, s, 
CJj3CO), 4.24 (2H, m, OCJfHCHN and OCHHCHN), 4.43 (1H, m, OCH2C$N); 6c 
17.97 (CH3CH), 23.78 QH3CH), 27.02 ((H(CH3)2), 28.35 (QH3CO), 58.35 (AHN), 
63.31 (H2O), 154.29 (C=O), 170.33 (CH3_QON); m/z 171 (M+, 31%), 158 (10), 129 
90 
(7), 128 (67), 86 (100), 71 (7), 68 (14), and 57 (32). 
Further eluting with 50% ethyl acetate/petroleum ether 40-60'C yielded the starting 
material, 4-(1-methylethyl)-2-oxazolidonone (122) (0.93 g), as a white crystalline solid. 
Spectral data as before. 






A solution of 3-acetyl-4-(1-methylethyl)-2-oxazolidonone (116) (0.21 g, 1.21 mmol) in 
THE (2 cm3) at -78 'C under a nitrogen atmosphere was added over 5 minutes to sodium 
hexamethyldisilazide (iM in THF, 1.5 cm3,1.50 mmol), and the solution was stirred for 
0.5 h. Hexamethylphosphoramide (0.43 g, 0.42 cm3,2.40 mmol) was added, 
immediately followed by formaldehyde (large excess). (This was generated by the 
depolymerisation of paraformaldehyde by heating paraformaldehyde in an oil bath, and 
by passing the formaldehyde gas over a steady stream of nitrogen). The reaction mixture 
was stirred for 1 hour at -78 'C, and then quenched by addition of saturated ammonium 
chloride (50 cm3). The mixture was then acidified to pH 2.0 with 2M hydrochloric acid, 
and extracted with ethyl acetate (3 x 40 cm3). The combined organic extracts were dried 
over magnesium sulphate, filtered and concentrated in vacuo. Purification by flash 
column chromatography (Si02,30% ethyl acetate/petroleum ether 40-60'C) yielded 3- 
hydroxymethyl-4-(1-methylethyl)-2-oxazolidonone (124) (0.16 g, 83%) as a 
colourless oil. 6H 0.91 (3H, d, J 5.2, CLj3CH), 0.94 (3H, d, J 5.2, CJj3CH), 2.15 
(1H, m, CFf(CH3)2), 3.29 (1H, br s, Off), 4.01 (1H, m, OCJIHCHN), 4.12 (1H, m, 
OCfIHCHN), 4.28 (1H, m, OCH2CJ N), 4.68 (1H, d, J 11.6, HOCHHN), 4.95 (1H, 
d, J 11.6, HOC_HHN); m/z (CI) 159 (M+, 1%), 158 (M'-I, 2), 142 (M+-OH, 36), 130 






To a stirred solution of 8-bromo-l-octanol (3.11 g, 14.9 mmol) in distilled methanol (15 
cm3) was added sodium cyanide (0.73 g, 14.9 mmol) in distilled water (30 cm3). The 
reaction mixture was then heated to reflux for 16 hours. This solution was cooled in an 
ice-bath to 0 'C, and then extracted with ethyl acetate (3 x 75 cm3). The combined 
organic extracts were dried over magnesium sulphate, filtered, and concentrated in vacuo. 
Purification by Kugelrohr distillation (125 'C, 0.5 mmHg) yielded 9. 
hydroxynonanitrile (213) (1.75 g, 76%) as a colourless oil. Umax 3330,2245 cm-1; 
SH 1.25-1.72 (12H, m, 6x CH2), 2.34 (2H, t, J 7.2, C$2CN), 3.64 (2H, t, J 6.4, 
Ci2OH); mz 155 (M', 1%), 154 (6), 138 (13), 110 (32), 97 (92), 82 (67), 69 (69), 
and 55 (100). Found MH', 156.1391 C9H18NO requires MH+, 156.1388. 
9-Hydroxynonanoic acid (69) 
O 
H 9' 1, OH 
(69) 
To 9-hydroxynonanitrile (213) (0.3 g, 1.94 mmol) was added 2M sodium hydroxide 
solution (1 cm3,2.00 mmol), and the resulting mixture was heated to reflux for 72 
hours. The aqueous layer was extracted with ethyl acetate (20 cm3). The aqueous extract 
was acidified to pH 1.0 using hydrochloric acid (2M), stirred at room temperature for 15 
minutes, and then extracted with ethyl acetate (5 x 20 cm3). The combined organic 
extracts were dried over magnesium sulphate, filtered and concentrated in vacuo to yield 
9-hydroxynonanoic acid (69) (0.33 g, 98%) as a white crystalline solid. mp. 43-44 
'C; v (nujol) 3367,1734 cm-1; 6H (d6-acetone) 1.31-1.71 (12H, m, 6x CH 2), 2.28 
(2H, t, J 7.4, CH2CO2H), 2.88 (1H, br s, Off), 3.52 (2H, t, J 6.4, Cff2OH), 10.46 
(1H, br s, C021j); SC (d6-acetone) 25.01,25.99,28.63,28.91,29.20,29.61 (a-3', a- 
4', -5', -C-6', 
-, -7', -C-8'), 
33.55 (CH2CO2H), 61.81 (CH2OH), 174.06 (ýO2H); m/z 
(CI) 175 (MH+, 13%), 174 (8), 157 (43), 139 (100), 121 (18), 97 (23), 69 (12), and 55 





(a) Using pTSA and dihydropyran 
To 7-bromo-1-heptanol (135) (3.26 g, 16.7 mmol) was added freshly distilled diethyl 
ether (30 cm3). Dihydropyran (1.55 g, 18.4 mmol) in diethyl ether (5 cm3) was added 
dropwise. pTSA (0.07 g, 0.37 mmol) was added, and the solution was stirred at room 
temperature for 24 hours. The mixture was then extracted with diethyl ether (2 x 50 cm3). 
The combined organic extracts were washed with 2M sodium hydroxide solution (50 
cm3), water (50 cm3) and brine (50 cm3). They were then dried over magnesium 
sulphate, filtered and concentrated in vacuo. Purification by Kugelrohr distillation (235 
'C, 3 mmHg) yielded 7-bromo-l-(1'-tetrahydropyran-2-yl)oxyheptane (136) (4.30 g, 
92%) as a colourless oil. lit. bp., 106 125 'C at 1 mmHg; uma. 726 cm-1; 8H 1.35-1.92 
(16H, m, 8x Cj 2), 3.41 (2H, t, J 6.8, CH2Br), 3.46-3.92 (4H, m, 2x C$20), 4.57 
(1H, t, J 3.5, OCJjO); SC 19.65,25.43,26.02,28.05,29.59,30.64,32.57,34.08, 
62.32 ((H2O), 67.48 (H2O), 98.82 (O-CHO); m/z 280 (M+, I%) & 278 (M*, 1), 279 
((M-1)+, 5) & 277 ((M-1)+, 5), 225 (1) & 223 (1), 207 (1) & 205 (1), 179 (3) & 177 
(3), 150 (2) & 148 (2), 97 (37), 85 (100), 56 (41), and 55 (49). 
(b) Using conc. HCI and dihydropyran 
To a stirred solution of 7-bromo-l-heptanol (135) (1.08 g, 5.54 mmol) in concentrated 
HC1(0.3 cm3) was added dihydropyran (0.78 g, 9.27 mmol). The reaction mixture was 
heated to reflux for 2 days, and then cooled in ice. This was washed with benzene (2 x 30 
cm3), sodium hydrogen carbonate (3 x 20 cm3), brine (2 x 20 cm3). The combined 
organic extracts were dried over magnesium sulphate, filtered and concentrated in vacuo. 
Purification by flash column chromatography (SiO2,15% ethyl acetate/petroleum ether 
40-60'C) yielded 7-bromo-l-(1'-tetrahydropyran-2-yl)oxyheptane (136) (0.27 g, 18%) 





To 7-bromo-l-heptanol (135) (10.00 g, 51.3 mmol) was added dimethylformamide (20 
cm3). TBDMS chloride (8.30 g, 55.1 mmol) and imidazole (6.80 g, 100.0 mmol) were 
then added. This solution was then stirred at room temperature, under a nitrogen 
atmosphere, for 20 hours. Distilled water (50 cm3) and diethyl ether (50 cm3) were 
added, followed by extraction with diethyl ether (3 x 50 cm3). The combined organic 
extracts were washed with hydrochloric acid solution (2M, 50 cm3) and brine (50 cm3). 
They were then dried over magnesium sulphate, filtered and concentrated in vacuo to 
yield 7-bromo-l-(1'-tert-butyldimethylsilyl)oxyheptane (138) (15.2 g, 96%) 
as a colourless oil. SH 0 (6H, s, (Ct3)2Si), 0.90 (9H, s, (Cff3)3C), 1.32-1.56 (8H, m, 
4xC H2), 1.71-1.90 (2H, m, 1x Cth), 3.35 (2H, t, J 7.0, CtBr), 3.55 (2H, t, J 
6.6, C H20); SC 0,18.38,25.65,26.00,28.16,28.57,32.72,34.00,63.18; m/z (CI) 
309 ((M-1)*, 1%) & 307 ((M-1)+, 1), 253 (1) & 251 (1), 179 (4) & 177 (4), 115 (14), 





To 7-bromo-l-heptanol (135) (2.51 g, 12.9 mmol) was added ethoxyethene (15 cm3, 
157 mmol), together with a catalytic amount of trifluoroacetic acid. This solution was 
stirred at room temperature, under a nitrogen atmosphere, for 24 hours. A dark brown 
solution resulted, after which time the solvent was removed in vacua. Purification by 
Kugelrohr distillation (125 'C, 1 mmHg) yielded 7-bromo -1- (1' - 
ethoxy)oxyheptane (139) (2.97 g, 87%) as a colourless oil. »max 726 cm-1; SH 1.21 
(3H, t, J 7.5, CUI3CH2), 1.28 (3H, d, J 6.0, OCH(CH3)O), 1.30-1.60 (8H, m, 4x 
Cfi2), 1.80-1.91 (2H, m, CtCH2OH), 3.41 (2H, t, J 7.0, CJj2Br), 3.40-3.80 (4H, 
m, 2x CEO), 4.65 (1H, q, J 3.5, OCIjO); 8C 15.31,20.00,26.14,28.11,28.56, 
29.79,32.59,34.02,60.61 (CH3QH2O), 65.11 (O_CH2CH2), 99.49 (O. QHO); m/z 269 
(MH+, 1 %) & 267 (MH , 2), 253 (5) & 251 (6), 223 (17) & 221 (17), 179 (14) & 177 
(14), 150 (42) & 148 (43), 137 (7) & 135 (7), 97 (84), 73 (89), 69 (72), and 55 (100). 
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A 50 cm3 round bottomed flask, equipped with a reflux condenser, was charged with 
diethyl malonate (102) (1.50 g, 9.38 mmol), 7-bromo-l-(1'-tetrahydropyran-2- 
yl)oxyheptane (136) (2.87 g, 10.29 mmol), and acetonitrile (6 cm3), and was stirred 
under a nitrogen atmosphere. To this solution was added 18-Crown-6 (0.09 g, 0.36 
mmol), and potassium carbonate (1.49 g, 10.8 mmol), and this was heated to reflux for 
24 hours. This solution was cooled in an ice-bath, and extracted with dichloromethane (3 
x 50 cm3). The combined organic extracts were dried over magnesium sulphate, filtered, 
and concentrated in vacuo. Purification by Kugelrohr distillation (225 'C, 2 mmHg) 
yielded diethyl 9-(1'-tetrahydropyran-2. yl)oxynon-1-ylmalonate (144) (3.29 
g, 98%) as a colourless oil. umax 1733 cm-1; 6H 1.27 (6H, t, J 7.0,2 x C$3CH2O), 
1.51-1.88 (18H, m, 9x C&), 3.31 (1H, t, J 7.0, Cff(CO2Et)2), 3.35-3.91 (4H, m, 2 
x C1120), 4.17 (4H, q, J 7.0,2 x CH3CtO), 4.57 (1H, t, J 3.5, OCjjO); 8C 14.05 
(_QH3CH20), 19.66,25.69,26.08,27.22,28.52,28.68,29.13,29.63,30.71,51.87 
(_CH(CO2Et)2), 60.87 (CH3. QH2O), 62.30 (O. QH2CH2), 67.54 (Of'H2), 98.81 (OHO), 
169.54 (2 x -CO2Et); m/z 
(CI) 389 (100), 359 (MII+, 5%), 358 (M*, 1), 276 (13), 275 
(77), and 85 (66). Found M+, 359.2365 C19H3406 requires M+, 359.2374. 
9-(1'-Tetrahydropyran-2-yl)oxynon-1-ylmalonic acid (145) 
C: 1 O OH 
O OH 
(145) 
To diethyl9-(1'-tetrahydropyran-2-yl)oxynonylmalonate (144) (1.00 g, 2.79 mmol) was 
added sodium hydroxide solution (2M, 2.79 cm3,5.58 mmol), together with the phase 
transfer catalyst, tetrabutyl ammonium bromide (10mg). The mixture was stirred at room 
temperature for 48 hours. This solution was acidified to pH 1.0 with hydrochloric acid 
(2M), and extracted with ethyl acetate (4 x 20 cm3). The combined organic extracts were 
dried over magnesium sulphate, filtered, and concentrated in vacuo to yield 9-(1'- 
tetrahydropyran-2-yl)oxynon-1-ylmalonic acid (145) (0.75 g, 89%) as a 
colourless oil. oma. 3324,1713 cm-1; 5H 1.20-1.94 (18H, m, 9x Cam), 3.41 (1H, t, J 
95 
7.0, CH(CO2H)2), 3.48-3.93 (4H, m, 2x CJj20), 4.60 (1H, t, J 3.5, OCJjO), 9.45 
(2H, br s, CH(C02H)2); 6c 19.60,25.37,25.57,26.87,27.62,28.87,29.07,29.63, 
30.71,51.06 (-CH(CO2H)2), 62.46 (O_QH2CH2), 67.76 (O. CH2), 98.98 (O. QHO), 
173.64 (2 x IC02H); m/z 
302 (M*, 1%), 256 (1), 173 (41), 101 (11), 97 (33), 85 (14), 
84 (28), and 55 (100). 
S-2-(Acetylamino)ethyl bromoethanethioate (152) (N-acetylcysteamine 







To freshly prepared N-acetylcysteamine (73) (3.58 g, 30.1 mmol) was added freshly 
distilled dichloromethane (10 cm3). This was stirred at 0 'C under a nitrogen atmosphere. 
Dicyclohexylcarbodiimide (83) (4.99 g, 24.2 mmol) in distilled dichloromethane (10 
cm3) was added, followed by 4-dimethylaminopyridine (84) (0.16 g, 1.30 mmol), in 
distilled dichloromethane (3 cm3). Bromoacetic acid (107) (3.18 g, 22.9 mmol) in 
distilled dichloromethane (10 cm3) was then added dropwise. An immediate white 
precipitate of dicyclohexylurea formed. The solution was left at 0 'C for 3 hours and was 
then allowed to warm to room temperature overnight. The resulting solution was filtered 
through Celite to remove the precipitate. To the filtrate was added saturated ammonium 
chloride (50 cm3). This was extracted with dichloromethane (2 x 20 cm3), after which 
the organic extracts were dried over magnesium sulphate, filtered and concentrated in 
vacuo. Recrystallisation from ethyl acetate yielded the S-2-(acetylamino)ethyl 
bromoethanethioate (152) (4.67 g, 85 %) as a white crystalline solid. mp. 95-97 'C; 
Umax (nujol) 3260,1665,, 1628,723 cm-1; 8H 1.99 (3H, s, CH3CO), 3.11 (2H, t, J 6.5, 
CJI2S), 3.47 (2H, q, J 6.5, Cff2NH), 4.06 (2H, s, BrC$2CO), 6.02 (1H, br s, N$); 
SC 23.16 (('H2N), 29.70 QH2S), 33.32 QH2Br), 39.03 QH3CO), 170.40 (EON), 
193.07 ((SOS); mz (CI) 242 (MH*, 4%) & 240 (MH+, 4), 225 (7), 198 (4), 161 (5), 
160 (13), 120 (95) & 118 (100). Found M*, 239.9870 C6H1ONO2SBr requires M+, 
239.9871. 
96 
S-2-(Acetylamino)ethyl triphenylphosphonium ethanethioate bromide 
(153) (N-acetylcysteamine thioester of (triphenylphosphonium acetate) bromide) 
OH 
Ph3IU K Me Bra 
0 
(153) 
The N-acetylcysteamine thioester (152) of bromoacetic acid (2.28 g, 9.50 mmol) was 
suspended in distilled toluene (40 cm3). Triphenylphosphine (2.51 g, 9.58 mmol) was 
added, and the mixture was stirred for 4 days under a nitrogen atmosphere. The reaction 
mixture was filtered under vacuum Recystallisation from ethyl acetate, followed by the 
solid being dried over phosphorous pentoxide in a dessicator overnight, yielded the S-2- 
(acetylamino)ethyl triphenyiphosphonium ethanethloate bromide (153) 
(3.42 g, 72%) as a pale yellow solid. mp. >250 'C; l max (nujol) 3285,1731,1665 cm-1; 
SH 1.95 (3H, s CJj3CO), 3.02 (2H, t, J 5.5, C$2S), 3.32 (2H, q, J 6.0, Cj NH), 
5.81 (2H, d, J 12.5, Cj 2P), 7.50 -7.83 (15H, m, (C6H5)3P), 8.17 (1H, t, J 6.0, Njf); 
Sc 22.97 (CH2N), 30.52 (QH2S), 37.95 QH3CO), 117.19 (CH2P), 118.49 (((-P)3), 
130.11 & 130.30 (p-( H5)3P), 133.76 & 133.92 (m-(r, 6H5)3P), 135.07 & 135.21 (o- 
(QH5)3P), 170.52 (CON), 181.66 (COS); m/z (FAB) 422 ((M-Br)+, 100%), 337 (27), 
303 (72), 275 (34), 262 (6), 183 (16), 153 (7), and 133 (16). 
S-2-(Acetylamino)ethyl triphenyiphosphorane ethanethloate (151) (N- 






The N-acetylcysteamine thioester (153) of (triphenylphosphonium acetate) bromide (0.53 
g, 1.1 mmol) was dissolved in water (30 cm3). The solution was adjusted to pH 9.0 with 
2M sodium hydroxide, and then extracted with dichloromethane (5 x 25 cm3). The 
combined organic extracts were dried over magnesium sulphate, filtered and concentrated 
in vacuo to yield the S-2-(acetylamino)ethyl triphenylphosphorane 
ethanethioate (151) as a white crystalline solid (0.35 g, 79%). This was used without 
further purification. vmax (nujol) 3270,1731,1625 cm-1; SH 1.70 (3H, s, Cff 3CON), 
2.99 (2H, t, J 6.0, CtS), 3.37 (2H, q, J 6.0, CtN), 3.85 (1H, br s, C$P), 7.43- 
7.73 (15H, m, (C6 i )3P); SC 23.21 (-QH2N), 27.62 (QH2S), 43.04 (QH3CO), 48.08 
(. QHP), 126.78 & 128.97 (p-(r, 6H5)3P), 129.32 & 132.30 (m-(H5)3P), 133.04 & 
97 
133.12 (o-(C6H5)3P), 170.52 (CON), 181.66 (COS), mlz 303 ((M-118)+, 2%), 119 
(20), 118 (12), 77 (15), 72 (17), 60 (81), 43 (76), 30 (100). 
7-(1'-Tetrahydropyran-2-yl)oxyheptan-l-ol (156) 
a OO OH (156) 
To a stirred solution of 1,7-heptanediol (155) (3.00 g, 22.73 mmol) in diethyl ether (20 
cm3) was added dihydropyran (1.92 g, 22.82 mmol) in diethyl ether (5 em3) and a 
catalytic amount of pTSA (0.1 g, 0.53 mmol). The mixture was stirred at room 
temperature for 18 hours, then quenched with water (100 cm3), and was extracted with 
ethyl acetate (3 x 50 cm3). The combined organic extracts were dried over magnesium 
sulphate, filtered and concentrated in vacuo, and then purified by flash column 
chromatography (Si02,35% ethyl acetate/ petroleum ether 40-60 'C) to yield two 
compounds. One band at Rf=0.78 yielded 1,7-[(tetrahydropyran-2- 
yl)oxy]heptane (1.37 g, 20%) as a pale yellow oil. Umax 1400-1000 cm-1; SH 1.36- 
1.92 (22H, m, 11 x Cth), 3.33-3.91 (8H, m, 4x CH2O), 4.58 (1H, t, J 3.5, OCHO); 
Sc 19.71,25.48,26.16,29.32,29.66,30.79,62.41 (O. QH2CH2), 67.72 (O 
. 
H2), 
98.90 (O-CHO); m/z (CI) 299 ((M-1)*, 1%), 215 (6), 199 (3), 185 (2), 133 (9), 86 (13), 
85 (100), and 55 (22). Found (M-1)+, 299.2213 C17H3104 requires (M-1)+, 299.2222. 
The second band at R-0.55 yielded 7-[(tetrahydropyran-2-yl)oxy]heptan-l-ol 
(156) (1.92 g, 39%) as a pale yellow oil. Umax 3397,1400-1000 cm4; SH 1.30-1.88 
(16H, m, 8x CH 2), 3.34-3.91 (4H, m, 2x CH20), 3.63 (2H, t, J 6.6, CH2OH), 4.58 
(1H, t, J 3.4, OCIJO); Sc 19.69,25.52,25.68,26.22,29.18,29.33,30.81,32.69, 
62.35 (OH2OH), 62.90 (O_CH2CH2), 67.62 (O_QH2), 98.86 (O. QHO); m/z 216 (M+, 
1%), 215 (9), 199 (2), 115 (6), 101 (19), 97 (23), 85 (100), and 55 (40). Found (M- 




Aleuritic acid (157) (10 g, 32.8 mmol) was added with vigorous stirring to a solution of 
sodium hydroxide (1.33 g, 33.3 mmol) in water (40 cm3). The resulting turbid solution 
98 
was treated with chloroform (40 cm3), and then sodium periodate (8.43 g, 39.4 mmol) 
was added in portions at 35-40 'C over 10 minutes. The mixture was stirred at room 
temperature for a further 15 minutes, then filtered, and the filter cake was washed with 
chloroform (40 cm3). The aqueous layer was extracted with chloroform (4 x 50 cm3). 
The combined organic extracts were stirred for 1.25 h. with a mixture of saturated 
sodium hydrogen carbonate (90 cm3) and sodium carbonate (60 cm3). The organic layer 
was evaporated in vacuo to yield 7-hydroxyheptanal (147) (3.56 g, 83%) as a white 
crystalline solid. This was used without further purification. mp. 65-66'C (lit., 107 65-67 
'C); umax 3411,1729 cm"; SH 1.33-1.91 (8H, m, 4x CH2), 2.45 (2H, t, J 7.4, 






To a stirred solution of 6-bromo-l-hexanol (158) (2.03 g, 11.2 mmol) in distilled 
methanol (5 cm3) was added sodium cyanide (0.67 g, 13.7 mmol) in distilled water (15 
cm3). The mixture was heated to reflux for six hours. After cooling this mixture in an ice- 
bath, the mixture was extracted with. dichloromethane (5 x 25 cm3). The combined 
organic extracts were dried over magnesium sulphate, filtered and concentrated in vacuo. 
Purification by flash column chromatography (SiO2,50% ethyl acetate/petroleum ether 
40-60 'C) yielded 7-hydroxyheptanitrile (159) (0.98 g, 69%) as a colourless oil 
(RF0.3). vmax 3402,2245 cm't; SH 1.27-1.79 (8H, m, 4x Ckb), 1.83 (1H, br s, O$), 
2.36 (2H, t, J 7.2, CH2CN), 3.64 (2H, t, J 6.4, CHhOH); Sc 17.08 24.99,25.30, 
28.45,32.32,62.54 (-CH2OH), 119.82 (CN); m/z 127 (M+, 7%), 126 ((M-1)+, 4), 110 
((M-OH)+, 36), 83 (68), 82 (48), 69 (69), 68 (27), and 55 (100). Found MH*, 
128.1078 C7H14NO requires MH+, 128.1075. 
7-(1'-Tetrahydropyran-2-yl)oxyheptanitrile (160) 
(160) 
To 7-hydroxyheptanitrile (159) (0.66 g, 5.20 mmol) was added concentrated 
hydrochloric acid (0.03 cm3), and the solution was heated to 50 Sc. Then dihydropyran 
(0.73 g, 8.68 mmol) was added as a concentrated solution dropwise. The mixture was 
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stirred for 0.5 h., and then the temperature was increased to 80 Sc, and was stirred 
overnight. The mixture was cooled in ice, and then extracted with benzene (2 x 30 cm3). 
The combined organic extracts were washed with saturated sodium hydrogen carbonate 
(30 cm3), and brine (30 cm3). The organic extracts were dried over sodium sulphate, 
filtered, and concentrated in vacuo. Purification by Kugelrohr distillation (225 'C, 2 
mmHg) yielded 7-(1'-tetrahydropyran-2-yl)oxyheptanitrile (160) (0.98 g, 
89%) as a colourless oil. 1)max 2244 cm-1; SH 1.31-1.92 (14H, m, 7x Cam), 2.36 (2H, 
t, J 6.8, CtCN), 3.41-3.89 (4H, m, 2x CtO), 4.65 (1H, q, J 3.6, OCHO); SC 
17.11,19.75,23.41,25.37,25.52,28.51,29.46,30.80,62.52 (O. QH2CH2), 67.31 
((H2O), 99.00 (O-CHO), 119.83 (EN); m/z 211 (M+, 1%), 210 (M+-1,3), 138 (3), 
110 (49), 85 (100), 83 (16), 69 (20), and 55 (20). Found MH*, 212.1653 C12H2203 





(a) Via PDC oxidation of 7-[(tetrahydropyran-2-yl)oxy]heptan-l-ol (156) 
To a stirred solution of pyridinium dichromate (0.19 g, 0.55 mmol) in freshly distilled 
dichloromethane (25 cm3), with some dried, ground molecular sieves (3A), was added 7- 
[(tetrahydropyran-2-yl)oxy]heptan-l-ol (156) (0.06 g, 0.28 mmol), as a solution in 
freshly distilled dichloromethane (2 cm3), under a nitrogen atmosphere. The resulting 
solution was left for 5 hours, then filtered through florisil and Celite. The filtrate was 
washed with HCl (2M, 25 cm3), saturated sodium hydrogen carbonate (25 cm3), and 
brine (25 cm3). The combined organic extracts were dried over magnesium sulphate, 
filtered, and concentrated in vacuo to yield 7-(1'-tetcahydropyran-2-yl)oxyheptanal (154) 
(0.05 g, 84%) as a pale yellow oil. This was used without further purification. Umax 
1725 cm-1; SH 1.33-1.81 (14H, m, 7x Cam), 2.40 (2H, t, J 7.4, CH2CHO), 3.31-3.88 
(4H, m, 2x CHhO), 4.54 (1H, t, J 3.5, OC$O), 9.73 (1H, t, J 1.8, C$O); SC 19.61, 
21.89,25.36,25.87,28.91,29.42,30.73,43.68,62.16 (O-QH2CH2), 67.29 (H2O), 
98.80 (OCHO), 202.61 (CHO); nilz 215 (MH+, 8%), 213 (2), 199 (1), 185 (1), 157 
(2), 101 (17), 85 (100), and 55 (19). Found MH*, 215.1646 C12H23O3 requires MH*, 
215.1647. 
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(b) Via Swern oxidation of 7-[(tetrahydropyran-2-yl)oxy]heptan-l-ol 
(156)138 
To a stirred solution of oxalyl chloride (0.26 cm3,2.98 mmol) in dichloromethane (15 
cm 3) at -78 'C under a dry nitrogen atmosphere was added a solution of 
dimethylsulphoxide (0.44 cm3,6.20 mmol) in dichloromethane (15 cm3). After 5 
minutes, 7-[(tetrahydropyran-2-yl)oxy]heptan-l-ol (156) (0.50 g, 2.31 mmol) in 
dichloromethane (5 cm3) was added. The solution was allowed to warm to room 
temperature. Triethylamine (1 cm3,7.17 mmol) was added, and a white precipitate 
formed. The resultant mixture was stirred at room temperature for 2 hours, then was 
quenched with water (20 cm3), and extracted with dichloromethane (4 x 40 cm3). The 
organic extracts were washed with brine (75 cm3), and were dried over magnesium 
sulphate, filtered and concentrated in vacuo to yield 7-(1'-tetrahydropyran-2- 
yl)oxyheptanal (154) (0.36 g, 73%) as a pale yellow oil. This was used without further 
purification. Spectral data as before. 
(c) Via DIBAL reduction of 7-(1'-tetrahydropyran-2-yl)oxyheptanitrile 
(160)107 
To a stirred solution of 7-(1'-tetrahydropyran-2-yl)oxyheptanitrile (160) (0.39 g, 1.9 
mmol) in distilled ether (10 cm3) under a nitrogen atmosphere at room temperature was 
added DIBAL-H (1M in toluene, 2.8 cm3,2.8 mmol). The mixture was stirred for 30 
minutes. Ice-cold sulphuric acid (2M, 15 cm3) was added, and the mixture was stirred 
for 45 minutes. It was then heated at 30 'C for 30 minutes. After this time, the solution 
was saturated with sodium chloride, and extracted with diethyl ether (3 x 20 cm3). The 
combined organic extracts were washed with saturated sodium hydrogen carbonate (20 
cm3), brine (20 cm3), and then dried over sodium sulphate. They were filtered and 
concentrated in vacuo to yield 7-(1'-tetrahydropyran-2-yl)oxyheptanal (154) (0.29 g, 
73%) as a pale yellow oil. This was used without further purification. This was used 
without further purification. Spectral data as before. 
(d) Via protection of 7-hydroxyheptanal (147)107,139 
To 7-hydroxyheptanal (147) (2.36 g, 18.2 mmol) was added freshly distilled diethyl 
ether (35 cm3). Dihydropyran (1.68 g, 20.0 mmol) in diethyl ether (5 cm3) was added 
dropwise. pTSA (0.07 g, 0.37 mmol) was added, and the solution was stirred at room 
temperature for 24 hours. The mixture was then extracted with diethyl ether (2 x 50 cm3). 
The combined organic extracts were washed with sodium hydroxide solution (2M, 40 
101 
cm3), water (40 cm3) and brine (40 cm3). They were then dried over magnesium 
sulphate, filtered and concentrated in vacuo to yield 7-(1'-tetrahydropyran-2- 
yl)oxyheptanal (154) (3.03 g, 78%) as a pale yellow oil. This was used without further 
purification. Spectral data as before. 
S-2-(Acetylamino)ethyl 9-(1'-tetrahydropyran-2-yl)oxynon-(2E) - 






To 7-(1'-tetrahydropyran-2-yl)oxyheptanal (154) (0.07 g, 0.33 mmol) in chloroform (20 
cm3) was added the N-acetylcysteamine thioester (151) of triphenylphosphorane acetate 
(0.13 g, 0.31 mmol), and the reaction mixture was heated to reflux, under a nitrogen 
atmosphere, for 4 days. The solvent was removed in vacuo to yield S-2- 
(acetylamino)ethyl 9. (1'-tetrahydropyran. 2. yl)oxynon-(2E)-enethioate 
(161) (0.10 g, 90%) as a yellow oil (Rp0.35). vmax 3283,1717,1656,1551 cm-1; SH 
1.34-1.71 (16H, m, 8x Cth), 2.00 (3H, s, CI3CON), 2.66 (2H, dt, J 8.5,6.5, 
CH 2S), 3.39 (2H, q, J 6.5, C) NH), 3.42-3.92 (4H, m, 2x CtO), 4.57 (1H, dd, J 
3.5, OCILO), 5.80 (1H, dt, J 15.4,1.5, CH=CkLCOS), 6.09 (1H, br s, NIJ), 6.95 
(1H, m, Cff=CHCOS); SC 19.66,24.55 (-QH2NH), 25.44,25.98,26.43,27.92,28.90 
(C, H2S), 29.57,30.74,32.04,42.61 (rH2CON), 62.33 (O. QH2CH2), 67.51 (H2O), 
98.84 (OQHO), 128.40 (CH=-CHCOS), 131.64 (. H=CHCOS), 170 . 16 (-, ON), 
191.42 (rOS). m/z (CI) 274 ((M-THP)*, 39%), 237 (85), 155 (24), 120 (70), 118 
(100), and 86 (60). 




Sodium hydride (60% dispersion oil, 0.06 g, 1.50 mmol) was stirred in THE (15 cm3) 
under a nitrogen atmosphere. Ethyl phosphonoacetate (162) (0.27 g, 1.21 mmol) in 
distilled THE (3 cm3) was added dropwise at 0 'C, and stirred for 0.5 h. Then 7-(1'- 
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tetrahydropyran-2-yl)oxyheptanal (154) (0.23 g, 1.07 mmol) in THE (3 cm3) was added 
dropwise at 0 C. The resulting solution was stirred overnight at room temperature. The 
reaction mixture was then quenched with distilled water (100 cm3), and was extracted 
with ethyl acetate (3 x 75 cm3). The combined organic extracts were dried over 
magnesium sulphate, filtered and concentrated in vacuo. Purification by flash column 
chromatography (Si02,10% ethyl acetate/ petroleum ether 40-60 'C) yielded ethyl 9. 
(1'-tetrahydropyran-2. yl)oxynon-(2E)-enoate (163) (0.19 g, 62%) as a pale 
yellow oil (Rf=0.3). umax 1724,1650 cm-1; 6H 1.29 (3H, t, J 7.0, CH3CH2O), 1.36- 
1.95 (14H, m, 7x CI 2), 2.20 (2H, q, J 7.4, CH2CH=CHC02Et), 3.33-3.91 (4H, m, 2 
x CH2O), 4.18 (2H, q, J 7.0, CH3CH2O), 4.58 (1H, dd, J 3.5, OCHO), 5.80 (1H, dt, 
J 15.7,1.5, CH=CHC02Et), 6.96 (1H, m, CH=CHC02Et); SC 14.25 QH3CH2O), 
19.71,26.17,27.92,28.94,29.30,29.67,30.75,32.08,60.11 (CH3. QH20), 62.36 
(. H2O), 67.62 (O. H2), 98.83 (O 
. 
HO), 121.24 (CH= iC02Et), 149.31 
(QH=CHC02Et), 166.91 (-02Et); m/z (CI) 283 ((M-1)*, 1%), 279 (5), 155 (21), 109 
(17), 97 (17), 85 (100), 67 (10), and 57 (24). Found (M-1)+, 283.1915 C16H2704 
requires (M-1)+, 283.1909. 




To a solution of ethyl 9-(1'-tetrahydropyran-2-yl)oxynon-(2E)-enoate (163) (0.39 g, 
1.37 mmol) in methanol (5 cm3) was added palladium on activated charcoal (37mg), and 
the reaction mixture was stirred at room temperature under a hydrogen atmosphere for 4 
hours. The solution was then filtered, in order to remove the catalyst, and the solvent was 
removed in vacuo to yield ethyl 9-(1'-tetrahydropyran-2-yl)oxynonanoate 
(164) (0.28 g, 71%) as a pale yellow oil. SH 1.28 (3H, t, J 7.0, CU3CH2O), 1.36-1.95 
(18H, m, 7x CH 2), 2.26 (2H, t, J 6.4, ClhCO2Et), 3.33-3.91 (4H, m, 2x Cth0), 
4.17 (2H, q, J 7.0, CH3Cth0), 4.58 (1H, t, J 3.5, OCIJO); m/z (CI) 287 (MH*, 
2%), 242 (32), 240 (26), 200 (14), and 85 (100). 
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To a stirred solution of ethyl9-(1'-tetrahydropyran-2-yl)oxynonanoate (164) (0.5 g, 1.75 
mmol) was added sodium hydroxide solution (2M, 1.0 cm3,2.00 mmol), together with 
the phase transfer catalyst, tetrabutyl ammonium bromide (10mg). The mixture was 
stirred at room temperature overnight. Hydrochloric acid (2M, 30 cm3) was added, the 
solution was stirred at room temperature for 3 hours, and was then extracted with diethyl 
ether (5 x 50 cm3). The combined organic extracts were dried over magnesium sulphate, 
filtered and concentrated in vacuo to yield 9-(1'-tetrahydropyran-2. 
yl)oxynonanoic acid (165) (0.35 g, 78%) as a colourless oil. This was used without 
further purification. vmax 3400,1708 cm-1; 8H 1.32-1.86 ( 18H, m, 9x Cam), 2.35 
(2H, t, J 7.4, CtCO2H), 3.34-3.92 (4H, m, 2x CtO), 4.58 (1H, t, J 3.5, OCHO), 
10.42 (1H, br s, C02M; SC 19.62,24.62,25.45,26.12,28.96,29.12,29.21,29.69, 
30.73,33.93 (H2CO2H), 62.91 (H2O), 67.62 (O. QH2), 98.80 (O_QHO), 179.26 
(QO2H) ; m/z (CI) 258 (M+, 4%), 175 (11), 174 (6), 157 (8), 139 (16), 121 (3), 85 
(100), and 57 (6). Found MH+, 259.1918 C14H2704 requires MH+, 259.1909. 
S-2-(Acetylamino)ethyl 9-(1'-tetrahydropyran-2-yl)oxynonanethioate 





Freshly prepared N-acetylcysteamine (73) (0.47 g, 3.95 mmol) in dichloromethane (4 
cm3) was stirred at 0 'C, under a nitrogen atmosphere. Dicyclohexylcarbodiimide (83) 
(0.80 g, 3.88 mmol) in dichloromethane (4 cm3) was added, followed by 4- 
dimethylaminopyridine (84) (0.024 g, 0.20 mmol), in dichloromethane (2 cm3). 9-(1'- 
tetrahydropyran-2-yl)oxynonanoic acid (165) (0.90 g, 3.49 mmol) in dichloromethane (4 
cm3) was then added dropwise. An immediate white precipitate of dicyclohexylurea 
formed. The solution was left at 0 'C for 2 h., and was then allowed to warm to room 
temperature overnight. The resulting solution was filtered through Celite to remove the 
precipitate. To the filtrate was added saturated ammonium chloride (50 em3), and was 
extracted with dichloromethane (2 x 20 cm3). The combined organic extracts were dried 
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over magnesium sulphate, filtered and concentrated in vacuo to yield the S-2- 
(acetylamino)ethyl 9-(1'-tetrahydropyran-2-yl)oxynonanethioate (166) 
(1.15 g, 93 %) as a colourless oil. This was used without further purification. unax 3356, 
1693,1665 cm-1; 8H 1.31-1.82 ( 18H, m, 9x Cam), 2.62 (2H, t, J 7.6, CtCOS), 
3.06. (2H, t, J 7.4, C 2S), 3.30-3.91 (4H, in, 2x CEO), 3.41 (2H, t, J 7.4, 
CH-)NH), 4.58 (1H, t, J 3.5, OCI. O), 5.93 (1H, br s, NH); SC 19.75,23.24 
(. H2NH), 24.71,25.50,26.16,28.44 (, r-H2S), 28.85,29.22,29.71,30.79,33.97, 
34.92,39.78 (CH3CON), 62.42 (H2O), 67.64 (O_CH2), 98.92 (O 
. 
HO), 170.28 
(CON), 200.27 (COS); m/z (CI) 360 (MH+, 4%), 276 (90), 139 (6), 120 (100), 85 
(31), and 57 (10). Found MH+, 360.2214 C18H34NO4S requires MH+, 360.2209. 
Treatment of the N-acetylcysteamine thioester (166) of 9-(1'- 




To a solution of the N-acetylcysteamine thioester (166) of 9-(1'-tetrahydropyran-2- 
yl)oxynonanoic acid (1.05 g, 2.92 mmol) in freshly distilled methanol (20 cm3) was 
added a catalytic amount of amberlyst-15. The resulting solution was then stirred at room 
temperature for 18 h. The mixture was then filtered, and the solvent was concentrated in 
vacuo. Purification by flash column chromatography (SiO2,25% ethyl acetate, petroleum 
ether 40-60 'C) yielded methyl 9-(1'-tetrahydropyran-2-yl)oxynonanoate 
(167) (0.61 g, 77%) as a colourless oil (Rf--0.7). 6H 1.31-1.88 (18H, m, 9x Cth), 
2.31 (2H, t, J 7.5, CI CO2Me), 3.33-3.91 (4H, in, 2x CtO), 3.67 (3H, s, OCff 3), 
4.58 (1H, t, J 3.5, OCjO); SC 19.72,24.94,25.51,26.18,29.07,29.23,29.44, 
29.72,30.79,34.10,51.46 (O-CH3), 62.36 ((H2O), 67.65 O-QH2), 98.86 (O iO), 
174.33 (-CO2Me). m/z (CI) 256 ((M-Me)', 16%), 237 (100), 225 (42), 195 (32), 125 
(12), 120 (40), 118 (82), and 86 (61). 




To a stirred solution of 9-(1'-tetrahydropyran-2-yl)oxynonanoic acid (165) (0.15 g, 0.58 
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mmol) was added freshly distilled methanol (15 cm3), and a catalytic amount of 
amberlyst-15. The resulting solution was stirred overnight at room temperature. This was 
then filtered, and the solvent removed in vacuo to yield 9-hydroxynonanoic acid 
(69) (0.05 g, 49%) as a white crystalline solid. Spectral data as before. 
S-2-(Acetylamino)ethyl 9-hydroxynonanethioate (137) (N-acetylcysteamine 
thioester of 9-hydroxynonanoic acid) 
0H 
H S,, -%,,,, 
N y Me 
0 
(137) 
Freshly prepared N-acetylcysteamine (73) (0.04 g, 0.34 mmol) in dichloromethane (5 
cm3) was stirred at 0'C, under a nitrogen atmosphere. Dicyclohexylcarbodiimide (83) 
(0.05 g, 0.26 mmol) in dichloromethane (1 cm3) was added, followed by 4- 
dimethylaminopyridine (84) (0.003 g, 0.02 mmol), in dichloromethane (0.2 cm3). This 
was stirred for 10 minutes, and then followed by addition of 9-hydroxynonanoic acid 
(69) (0.04 g, 0.23 mmol) in dichloromethane (1 cm3). The solution was left at 0 'C for 2 
h., and was then allowed to warm to room temperature overnight. The solution was 
quenched with saturated ammonium chloride (50 cm3), and was extracted with 
dichloromethane (2 x 20 cm3). The combined organic extracts were dried over 
magnesium sulphate, filtered and concentrated in vacuo to yield the S-2- 
(acetylamino)ethyl 9-hydroxynonanethioate (137) (0.05 g, 79%) as a colourless 
oil (Rf=0.4). 8H 1.31-1.66 ( 12H, m, 6x Cth), 1.97 (3H, s, Cf 3CO), 2.57 (2H, t, J 
7.4, Cf COS), 2.80 (1H, br s, Off), 3.02 (2H, t, J 6.4, C&S), 3.39 (2H, t, J 6.4, 
CH&NH) , 3.63 (2H, t, J 6.6, CH2OH), 6.32 (1H, br s, Nfl); SC 23.12 (CH2S), 
25.58,25.63,28.35 (_QH2NH), 28.73,29.10,32.65,39.53 (-QH2COS), 39.70 
(rH3CON), 44.06 (CH2CH2OH), 62.76 (-CH2OH), 170.67 (EON), 200.35 (COS); m/i 
(CI) 276 (MH+, 59%), 237 (42), 195 (10), 157 (11), 139 (28), 120 (100), and 86 (28). 





To a stirred solution of methyl-9-(1'-tetrahydropyran-2-yl)oxynonanoate (167) (0.20 g, 
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0.74 mmol) was added freshly distilled methanol (10 cm3), and a catalytic amount of 
amberlyst-15. The resulting solution was stirred at room temperature overnight. This was 
then filtered, and the solvent removed in vacuo. Purification by flash column 
chromatography (SiO2,50% ethyl acetate/ petroleum ether 40-60 'C) yields methyl-9- 
hydroxynonanoate (168) (0.09 g, 65%) as a colourless oil (Rf=0.5). 8H 1.21-1.89 (12H, 
m, 6x CnH2), 2.31 (2H, t, J 7.4, CH2CO2Me), 2.63 (1H, br s, Off), 3.61 (2H, t, J 
6.5, CH20H), 3.67 (3H, s, OCt); 8C 24.91,25.66,29.09,29.19,29.71,32.73 
(. H2CH2OH), 34.08 (. H2CO2Me), 51.49 (O. H3), 62.36 (. H2OH), 174.38 
(. O2Me); m! z (CI) 189 (MH+, 30%), 171 (40), 157 (58), 139 (83), 129 (10), 111 (37), 
85 (100), and 69 (21). 
9-Hydroxynonanoic acid (69) 
x OH 
(69) 
Methyl-9-hydroxynonanoate (168) (0.20 g, 0.84 mmol) in iM sodium hydroxide 
solution (1.0 cm3,1.00 mmol) was stirred at room temperature overnight. Hydrochloric 
acid (1M, 2 cm3) was then added, the solution was stirred at room temperature for 0.5 
h., and then extracted with diethyl ether (4 x 10 cm3). The combined organic extracts 
were dried over magnesium sulphate, filtered and concentrated in vacuo to yield 9- 
hydroxynonanoic acid (69) (0.09 g, 62%) as a white crystalline solid. Spectral data 
as before. 




To THE (50 cm3) was added hexamethyldisilazane (6.62 g, 41.0 mmol) at -78 'C under 
a nitrogen atmosphere, followed by n-butyl lithium (2.5M, 14.8 cm3,37.0 mmol). The 
solution was warmed to 0 'C over 15 minutes, and then cooled again to -78 'C over a 
further 15 minutes. Ethyl acetate (101) (2.00 g, 22.7 mmol) in THE (3 cm3) was added 
dropwise. This solution was left stirring for 0.5 h. at -78 'C. Acetyl chloride (1.97 g, 
25.1 mmol) in freshly distilled THE (3 cm3) was added dropwise at -78 'C, the mixture 
was stirred for 45 minutes, and then warmed to room temperature. The reaction mixture 
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was quenched with hydrochloric acid solution (5%), and stirred for 5 minutes. The THE 
was removed in vacuo, and the residue was extracted with ethyl acetate (3 x 75 cm3). The 
combined organic extracts were dried over magnesium sulphate, filtered, and 
concentrated in vacuo. Purification by Kugelrohr distillation (58 'C, 5 mmHg) yielded 
ethyl acetoacetate (172) (1.84 g, 62%) as a colourless oil. lit., 136 bp. 54'C at 5 mmHg; 
1 max 1732,1649 cm-1; 6H 1.29 (3H, t, J 7.2, Cf 3CH2), 2.28 (3H, s, C$3CO), 3.46 
(2H, s, COCII2CO), 4.21 (2H, q, J 7.2, CH3CH2); Sc 14.2 (. H3CH2O), 30.1 
(CH3CO), 50.1 (OC-CH2CO), 61.3 (CH3-CH2O)9 167.1 (SQOZEt), 200.7 (CH3. QO); m/z 
(CI) 131 (MH+, 35%), 130 (18), 85 (74), 84 (11), and 65 (100). 
Ethyl (3S)-3-hydroxybutanoate (173)112 
Me OR 
(173) 
To each of ten conical flasks (250 cm3) were added glucose (20 g), distilled water (100 
cm3), and dried Baker's yeast (Sacchoromyces cerevisiae) (10 g). These flasks were 
incubated for 1 hour at 35 'C at 150rpm. To each flask was added ethyl acetoacetate (172) 
(1 g), and the flasks were shaken for 48 hours at 30 'C at 250rpm. After this time, Celite 
(10 g) was added to each flask, and the mixture was filtered under reduced pressure. The 
filtrate was then extracted with diethyl ether (5 x 250 cm3). The combined organic 
extracts were washed with brine (3 x 250 cm3), and then dried over magnesium sulphate, 
filtered, and concentrated in vacuo. Purification by Kugelrohr distillation (50 'C, 2 
mmHg) yielded ethyl (3S)-3-hydroxybutanoate (173) (5.45 g, 53%) as a colourless oil. 
[a]D +32.0 (c 2.19 CHC13), [lit., 112 +41.5 (c 1.0, CHC13)]; u 3450,1728 cm-1; 8g 
1.23 (3H, d, J 6.4, Ct3CH(OH)), 1.28 (3H, d, J 7.2, Cff3CH2O), 2.46 (2H, m, 
CHIC02), 3.46 (1H, br s, O]f), 4.17 (2H, q, J 7.2, CH3CH2O), 4.22 (1H, m, 
CH3Cf(OH)); SC 14.21 (CH3CH2O), 22.43 ((H3CH(OH)), 42.74 (CCO2), 60.71 
(CH3-CH(OH)), 64.29 (CH3CH20), 173.00 (CH O2); m/z (CI) 133 (MH+, 8%), 131 
(3), 115 (31), 103 (6), 87 (51), 85 (75), 83 (100), and 73 (36). 
N. B. This Baker's yeast reduction gave ethyl (3S)-3-hydroxybutanoate in 
70% e. e., based on the values of optical purity obtained from the [a]p. 
Therefore, all subsequent steps, using this compound as a starting 
material can only be carried out, at best, in 70 % e. e. 
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To a stirred solution of freshly distilled THE (20 cm3), under a nitrogen atmosphere at 
-78 'C was added LDA (Aldrich Chemicals, 1.5M, 15.1 cm3,22.7 mmol). Ethyl (3S)-3- 
hydroxybutanoate (173) (1 g, 7.6 mmol) was added dropwise, as a solution in THE (5 
cm3). The mixture was stirred at -78 'C for 0.5 h., warmed to 0 Sc, and then recooled to 
-78 C. Methyl iodide (4.76 cm3,76.0 mmol) was then added dropwise, and the 
resulting solution was warmed to room temperature overnight. The reaction was 
quenched with saturated ammonium chloride solution (50 cm3), and then extracted with 
diethyl ether (4 x 25 cm3). The combined organic extracts were then dried over 
magnesium sulphate, filtered and concentrated in vacuo. Purification by flash column 
chromatography (Si02,20% ethyl acetate/ petroleum ether 40-60 'C) yielded ethyl 
(2S, 3S)-3-hydroxy-2-methylbutanoate (179) (0.60 g. 54%) as a colourless oil. [aID20 
+20.4 (c 1.6, CHC13), [lit., 140 +19.1 (c 1.3 CHC13)]; Umax 3450,1730 cm-1; SH 1.19 
(3H, d, J 7.2, Cff3CH), 1.22 (3H, d, J 7.2, Ct3CH), 1.28 (3H, t, J 7.2, CH3CH2O), 
2.44 (1H, in, Cff (CH3)CO2Et), 2.72 (1H, d, J 5.5, Off), 3.88 (1H, in, CH3Cff (OH)), 
4.18 (2H, q, J 7.2, CH3CU20); Sc 14.39 (. H3CH), 14.45 (C. H3CH2O), 21.03 
(-QH3CH), 47.19 (-QH(CH3)C02Et), 60.87 (CH3. CH2O), 69.69 (CH3-, H(OH)), 176.21 
(Q02Et); m! z (CI) 147 (MH+, 11 %), 146 (4), 145 (7), 129 (10), 101 (11), 85 (22), 57 
(100), and 55 (63). 
N. B. The Baker's yeast reduction gave ethyl (3S)-3-hydroxybutanoate in 
70% e. e. Therefore, this compound is only, at best, synthesised in 70% 
e. e. 





Ethyl (2S, 3S)-3-hydroxy-2-methylbutanoate (179) (0.50 g, 3.4 mmol) in sodium 
hydroxide solution (2M, 1.7 cm3,3.4 mmol) was stirred at room temperature for 18 
hours. After this time, the solution was adjusted to pH 1.0 using hydrochloric acid 
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solution (2M). This was then extracted using ice-cold ethyl acetate (5 x 20 cm3). The 
combined organic extracts were dried over magnesium sulphate, filtered and concentrated 
in vacuo to yield (2S, 3S)-3-hydroxy-2-methylbutanoic acid (180) (0.37 g. 
92%) as a pale yellow oil. This was used without further purification. [a]D20 +17.4 (c 
3.0, CHC13); vmax 3393,17.12 cm-1; 8H 1.21 (3H, d, J 7.2, CH3CH), 1.26 (3H, d, J 
8.0, Ct3CH(OH)), 2.49 (1H, in, CH3Cff), 3.93 (1H, in, CH3C$(OH)), 6.37 (2H, br 
s, 2x O11); SC 13.70 (CH3CH), 19.99 (CH3CH), 46.69 (_QH(CH3)CO2H), 69.26 
(CH3_QH(OH)), 180.31 (Q02H); m/z (CI) 119 (MH*, 31%), 117 (2), 101 (100), 83 
(29), 73 (21), and 57 (24). 
N. B. The Baker's yeast reduction gave ethyl (3S)-3-hydroxybutanoate in 
70% e. e. Therefore, this compound is only, at best, synthesised in 70% 
e. e. 
S-2-(Acetylamino)ethyl (2S, 3S)-3-hydroxy-2-methylbutanethioate (169) 





Freshly prepared N-acetylcysteamine (73) (0.49 g, 4.12 mmol) in dichloromethane (2 
cm3) was stirred at 0 'C, under a nitrogen atmosphere. Dicyclohexylcarbodiimide (83) 
(0.72 g, 3.49 mmol) in dichloromethane (2 cm3) was added, followed by 4- 
dimethylaminopyridine (84) (0.02 g, 0.16 mmol), in dichloromethane (1 cm3). (2S, 3S)- 
3-hydroxy-2-methylbutanoic acid (180) (0.37 g, 3.14 mmol) in dichloromethane (2 cm3) 
was then added dropwise. An immediate white precipitate of dicyclohexylurea formed. 
The solution was left at- 0 'C for 3 hours, and was then allowed to warm to room 
temperature overnight. The resulting solution was filtered through Celite to remove the 
precipitate. The filtrate was washed with saturated ammonium chloride (10 cm3), and 
was extracted with dichloromethane (2 x 10 cm3). The combined organic extracts were 
dried over magnesium sulphate, filtered and concentrated in vacuo . Purification by flash 
column chromatography (A1203,99% ethyl acetate/1% methanol) yielded the S-2- 
(acetylamino)ethyl (2S, 3S)-3-hydroxy-2-methylbutanethioate (169) (0.17 
g, 25%) as a colourless oil. [a]D20 +21.4 (c 2.9, CHC13); Umax 3424,3289,1732, 
1658 cm-1; 6H 1.20 (3H, d, J 7.0, Ct3CH), 1.24 (3H, d, J 6.4, Cf3CH(OH)), 1.73 
(1H, br s, OH), 1.97 (3H, s, Cff3CO), 2.68 (1H, in, CH3C13), 3.05 (2H, in, CtS), 
3.45 (2H, in, C 2N), 3.95 (1H, in, CH3CkL(OH), 5.91 (1H, br s, NH. ); SC 14.93 
(-QH3CH), 21.10 (CH3CH(OH)), 23.22 ((H3CON), 28.64 (CH3_CH), 39.36 (CH2S), 
55.91 (rH2NH), 69.99 (CH3-CH(OH)), 170.53 (SON), 203.99 (COS); m/z (CI) 220 
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(MH+, 100%), 219 (M+, 1), 202 (21), 183 (20), 120 (93), 119 (26), 118 (52), and 101 
(35). Found MH+, 220.1010 C9H18N03S requires MH*, 220.1007. 
N. B. The Baker's yeast reduction gave ethyl (3S)-3-hydroxybutanoate in 
70% e. e. Therefore, this compound is only, at best, synthesised in 70% 
e. e. 





Ethyl (2S, 3S)-3-hydroxy-2-methylbutanoate (179) (0.80 g, 5.48 mmol) in 
dichloromethane (25 cm3) was stirred with dihydropyran (0.55 cm3,6.03 mmol), and a 
catalytic amount of pTSA, was stirred overnight at room temperature, under a nitrogen 
atmosphere. The mixture was concentrated in vacuo, and dissolved in diethyl ether (50 
cm3). The organic layer was washed with water (30 cm3), sodium hydrogen carbonate 
(30 cm3), and brine (30 cm3). The remaining aqueous layers were re-extracted with 
diethyl ether (2 x 50 cm3). The combined organic extracts were dried over magnesium 
sulphate, filtered, and concentrated in vacuo. Purification by flash column 
chromatography (Si02,10% ethyl acetate/petroleum ether 40-60 'C) yielded ethyl 
(2S, 3S)-3-(1'-tetrahydropyran-2-yl)oxy-2-methylbutanoate (187) (1.20 g, 
95%) as a colourless oil. Umax 1737 cm-1; 6H 1.10 (1.5H, d, J 7.0, C$3CHCO), 1.15 
(1.5H, d, J 7.2, Ct3CH(OTHP)), 1.23 (1.5H, d, J 7.0, Ct3CHCO), 1.25 (3H. t, J 
7.0, CtCH2O), 1.29 (1.5H, d, J 7.2, Cf3CH(OTHP)), 1.41-1.86 (6H, m, 3x Ch), 
2.58 (0.5H, dq, J 6.2,6.2, CH3C1JCO), 2.65 (0.5H, dq, J 6.2,6.2, CH3C$CO), 
3.55 (1H, m, CH3CHLÖTHP)), 3.78-4.00 (2H, m, CEO), 4.18 (2H, q, J 7.0, 
CH3C ihO), 4.63 (O. 5H, dd, J 3.5, OCJjO), 4.79 (O. 5H, dd, J 3.5, OC$O). m/z 
(CI) 185 ((M-OEt)'', 62%), 183 (75), 129 (11), 101 (21), 85 (100), 71 (15), and 57 
(15). Found MH*, 185.1181 C10H17O3 requires MH+, 185.1178. 
N. B. The Baker's yeast reduction gave ethyl (3S)-3-hydroxybutanoate in 
70% e. e. Therefore, this compound is only, at best, synthesised in 70% 
e. e. 
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DIBAL-H solution in toluene (1M, 1 cm3,1.0 mmol) was added dropwise to a solution 
of ethyl (2S, 3S)-3-(1'-tetrahydropyran-2-yl)oxy-2-methylbutanoate (187) (0.23 g, 1.0 
mmol) in dry toluene (10 cm3) at -78 'C under a nitrogen atmosphere. The reaction was 
monitored by TLC, and was found to be complete after 1 hour. The reaction mixture was 
quenched with methanol (2 cm3) at -78 'C, and then allowed to warm to room 
temperature. Saturated ammonium chloride solution (1 cm3) was added and stirred 
vigorously for 10 minutes. The precipitated alumina was then removed by filtering 
through Celite, which was then washed with toluene. The filtrate was washed with water 
(20 cm3) and brine (20 cm3). The combined organic extracts were dried over magnesium 
sulphate, filtered, and concentrated in vacuo to yield (2S, 3S)-3-(1'- 
tetrahydropyran-2-yl)oxy-2-methylbutanal (188) (0.16 g, 86%) as a pale yellow 
oil. This was used without further purification. vmax 1727 cm-1; 6H 1.07 (1.5H, d, J 
6.4, C hCHCO), 1.11 (1.5H, d, J 7.2, Cff3CH(OTHP)), 1.18 (1.5H, d, J 6.4, 
CU3CHCO), 1.26 (1.5H, d, J 7.2, CT3CH(OTHP)), 1.41-1.83 (6H, m, 3x CIL), 
2.52 (0.5H, dq, J 6.4,6.4, CH3CJjCO), 2.56 (0.5H, dq, J 6.4,6.4, CH3CHCO), 
3.45 (1H, m, CH3CHLOTHP)), 3.72-3.96 (2H, m, CtO), 4.63 (O. 5H, dd, J 3.5, 
OCffO), 4.74 (O. 5H, dd, J 3.5, OCJjO), 9.74 (0.5H, d, J 2.4, CHO), 9.77 (0.5H, d, 
J 2.4, CIiO); 6C 16.58,19.30,19.78,21.47,25.38,30.70,62.86 (CH3. QH(OTHP)), 
62.97 (-CH2O), 99.79 (OHO), 203.41 (MHO) m/z (CI) 101 ((M-84)+, 6%), 93 (4), 86 
(32), 85 (100), 84 (53), 73 (13), 69 (11), and 57 (53). 
N. B. The Baker's yeast reduction gave ethyl (3S)-3-hydroxybutanoate In 
70% e. e. Therefore, this compound is only, at best, synthesised in 70% 
e. e. 
S-2-(Acetylamino)ethyl (2E, 4S, 5S)-5-(1'-tetrahydropyran-2-yl)oxy-4- 








To (2S, 3S)-3-(1'-tetrahydropyran-2-yl)oxy-2-methylbutanal (188) (0.16 g, 0.86 mmol) 
was added THE (20 cm3). The N-acetylcysteamine thioester (151) of 
triphenylphosphorane acetate (0.4 g, 0.95 mmol) was added, and the reaction mixture 
was heated to reflux, under a nitrogen atmosphere, for 4 days. The solvent was removed 
in vacuo. Purification by flash column chromatography (Si02,10% ethyl 
acetate/petroleum ether 40-60 'C) yielded the S-2-(acetylamino)ethyl (2E, 4S, SS)- 
5-(1'-tetrahydropyran-2-yl)oxy-4-methylhex-2-enethioate (189) (0.26 g, 
92%) as a colourless oil (Rf=0.35). vmax 3269,1720,1664 cm-1; SH 1.04 (1.5H, d, J 
5.0, CH3CH), 1.10 (1.5H, d, J 6.2, CH3CH(OTHP)), 1.12 (1.5H, d, J 5.0, C$3CH), 
1.18 (1.5H, d, J 6.2, Ct3CH(OTHP)), 1.41-1.90 (6H, m, 3x CH), 1.97 (3H, s, 
CH3CON), 2.43 (1H, m, CH3CJ. CH=CH), 3.09 (2H, t, J 6.2, CHAS), 3.46 (2H, t, J 
6.2, C&NH), 3.65 (1H, m, CH3CH OTHP)), 3.75-3.96 (2H, m, CHZO), 4.60 (O. 5H, 
dd, J 3.5, OCJIO), 4.73 (O. 5H, dd, J 3.5, OCiO), 6.05 (1H, br s, NH), 6.13 (0.5H, 
dd, J 15.4,0.5, CH=CJ, COS), 6.15 (0.5H, dd, J 15.4,0.5, CH=CJjCOS), 6.92 
(0.5H, dd, J 15.4,5.5, 
-CH=CHCOS), 
6.97 (0.5H, dd, J 15.4,5.5, C$=CHCOS); 
rn/z (CI) 307 (28%), 279 (100), 228 (10), 201 (16), 127 (8), 120 (40), 109 (43), and 60 
(14). Found (M-OTHP)+, 228.1063 C11H18NO2S requires (M-OTHP)*, 228.1058. 
N. B. The Baker's yeast reduction gave ethyl (3S)-3-hydroxybutanoate in 
70% e. e. Therefore, this compound is only, at best, synthesised in 70% 
e. e. 
S-2-(acetylamino)ethyl (2E, 4S, 5S)-5-hydroxy-4-methylhex-2-enethioate 






To a solution of the N-acetylcysteamine thioester (189) of (2E, 4S, 5S)-5-(1'- 
tetrahydropyran-2-yl)oxy-4-methylhex-2-enoic acid (0.01 g, 0.03 mmol) in freshly 
distilled methanol (10 cm3) was added a catalytic amount of amberlyst. The resulting 
solution was then stirred at room temperature for 18 hours. The mixture was filtered, and 
then the solvent was concentrated in vacuo. Purification by flash column chromatography 
(S i 02,25% ethyl acetate, petroleum ether 40-60 'C) yielded the S-2- 
(acetylamino)ethyl (2E, 4S, 5S)-5-hydroxy-4-methylhex-2-enethioate (170) 
(0.002 g, 27%) as a colourless oil (Rf=0.3). umax 3346,1720,1681,1662,1567cm'1; 
SH 1.10 (3H, d, J 6.8, Cf3CH(OH)), 1.21 (3H, d, J 6.8, C$3CH), 1.97 (3H, s, 
CtCON), 2.36 (1H, m, CH3CfCH=CH), 3.10 (2H, t, J 6.4, C&S), 3.47 (2H, t, J 
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6.4, CI2NH), 3.75 (1H, m, CH3C iIOH)), 5.95 (1H, br s, Nom, 6.15 (1H, dd, J 
15.4,1, CH=CI. COS), 6.92 (1H, dd, J 15.4,7.8, 
_QH=CHCOS); 
8C 15.51 
(CH3CH(OH)), 20.92 (. H3CHCH=CH), 23.27 (CH2S), 28.41 (CH2NH), 39.77 
(r, H3CON), 44.15 (CH3_CHCH=CH), 70.81 (CH3_QH(OH)), 128.99 (CH=_QHCOS), 
151.06 (rH=CHCOS), 170.64 (CON), 190.46 (COS); m/z (CI) 246 (MP, 71%), 228 
(10), 127 (100), 120 (79), 109 (37), 86 (22), 83 (60), and 55 (30). Found MH*, 
246.1166 C11H20NO3S requires MH*, 246.1164. 
N. B. The Baker's yeast reduction gave ethyl (3S)-3-hydroxybutanoate in 
70% e. e. Therefore, this compound is only, at best, synthesised in 70% 
e. e. 
(2S, 3R, 4R, 5S)-3,4-hydroxy-5-((2S, 3S, 4S, 5S)-2,3-Epoxy-5-hydroxy-4- 








Methyl pseudomonate (197) (0.5 g, 0.95 mmol) was dissolved in methanol (8 cm3), 
pyridine (2 drops) was added, and ozonised oxygen was bubbled into the solution at -78 
'C until it remained persistently blue. Any excess ozone was then blown off by a flow of 
nitrogen at -78 'C, until colourless. Triethyl phosphite (0.3 cm3) was then added, and the 
reaction mixture was warmed slowly to room temperature. The solvent was removed in 
vacuo. Purification by flash column chromatography (Si02,20% ethyl acetate, petroleum 
ether 40-60 'C) yielded the methyl ketone (196) (0.18 g, 63%) as a colourless oil 
(R =0.3). [a]D20 +10.2 (c 2.0, CHC13), [lit., 49 +11.9 (c 1.0, CHC13)]; vnm 1708 cm-1; 
6H 0.90 (3H, d, J 7.2,17-H), 1.20 (3H, d, J 6.4,14-1j), 1.30 (1H, 
, m, 
12-if, ), 1.65 
(2H, m, 9-ii), 2.00 (1H, in, 8-ii), 2.19 (3H, s, 15-1j), 2.57-2.83 (4H, m, 4-1j, 11-if, 
10-H), 3.07 (3H, br s, OH), 3.50-3.60 (2H, m, 6-H_, 16eq-1i), 3.64-3.97 (3H, m, 
16ax-f-I, 7-ii, 13-if, 5-1.1); 8c 12.58 (C_-17), 20.65 (_C-14), 30.84 (Q-15), 31.44 (Q-9), 
39.57 (a-8), 42.62 (a-12), 46.59 (a-4), 55.54 (-10), 61.06 (a-11), 65.41 (-16), 
68.77 (r-6), 69.98 (a-7), 71.10 (a-13), 72.75 Q-5), 208.91 Q-3); m/z 302 (M*, 
1%), 284 (1), 269 (1), 241 (4), 227 (11), 154 (60), 112 (37), and 83 (100). 
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(2S, 3R, 4R, 5S)-3,4-trimethylsilyloxy-5-((2S, 3S, 4S, 5S)-2,3-Epoxy -5- 
trimethylsilyloxy-4-methylhexyl)tetrahydropyran-2-ylacetone (201) 











Trimethylsilyl chloride (0.14 cm3,1.06 mmol) was added to the methyl ketone 0 (0.1 g, 
0.33 mmol) in THE (30 cm3) and triethylamine (0.15 cm3,1.07 mmol), and a catalytic 
amount of 4-dimethylaminopyridine. The reaction mixture was stirred at room 
temperature for 4 hours. The solution was then filtered, in order to remove triethylamine 
hydrochloride, and was then concentrated in vacuo. The residue was then taken up in 
diethyl ether (30 cm3), the solution was filtered, and the solvent removed in vacuo to 
yield the protected ketone (201) (0.12 g, 70%) as a colourless, sticky gum. This was 
used without further purification. [oc]D20 -11.1 (c 7.9, CHC13); SH 0.0 (9H, s, 
OSi(Cth)3), 0.90 (3H, d, J 7.0,17-ii), 1.20 (3H, d, J 6.24,14-fl), 1.38 (1H, m, 12- 
H), 1.57 (2H, m, 9-fl), 1.79 (1H, m, 8-fl), 2.20 (3H, s, 15-1l), 2.35-2.75 (4H, m, 4- 
H, 11-lI, 10-11), 3.39-3.57 (2H, m, 6-fl, 16eq-fl), 3.80-4.17 (4H, m, 16ax-fl, 7-fl, 
13-f., 5-fl); SC 12.54 (a-17), 20.26 (C_-14), 29.94 (. -15), 31.43'(c-9), 41.72 (. - 
8), 42.64 (a-12), 46.48 (C-4), 55.72 (-10), 61.24 65.15 (a-16), 68.00 (r'- 
6), 69.88 (Q-7), 71.18 (a 13), 72.61 (. C-5), 207.34 (a-3); m/z (CI) 519 (MH*, 8%), 
518 (M+, 1), 295 (30), 117 (100), 91 (50), 75 (79), 73 (93), and 59 (43). 
Ethyl 4-[(2S, 3R, 4R, 5S)-3,4-trimethylsilyloxy-5-((2S, 3S, 4S, 5S)-2,3- 
Epoxy-5-trimethylsilyloxy-4-methylhexyl)tetrahydropyran-2-yl]-3- 
methylbut-(2E). enoate (202) 
Me CMS .. ".. "ýý ný 
AM 
OR 




Sodium hydride (60% dispersion in oil, 1.28 g, 32.0 mmol) was stirred in freshly 
distilled THE (15 cm 3) at 0 'C under a nitrogen atmosphere. Ethyl 
diethylphosphonoacetate (162) (9.15 g, 40.8 mmol) in THE (15 cm3) was added 
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dropwise, at 00C, over 15 minutes, after which time a pale yellow solution was present. 
The mixture was stirred for a further 15 minutes, after which time the protected ketone 
(201) (2.14 g, 4.13 mmol) in distilled THE (15 cm3) was added dropwise over 10 
minutes. The reaction mixture was allowed to warm to room temperature overnight, and 
then poured into an ice-cold phosphate buffer (K2HPO4) (0.1M, 100 cm3), and stirred at 
room temperature. The mixture was then extracted with ethyl acetate (4 x 50 cm3), and 
the combined organic extracts were dried over magnesium sulphate, filtered and 
concentrated in vacuo. Purification by flash column chromatography (Si02,30% ethyl 
acetate, petroleum ether 40-60'C) yielded ethyl 4-[(2S, 3R, 4R, 5S)-3,4- 
trimethylsilyloxy-5-((2S, 3S, 4S, 5S)-2,3-Epoxy-5-trimethylsilyloxy-4- 
methylhexyl)tetrahydropyran-2-yl]-3-methylbut-(2E)-enoate (202) (0.96 g, 
40%) as a colourless oil (Rf=0.6). [CL]D20 -11.7 (c 1.68, CHC13);, umax 1722,1649 cm-1; 
SH 0.0 (9H, s, OSi(Ct3)3), 0.86 (3H, d, J 7.0,17-a, 1.16 (3H, d, J 6.2,14-1j), 
1.24 (3H, t, J 7.0, C3CH2O), 1.35 (1H, m, 12-i), 1.56 (2H, m, 9-jf), 1.62-1.92 
(1H, m, 8-H), 2.16 (3H, s, 15-Jj), 2.48-2.68 (4H, m, 4-f,, 11-IL 10-f), 3.31-3.49 
(2H, m, 6-fl, 16eq-H), 3.75-3.89 (4H, in, 16ax-fl, 7-fl, 13-11,5-fl), 4.12 (2H, t, J 
7.0, CH3CH20), 5.71 (1H, s, 2-i); SC 0 (OSi(. H3)3), 12.55 Q-17), 14.36 
(-CH3CH2O), 18.80 (('-15), 20.90 (C-14), 32.14 (a-9), 41.93 (. -8), 42.75 (a-12), 
43.19 (C-4), 55.35 (C'-10), 59.38 (CH3-CH2O), 61.40 (a-11), 65.50 (-16), 70.40 (('- 
6), 70.78 Q-7), 73.10 (a-13), 73.91 (a-5), 117.14 (-Q-2), 157.15 (Q-3), 166.45 Q-1); 
m/z (CI) 589 (MH+, 100%), 588 (M*, 4), 542 (16), 518 (2), 371 (18), 117 (76.2), and 
73 (27.3). Found MH+, 589.3411 C28H57Si3O7 requires MH+, 589.3412. 
Ethyl 4-[(2S, 3R, 4R, 5S)-3,4-hydroxy-5-((2S, 3S, 4S, 5S)-2,3-Epoxy-5- 
hydroxy-4-methylhexyl)tetrahydropyran-2-yl]-3-methylbut-2(E)-enoate 











To a stirred solution of ethyl 6,7,13-trimethylsilyloxymonate A (202) (0.60 g, 1.02 
mmol) in freshly distilled THE (30 cm3) was added HCl (0.4M, 6 cm3) in one portion, 
and stirred for two minutes exactly from the time of addition. This solution was then 
immediately quenched with saturated sodium hydrogen carbonate (6 cm3), and the 
mixture was stirred for 5 minutes, and then extracted with ethyl acetate (3 x 25 cm3). The 
combined organic extracts were dried with sodium sulphate, filtered and concentrated in 
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vacuo to yield ethyl monate A (204) (0.32 g, 84%) as an opaque, sticky gum. [aID20 
-2.3 (c 2.5, CHCl3), [lit., 
117 -1.4 (c 1.8, CHC13)]; 0 ax 3406,1708,1656 cm-1; 
SH 
0.94 (3H, d, J 7.0,17-11), 1.22 (3H, d, J 6.4,14-f=), 1.27 (3H, t, J 7.0, 
Ct3CH2O), 1.74 (3H, m, 12-ii, 9-1j), 2.02 (1H, m, 8-11), 2.21 (3H, s, 15-1j), 2.50- 
2.84 (4H, m, 4-fl, 11-fl, 10-1j), 3.52-3.58 (2H, m, 6-fl, 16eq-H), 3.71-3.93 (4H, m, 
16ax-H 7-l, 13-if, 5-l)1 , 4.14 (2H, q, 
J 7.0, CH3C&O) 6.10 (1H, s, 2-1f); SC 
12.76 (C'-17), 14.32 QH3CH2O), 19.05 (a-15), 20.83 Q-14), 31.68 (r-9), 39.53 Q- 
C-4), 55.56 (a-10), 59.62 (CH3-QH2O), 61.37 (Q-11), 65.34 8), 42.83 Q-12), 42.95 
(a-16), 69.02 Q-6), 70.38 (C-7), 71.46 Q-13), 74.77 (C-5), 117.66 Q-2), 156.64 (_C- 
3), 166.68 (a-1); m/z (CI) 373 (MH+, 74%), 372 (M+, 2), 327 (84), 309 (100), 291 
(58), 279 (43), 227 (72), and 209 (38). 












To a stirred solution of ethyl 6,7,13-trimethylsilyloxymonate A (202) (0.52 g, 0.88 
mmol) was added sodium hydroxide solution (2M, 0.49 cm3,0.98 mmol),. The reaction 
mixture was stirred at room temperature overnight, and was quenched with hydrochloric 
acid (1M, 5 cm3). This was then extracted with ethyl acetate (5 x 25 cm3). The combined 
organic extracts were dried over magnesium sulphate, filtered and concentrated in vacuo 
to yield ethyl monate A (204) (0.28 g, 85%) as an opaque, sticky gum. Spectral data as 
before. 
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S-2-(Acetylamino)ethyl 4-[(2S, 3R, 4R, 5S)-3,4-hydroxy-5- 
((2S, 3S, 4S, 5S)-2,3-Epoxy-5-hydroxy-4-methylhexyl)tetrahydropyran-2- 
yl]-3-methylbut-(2E)-enethioate (194) (N-acetylcysteamine thioester of 4- 
[ (2S, 3R, 4R, 5S)-3,4-hydroxy-5-((2S, 3S, 4S, 5S)-2,3-Epoxy-5-hydroxy-4- 
methylhexyl)tetrahydropyran-2-yl]-3-methylbut-(2E)-enoic acid (N-acetylcysteamine 
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Monic acid A (50) (1.81 g, 5.26 mmol) was added to dichloromethane (50 cm3), under a 
nitrogen atmosphere. Freshly prepared N-acetylcysteamine (73) (1.01 g, 8.49 mmol) in 
dichloromethane (4 cm3), followed by dicyclohexylcarbodiimide (83) (1.16 g, 5.62 
mmol) in dichloromethane (4 cm3), and 4-dimethylaminopyridine (84) (0.06 g, 0.49 
mmol) in dichloromethane (2 cm3) was added. The reaction was left to warm to room 
temperature overnight. After 24 h., the solution was washed with saturated ammonium 
chloride (40 cm3), and was extracted with dichloromethane (2 x 25 cm3). The combined 
organic extracts were dried over magnesium sulphate, filtered and concentrated in vacuo. 
Purification by flash column chromatography (Si02,25 % ethyl acetate/ petroleum ether 
40-60 'C) yielded the S-2-(acetylamino)ethyl 4-[(2S, 3R, 4R, 5S)-3,4-hydroxy- 
5-((2S, 3S, 4S, 5S)-2,3-Epoxy-5-hydroxy-4-methylhexyl)tetrahydropyran- 
2-yl]-3-methylbut-(2E)-enethioate (194) (1.44 g, 62%) as an opaque, sticky 
gum. [a]D20 -2.1 (c 3.3, CHC13); u (nujol) 3400,1687,1653 cm-1; SH 0.94 (3H, d, 
J 7.0,17-ID, 1.22 (3H, d, J 6.2,14-if), 1.30 (1H, m, 12-f. ), 1.72 (2H, m, 9-if), 
1.98 (3H, s, CH3CON), 2.07 (1H, m, 8-11), 2.22 (4H, m, 4ax-jf, 15-if), 2.61 (1H, m, 
4eq-H), 2.71 (1H, m, 11-fl), 2.81 (1H, m, 10-fl), 3.07 (2H, t, J 6.5, C112S), 3.45 
(2H, q, J 6.5, CIf- 2NH), 3.54-3.64 (2H, m, 6-fl, 16eq-ff), 3.70-3.96 (4H, m, 16ax-fl, 
7-H 13-IL 5-if), 6.10 (1H, s, 2-f), 6.17 (1H, br s, NH); SC 12.67 (a-17), 20.32 (. Q- 
15), 20.86 Q-14), 23.18 (_CH2NH), 28.48 (_QH2S), 31.65 Q-9), 39.72 (CH3CON), 
39.91 (-C-8), 42.76 (a-12), 42.83 (a-4), 55.56 (('-10), 61.21 (a-11), 65.40 (Q-16), 
68.83 (. -6), 70.39 (Q-7), 71.31 (r, -13), 74.89 (-C-5), 124.17 (a-2), 155.50 (Q-3), 
170.64 (CON), 189.41 (('OS); m/z (CI) 446 (MH , 33%), 444 (1), 426 
(72), 327 (73), 
309 (78), 291 (56), 120 (100), and 60 (48). Found MH+, 446.2204 C21H36N07S 
requires MH+, 446.2213. 
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Triethylphosphite (0.86 cm3,5.00 mmol) was added to a solution of ethyl bromoacetate 
(0.70 g, 4.19 mmol) in dry toluene (10 cm3), and the reaction mixture was heated to 
reflux for 24 h. The solvent was then removed in vacuo to yield ethyl 
diethylphosphonoacetate (162) (0.74 g, 79%) as a colourless oil. This was used without 
further purification. SH 1.29 (3H, t, J 7.2, Ct3CH2O), 1.35 (6H, t, J 7.2,2 x 
(CH3CH2O)2P), 2.96 (2H, d, J 21.4, C&P), 4.16 (4H, q, J 7.2,2 x (CH3CtO)2P), 
4.20 (2H, q, J 7.2, CH3C& O). 
S-2-(Acetylamino)ethyl 2-diethylphosphonoethanethioate (190) 





To a solution of the N-acetylcysteamine thioester (152) of bromoacetic acid (1.12 g, 4.70 
mmol) in dry toluene (10 cm3) was added triethylphosphite (1.00 cm3,5.83 mmol). The 
reaction mixture was heated to reflex for 24 h. The solvent was then removed in vacuo to 
yield S-2-(acetylamino)ethyl 2-diethylphosphonoethanethioate (190) (1.10 g, 
79%) as a pale yellow oil. This was used without further purification. Vmax 3293,1655, 
1249 cm-1; 8H 1.36 (6H, 't, J 7.2,2 x (Ct3CH2O)2P), 1.98 (3H, s, Ct3CON), 3.03 
(2H, t, J 6.2, C&S), 3.25 (2H, d, J 21.4, CH2P), 3.41 (2H, q, J 6.2, CtNH), 
4.16 (4H, q, J 7.2,2 x (CH3CtO)2P), 6.51 (1H, br s, NH); SC 16.23 ((H3CH2O), 
23.04 ((H2NH), 29.47 (CH2S), 39.01 (CH3CON), 42.07 (02P), 62.96 (CH3-QH2O), 
170.70 (-ON), 196.90 (SOS); m/z (CI) 298 (MH+, 100%), 279 (30), 179 (10), 120 
(10), and 118 (5). Found MH+, 298.0892 C1oH2jN05PS requires MH+, 298.0880. 
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4.3 Experimental for the culture work discussed in Chapter 3 
Agar Slant Preparation 
The following ingredients were added in order, as follows: 
Constituents Weight ( itre) 
Spray dried yeatex 2.28 
D- glucose 1.10 
Na2HPO4 5.00 
(NH4)2SO4 5.00 
Aar No. 3 30.0 
Table 4.1: Constituents of the 1/10 6sp agar slant medium. 
The required volume of water was added, and the pH was then adjusted to pH 7.0.7 cm3 
was dispensed into each of ten test tubes. They were then autoclaved for 15 minutes at 
121 'C, after which time the test tubes were laid on their sides and left to set for 24 hours. 
The slopes were then inoculated with a 10µl loopful of Pseudomonasfluorescens NCIB 
10586, and left to grow at 25 'C for 5 days, after which time they were stored at 4 'C, 
and were viable for three months. 
Culturing of Pseudomonas fluorescens 
(a) Preparation of primary stage medium 
The following ingredients'were added in order, as follows: 
Constituents Weight (g/litre) 
Spray dried yeatex 22.8 
D- glucose 1.10 
NaH2PO4 5.00 
(NH4)2SO4 5.00 
Anti-foam 0.5 cm3/litre 
Table 4.2: Constituents of the primary stage medium. 
The required volume of water was added, and the pH was then adjusted to pH 7.0.50 
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cm3 was then dispensed into one 250 cm3 conical flask, and this flask was autoclaved at 
121 'C for 15 minutes. The flask was then inoculated with 10 µl loopful of Pseudomonas 
fluorescens NCIB 10586, and was shaken at 25 'C for 24 hours at 240rpm. 
(b) Preparation of final stage medium 
The following ingredients were added in order, as follows: 
Constituents Weight ( itre) 
D- glucose 100 
Arkasoy 50 20 





Anti-foam 0.5 cm3/litre 
Table 4.3: Constituents of the fmal stage medium. 
The required volume of water was added, and the pH was then adjusted to pH 7.0.25 
cm3 was then dispensed into each of ten baffled 250 cm3 conical flasks, and these flasks 
were autoclaved at 121 'C for 15 minutes. The ten flasks were then inoculated by 
transferring 1 cm3 of the primary medium to each of the ten flasks, and these flasks were 
shaken at 22 'C for 5 days at 240rpm. 
HPLC Assay 
An aliquot (1 cm3) was taken from a flask, so as to determine the titre of pseudomonic 
acid present in the medium at that time. The samples were micro-centrifuged before 
analysis by HPLC. The supernatant obtained from micro-centrifugation was then diluted 
ten-fold (i. e. 0.05 cm3 of supernatant, and 0.45 cm3 of distilled water). The 
pseudomonic acid content was determined by using reverse phase HPLC, using a C-18 
Whatman perisphere column, injecting 25 µl, and using a solvent system of ammonium 
acetate (0.58 g/litre), 'HPLC grade' methanol (200 cm3), and distilled water (800 cm3). 
The flow rate was 1.5 cm3 min-1, with the peaks being monitored at 233nm, the 
wavelength of the chromaphore of pseudomonic acid. Pseudomonic acid A was observed 
to have a retention time of 6.5 minutes with this solvent system. 
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Isolation of methyl pseudomonate (197)48 
H 
17 H 5,. "4 
j 8' 6 4' 2' OMe 







O 16 (197) 
OH 
The combined secondary media were centrifuged (10000 g, 2 'C, 15 minutes) and the 
supernatant was acidified to pH 4.5, saturated with sodium chloride and extracted with 
ethyl acetate (5 x 150 cm3). The combined organic extracts were dried over magnesium 
sulphate, filtered and concentrated in vacuo. The orange oil was taken up in 5 cm3 of 
methanol, and treated with an excess of ethereal diazomethane. After one hour the excess 
diazomethane was blown off with nitrogen, and the mixture was concentrated in vacuo. 
Purification by preparative TLC (2.5% methanol in ethyl acetate) yielded methyl 
pseudomonate (197) as a colourless oil (Rf=0.3). [a]D20 -8.2 (c 2.5, CHC13); [lit., 48 
-9.0 (c 1.5, CHCl3)]; umax (thin film) 3310,1750,1720,1655 cm71. The 1H and 13C 
nmr data can be found in Tables 3.1 and 3.2 respectively 
Preparation of ethereal diazomethane142,143 
Potassium hydroxide (14 g) in ethanol (50 cm3) and water (15 cm3) was heated in a 
water bath at 65 T. To this solution was added diazald (43 g) in diethyl ether (250 cm3) 
from a separating funnel. The mixture was then added at such a rate that a gentle reflux 
led to slow distillation of the yellow distillate into an ice-cooled conical flask. Once 
complete, the remaining mixture was quenched with acetic acid (10%) in diethyl ether. 
Diazomethane was then stored in a freezer until required. 
Methylation of pseudomonic acid 
The combined secondary media were centrifuged (10000 g, 2 Sc, 15 minutes) and the 
supernatant was acidified to pH 4.5, saturated with sodium chloride and extracted with 
ethyl acetate (5 x 150 cm3). The organic extracts were dried over magnesium sulphate, 
filtered and concentrated in vacuo. The resulting orange oil was taken up in methanol (5 
cm3), and treated with an excess of ethereal diazomethane. To test there was an excess of 
diazomethane, a few drops of acetic acid was added. Evolution of nitrogen indicated there 
was an excess. To remove the excess, the solution was quenched with acetic acid, until 
no more nitrogen evolved. Nitrogen was bubbled through the solution, and the resulting 
mixture was then concentrated in vacuo to yield crude methyl pseudomonate (197). 
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Growth production study 
An aliquot (1 cm3) was taken from at least two flasks from the secondary media every 
two hours, commencing 10 hours after inoculation. The pH of the combined media was 
taken for each sample. Analysis by HPLC then followed, using the same assay, as 
previously described. 
Time(hours) Titre(mg/ cm3) H 
0 0.000 7.00 
12 0.024 6.80 
15 0.094 5.90 
18 0.162 5.82 
21 0.233 5.73 
24 0.274 5.66 
27 0.355 5.61 
30 0.316 5.55 
33 0.380 5.50 
36 0.324 5.57 
39 0.446 5.53 
42 0.335 5.45 
45 0.364 5.29 
48 0.329 5.19 
50 0.300 5.12 
63 0.383 7.82 
66 0.363 7.75 
72 0.381 7.67 
120 0.388 8.40 
Table 4.4: Growth production results with NCIB 10586. 
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Incorporation studies with Pseudomonas fluorescens PF3/R 
(a) Sodium [1-13C]acetate 
Primary stage and secondary stage media were inoculated as described earlier for NCIB 
10586. A5 cm3 solution (sterile water), containing sodium [1-13C]acetate (250mg) was 
prepared. 0.5 cm3 was added to each of 10 flasks, 43 hours after inoculation. The cells 
were harvested as usual. HPLC analysis gave a value of 11.81%, of the value of the 
control flask. Methyl pseudomonate (31mg) was isolated. The IH & 13C nmr spectrum 
was identical to that of authentic methyl pseudomonate, showing that there was ' no 
significant incorporation. 
(b) Sodium [2-13C]acetate 
The same method was employed, as for sodium [1-13C]acetate, except sodium [2-13C] 
acetate (250mg) was added. The cells were harvested as usual. HPLC analysis gave a 
value of 11.64% of the value of the control flask. Methyl pseudomonate (14mg) was 
isolated. The 1H & 13C nmr spectrum was identical to that of authentic methyl 
pseudomonate, showing that there was no significant incorporation. 
(c) Sodium [1,2-13C2]acetate 
The same method was employed, as for sodium [1-13C]acetate, except sodium [1,2- 
13C2]acetate (250mg) was added. The cells were harvested as usual. HPLC analysis gave 
a value of 12.00%, of the value of the control flask. Methyl pseudomonate (25mg) was 
isolated. The 1H & 13C nmr spectrum was identical to that of authentic methyl 
pseudomonate, showing that there was no significant incorporation. 
(d) Sodium [1-13C]propionate 
The same method was employed, as for sodium [1-13C]acetate, except sodium [1-13C] 
propionate (250mg) was added. The cells were harvested as usual. HPLC analysis gave a 
value of 13.56%, of the value of the control flask. Methyl pseudomonate (30mg) was 
isolated. The 1H & 13C nmr spectrum was identical to that of authentic methyl 
pseudomonate, showing that there was no significant incorporation. 
(e) Sodium [2-13C]propionate 
The same method was employed, as for sodium [1-13C]acetate, except sodium [2-13C] 
propionate (250mg) was added. The cells were harvested as usual. HPLC analysis gave a 
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value of 13.69%, of the value of the control flask. Methyl pseudomonate (15mg) was 
isolated. The 1H & 13C nmr spectrum was identical to that of authentic methyl 
pseudomonate, showing that there was no significant incorporation. 
(f) Sodium [3-13C]propionate 
The same method was employed, as for sodium [1-13C]acetate, except sodium [3-13C] 
propionate (250mg) was added. The cells were harvested as usual. HPLC analysis gave a 
value of 15.09%, of the value of the control flask. Methyl pseudomonate (21mg) was 
isolated. The 1H & 13C nmr spectrum was identical to that of authentic methyl 
pseudomonate, showing that there was no significant incorporation. 
(g) Sodium [1-13CJbutyrate 
The same method was employed, as for sodium [1-13C]acetate, except sodium [1-13C] 
butyrate (250mg) was added. The cells were harvested as usual. HPLC analysis gave a 
value of 15.12%, of the value of the control flask. Methyl pseudomonate (27mg) was 
isolated. The 1H & 13C nmr spectrum was identical to that of authentic methyl 
pseudomonate, showing that there was no significant incorporation. 
(h) Disodium [1,2-13C2]malonate 
Seed stage and final stage media were inoculated as described earlier. A5 cm3 solution 
(sterile water), containing disodium [1,2-13C2]malonate (250mg) was prepared. 0.5 cm3 
was added to each of 10 flasks, 43 hours after inoculation. However, after shaking the 
flasks at 250rpm for 6 days, the medium had coagulated. The contents of the ten flasks 
were then centrifuged. However, it was impossible to spin out the cells, so no 
methylation of the pseudomonic acid isolated from this feed was carried out. 
Incorporation studies with Pseudomnas fluorescens N_QIB 10586 
(a) Sodium [1-13C]acetate 
Primary stage and secondary stage media were inoculated as described earlier. A5 cm3 
solution (sterile water), containing sodium [1-13C]acetate (250mg) was prepared. 0.5 
cm3 was added to each of 10 flasks, 15 hours after inoculation, as a single feed. The cells 
were harvested as usual. HPLC analysis showed very little pseudomonic acid production, 
compared with the control flask. Methyl pseudomonate (3mg) was isolated. There was 
not enough methyl pseudomonate to obtain a meaningful 13C nmr spectrum. 
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(b) Sodium [2-13C]acetate 
The same method was employed, as for sodium [1-13C]acetate, except sodium [2-13C] 
acetate (250mg) was added. The cells were harvested as usual. HPLC analysis showed 
very little pseudomonic acid production, compared with the control flask. Methyl 
pseudomonate (5mg) was isolated. There was not enough methyl pseudomonate to obtain 
a meaningful 13C nmr spectrum. 
(c) Sodium [1,2-13C2]acetate 
The same method was employed, as for sodium [1-13C]acetate, except sodium [1,2- 
13C2]acetate (250mg) was added. The cells were harvested as usual. HPLC analysis 
showed very little pseudomonic acid production, compared with the control flask. Methyl 
pseudomonate (5mg) was isolated. There was not enough methyl pseudomonate to obtain 
a meaningful 13C nmr spectrum. 
(d) Sodium [1-13C]propionate 
The same method was employed, as for sodium [1-13C]acetate, except sodium [1-13C] 
propionate (250mg) was added. The cells were harvested as usual. HPLC analysis 
showed very little pseudomonic acid production, compared with the control flask. Methyl 
pseudomonate (4mg) was isolated. There was not enough methyl pseudomonate to obtain 
a meaningful 13C nmr spectrum. 
(e) Sodium [2-13C]propionate 
The same method was employed, as for sodium [1-13C]acetate, except sodium [2-13C] 
propionate (250mg) was added. The cells were harvested as usual. HPLC analysis 
showed very little pseudomonic acid production, compared with the control flask. Methyl 
pseudomonate (2mg) was isolated. There was not enough methyl pseudomonate to obtain 
a meaningful 13C nmr spectrum. 
(f) Sodium [3-13C]propionate 
The same method was employed, as for sodium [1-13C]acetate, except sodium [3-13C] 
propionate (250mg) was added. The cells were harvested as usual. HPLC analysis 
showed very little pseudomonic acid production, compared with the control flask. Methyl 
pseudomonate (3mg) was isolated. There was not enough methyl pseudomonate to obtain 
a meaningful 13C nmr spectrum. 
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(g) Sodium [1-13C]butyrate 
The same method was employed, as for sodium [1-13C]acetate, except sodium [1-13C] 
butyrate (250mg) was added. The cells were harvested as usual. HPLC analysis showed 
very little pseudomonic acid production, compared with the control flask. Methyl 
pseudomonate (2mg) was isolated. There was not enough methyl pseudomonate to obtain 
a meaningful 13C nmr spectrum. 
(h) Sodium [1-13C]acetate 
Primary stage and secondary stage media were inoculated as described earlier. A5 cm3 
solution (sterile water), containing sodium [1-13C]acetate (250mg) was prepared. 0.5 
cm3 was added to each of 10 flasks, 14,16, an 18 hours after inoculation, as a pulse 
feed. The cells were harvested as usual. HPLC analysis showed very little pseudomonic 
acid production, compared with the control flask. Methyl pseudomonate (2mg) was 
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